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Abstract 
The eukaryotic interphase nucleus is well organised and the genome positioned non-
randomly. Nuclear structure is an important regulator of genome behaviour and function. 
Genome organisation and nuclear structure are compromised in diseases such as cancer and 
laminopathies. This study was to find out and to determine if there is any functional 
relationship between nuclear structure and genome mis-organisation in cancer cells. I have 
assessed the presence and distribution of specific nuclear structural proteins (A-type, B-type 
lamins and its receptor LBR, many of their binding proteins such as MAN1, LAP2α, LAP2, 
and Emerin and other nuclear proteins (PML, Nucleolin, and Ki67) using indirect 
immunofluorescence. From this study, it is found that the nuclear structure of breast cancer 
cells is often altered. The most severely affected proteins are the nuclear lamins B1 and B2 
and they found as large foci within the nucleoplasm with little LBR expression to localise the 
lamin B. I also assessed the chromosome positioning (HSA 7, 10, 11, 14 and 17) and gene 
positioning (AKT1, CCND1, HSP90AA1, EGFR, ERRBB2/HER2 and PTEN) in breast cancer 
cell lines (T-47D, GI-101, Sk-Br-3 and BT-474) and in normal breast cell lines (MCF-10A) 
using 2D-FISH technique. I also assessed the position of the genes in nuclei and correlated 
with gene expression using qRT-PCR. Breast cell lines have treated with a drug named 
lovastatin and it was found that the cells have restored LBR expression and localisation of 
lamin B, leading to altered gene positioning and changed expression of breast cancer genes.  
 
Since the drug (lovastatin, 12 µM/48 hours) affects the prenylation as a post-translation 
modification process and lamins B biosythensis, it is found that B-type lamins and its 
receptor expression and distribution were improved and increased in expression by 2-fold in 
expression levels in the most affected cells (T-47D, and BT-474) compared to the normal 
cells (MCF-10A) and these cells also showed abnormal nuclei and dead cells. When 
ii 
 
analysing the nuclear positioning of the genes (AKT1, HSP90AA1 and ERRBB2/HER2), it is 
found that AKT1 was positioned periphery in BT-474 and T-47D cells and interiorly in the 
normal cells (MCF-10A) before treatment whereas the same gene was positioned periphery in 
T-47D and MCF-10A cells and interiorly in BT-474 after treatment with lovastatin. It is also 
found that HSP90AA1 was positioned periphery in MCF-10A and T-47D cells and interiorly 
in BT-474 cells before and after treatment (no change). Moreover, ERRBB2/HER2 gene was 
positioned periphery in T-47D and BT-474 cells and interiorly in MCF-10A cells before 
treatment whereas the same gene was positioned periphery in MCF-10A and T-47D cells and 
interiorly in BT-474 after treatment with the same drug. Regarding LMNB1, LMNB2, and 
LBR genes, the study focussed only on their expression levels and no work has done on their 
chromosome positioning as well as gene position before and after treatment. These three 
genes were over expressed when assessed by measuring the relative and fold changes in 
expression. Therefore, it is suggestive that 2D-FISH experiment to assess their localisation 
and their specific chromosome territories is required. 
 
The results shown in this thesis demonstrate the importance and roles of nuclear architecture 
specifically nuclear lamins and the integral nuclear membrane proteins (B-type lamins and 
LBR) in mediating correct genome organisation and function. The breast normal 
(immortalised cells) and cancerous cell lines showed different nuclear structures as lamin B 
affect the position of specific target chromosomes and genes. These results will strength the 
finding that the nuclear lamina is a significant nuclear structure which associates, organises, 
and regulates numerous vital nuclear processes and the stability of the genome. 
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To Summarise This Work:  
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1. Introduction: 
1.1 Incidences and Risk Factors in Breast Cancer: 
Breast cancer (BC) is the most common cancer of women worldwide and is the second 
leading cause of cancer death in women after lung cancer, with around 50,000 women and 
around 400 men diagnosed each year. It is a multifactorial disease caused by genetic, 
lifestyle, and environmental factors (World Health Organisation (WHO) and Breakthrough 
Breast Cancer Websites, April 2013). The official website of the American Cancer Society 
shows the female breast cancer incidence rates began to decrease in 2000 then start to fall 
more about 7% in 2002. It has been found that there was a higher link between hormone 
replacement therapy (HRT) and breast cancer risk and mortality as the use of estrogen and 
progestrone is associated with increased breast cancer incidence (Chlebowski et al., 
2013). The death rates from breast cancer have been fallen since 1989 especially in women 
less than 50 years old. These decreases might be due to earlier detection through screening 
and increased awareness, as well as improved treatment (American Cancer Society Website, 
February 2013). Five out of six women diagnosed with breast cancer survive for at least five 
years (Breakthrough Breast Cancer Website, 2013). 
 
Studies suggest that the risk factors for BC may include duration of exposure to female 
hormones (early or late menopause), reproductive factors (late age of first pregnancy), dietary 
and low physical activity (obesity and high fat diet), ionising radiation during breast 
development, environmental factors due to geographical variation are of greater importance 
than genetic factors, chronic use of hormone replacement therapy (HRT), and genetic 
inheritance (family history) of BC (McPherson et al., 2000).  
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1.1.1 Steroid Hormones and Their Receptors: 
Progesterone and estrogen (17β-estradiol, E2) are ovarian steroid hormones and are essential 
co-regulators of the female reproductive activities as well as having non reproductive effects, 
which are induced by gonadotrophines, luteinising hormone (LH) and follicle-stimulating 
hormone (FSH), or other factors and genes. These effects are involved in development, 
differentiation, and maintaining the cardiovascular health by promoting blood clotting, bone 
integrity by its effect to minimise the loss of calcium from bones as well as other organs such 
as brain and pancreas (Edwards, 2005), in addition to their role in ageing (Pike et al., 1993). 
Normally, these hormones and their receptors have the ability to co-regulate the normal 
development and function of the ovary, the uterus and the mammary gland in addition to their 
role in breast and ovary tumourgenesis (Lydon and Edwards, 2009). At puberty, the 
hypothalamus induces the ovary to secrete estrogen and this will induce the development of 
mammary gland. This development is associated with proliferation of the epithelial cells and 
mammary ducts. In pregnancy, progesterone is synthesised by the corpus luteum and placenta 
to stimulate the growth of lobuloalveolar mammary structures for secretion (Lapidus et al., 
1998).  
 
In BC, the mechanism by which estrogen can induce the cellular changes is through binding 
directly to the estrogen receptor (ERα and ERβ, encoded by ESR1 and ESR2 genes, 
respectively) in the cell nucleus or indirectly to ER on the cell surface membrane (Nilsson et 
al., 2001). Furthermore, ERα and ERβ differ in their tissue distribution and ligand binding 
characteristics (Katzenellenbogen and Katzenellenbogen, 2000). The complex that binds 
directly to estrogen response element (ERE) sequences in the promotor of DNA sequence 
(Figures 1.1 and 1.2) resulting in production of co-regulatory proteins (co-activators or co-
repressors) (Demay et al., 1995). These receptors are composed of three interacting 
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functional domains: (1) NH2-terminal domain that encodes a ligand-independent activation 
function (AF1, involved in protein-protein interactions and transcriptional activation of target 
gene expression) and is a very active domain in the stimulation of gene expression. (2) DNA 
binding domain (DBD) that contains two zinc fingers and plays an important role in receptor 
dimerisation and binding of receptors to specific DNA sequences. (3) COOH terminal, and 
ligand binding domain (LBD, AF2) (Figure 1.1) that mediates ligand binding, receptor 
dimerisation, nuclear translocation and transactivation of target gene expression (Nilsson et 
al., 2001). Although both receptors have identical DBDs, they differ in their abilities to 
activate different estrogen-responsive genes. The activity of each activation function (AF) of 
ER is cell and promotor dependent (McInerney and Katzenellenbogen, 1996). These 
differences suggest the efficacy of different ligands interaction through the two ER subtypes 
(Katzenellenbogen and Katzenellenbogen, 2000). 
 
 
 
  
    AF1      DNA          Ligand             AF2 
 
Figure 1.1: The Structure and Functional Domains of Estrogen (E2) Nuclear Receptors 
The figure shows ER subtypes are composed of three interacting functional domains (AF1, 
DB, and AF2 domains) and their role in transcription and gene expression. The AF1 domain 
contains the NH2 terminus where transcription factors interact. The DNA binding domain 
contains the two-zinc finger structure that binds to DNA, and the ligand domain contains the 
ligand binding domain as well as the AF2 domain that directly binds co-activator proteins. 
Both nuclear receptors have identical DBDs but they differ in AF1 and AF2 efficacy 
interaction to ligands (By Mai H. Ahmed, 2010 based on Nilsson et al., 2001).  
 
 
NH2-Terminal 
Domain 
DNA Binding 
Domain (DBD) 
Ligand Binding 
Domain (LBD) 
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However, the mechanism of functional domains interaction can be achieved through their 
binding indirectly to receptors (ERα) on the cell surface membrane resulting in increased 
levels of calcium and activation of kinases (Nilsson et al., 2001; Deroo and Korach, 2006). 
Different studies suggest that estrogen and progesterone are implicated in BC and ovarian 
cancer (OC) development via their binding to ER and PR, respectively that stimulates cell 
proliferation and increase in cell division and DNA synthesis (Wittliff, 1984). 
Gonadotrophines are also implicated in the aetiology of OC since they stimulate 
steroidogenesis and increase the estrogen levels produced by ovary (Deroo and Korach, 
2006).  This may increase the risk for replication errors (double strand breaks and changes in 
daughter chromosomes) which may result in mutations that disrupt normal cellular processes 
such as apoptosis, normal proliferation or DNA repair mechanisms. In addition, estrogen 
metabolism leads to the production of toxic products that may directly damage DNA 
resulting in mutations. Mutation or aberrant expression of the regulators may affect their 
normal function and disrupt the normal development of the mammary gland and ovary which 
may lead to BC and OC, respectively. Since PR is induced by ER, its presence is a marker of 
functional and active ER. This supports the idea that the tumour is poorly differentiated when 
the ER and PR in BC patients are inactivated or lost. In addition, ER-positive tumours that 
lack PR in BC patients are less to responsive to hormonal therapies than those express both 
receptors (Lapidus et al., 1998).  
 
1.1.2 Other Cell Signalling Pathways: 
Clearly, estrogen and progestrone hormones have an important role in BC and OC via ERs 
and PRs. In the absence of estrogen, other signalling pathways can modulate and co-regulate 
ER by tyrosine phosphorylation (Katzenellenbogen and Katzenellenbogen, 2000). This can 
be achieved by protein kinases, STAT, growth factors, cytokines, neurotransmitters, and cell 
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cycle regulators (Demay et al., 1995; Buettner et al., 2002). These have been demonstrated to 
contribute directly to oncogenesis by stimulating cell proliferation and preventing apoptosis. 
Therefore, activation of these regulators participating in oncogenesis through up-regulation of 
genes encoding apoptosis deregulators and cell cycle regulators such as EGFR, PTEN, AKT1, 
HSP90AA1, HER2, cyclins D1/D2, and c-Myc (Buettner et al., 2002). Thus, the identification 
and understanding of these targets, that play an important role in diagnosis, prognosis, and 
therapeutics, are exciting new area of studying the biological roles of signalling responses 
(Lemoine, 1994; Deroo and Korach, 2006; Sárvári et al., 2010). In addition, E2 and 
progesterone, the role of epidermal growth factor receptor (EGFR) and ERBB2 is that to 
stimulate and promote cell growth, survival, proliferation, and suppresses cellular apoptotic. 
HER-2 act as an oncogenic product, phosphatase and tensin homolog (PTEN) expression in 
OC and cyclin D1 activation during G1 are involved in cell cycle regulation (Lakhani et al., 
2002; Bell, 2005; Drosten et al., 2010) (Figure 1.2). Furthermore, not only E2 regulates and 
activates phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway in tumour cells that 
poorly expresses ER and proliferate out of control (Figure 1.2) but also Erk, IGF and insulin 
(Guo et al., 2007; Drosten et al., 2010; Miah et al., 2012). Moreover, the synthesis of heat 
shock proteins (HSPs) or stress proteins in BC cells are induced by environmental factors, 
pathological conditions, or physiological stresses (Whitesell and Lindquist, 2005). HSPs play 
an important role in the control of the cell cycle and tumourgenesis (Figure 1.2). HSP90α is 
involved in the regulation of steroid receptors (ER) by binding to these receptors and 
activation of other proteins such as src-family and kinases to induce BC cells proliferation 
(Yano et al., 1999; Miah et al., 2012). Blockage of these pathways and cascades may become 
a potentially effective way to control tumour progression especially in ER-negative which 
shows no response to endocrinal therapy.  
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Figure 1.2: Cell Survival and Proliferation Induced By Different Cell Signalling 
Pathways 
The carton displays the binding of estrogen (E2) to estrogen receptor (ER) via ER elements in 
the nucleus to regulate transcription and gene expression. This figure also shows interesting 
genes that are capable of inducing cell proliferation in the absence of ER and are involved in 
breast cancer progression. A number of other signalling pathways can modulate and co-
regulate (co-activators or co-repressors) ER by phosphorylation. Activation of the 
RAS/RAF/MEK/Erk and PI3K/AKT as well as inhibition of PTEN and caspase 9 pathways 
induce signal transduction to cell cycle progression and cell survival. Moreover, toxic 
products from E2 metabolism may directly damage DNA resulting in mutation and 
replication errors. This will lead to cell survival, cell cycle progression and proliferation. 
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However, the loss of estrogen or its receptor contributes to the development of various 
diseases such as osteoporosis, neurodegenerative diseases, insulin resistance, stroke and 
coronary artery diseases, and obesity (Edwards, 2005) as well as E2 gene dysregulation are 
responsible for the mechanisms by which these cancers occur through activation of other 
genes involved in cancer progression such as breast cancer (Figure 1.2). Since the expression 
and activity of PR depends on ER transcriptional activity, it has been shown that PR 
expression has strong correlation with prognosis in BC than ER expression alone because 
progesterone contributes to early stages of breast tumourgenesis (Lydon and Edwards, 2009). 
Clearly, BC phenotype is dependent on ovarian steroids and matrix metalloproteinases 
(MMPs) activity which are also implicated in mammary epithelial transformation either 
through steroid hormones, tumour growth factor β1 (TGFβ1), or extracellular matrix (ECM) 
remodelling. This will lead to increased morphogenesis, hyperplasia, and tumours of these 
organs (Simian et al., 2009). 
 
1.1.3 The Principal Target Agents for Breast Cancer Therapy: 
The developments in molecular technologies have allowed researchers to gain a better 
understanding and improvement of the mechanisms in breast cancer (BC) transformation and 
progression. In general, the aim of targeted therapy is to target specific tumour cells leading 
to improved treatment with limited toxicity. BC is the most common female tumour with an 
increased morbidity in patients at different stages with different prognosis (Gasparini et al., 
2005). In the last few years, an improved understanding of molecular pathways involved in 
BC growth and progression allowed researchers for the identification of interesting targets 
that can be inhibited by new generations of anticancer drugs.  
 
 
9 
 
1.1.4 Targeting Farnesylation by Lovastatin:  
Farnesylation is an essential step for activation and maturation of several proteins involved in 
cellular and nuclear organisation, apoptosis, gene transcription and cell proliferation. The 3-
hydroxy 3-methylglutaryl-CoA reductase inhibitor, lovastatin, is used widely to treat 
hypercholesterolemia and has been shown to have cell cycle-specific effects (Holstein and 
Hohl, 2001). Furthermore, lovastatin causes growth inhibition and induces apoptosis in 
cancers. Activation of Ras oncogene is also farnesyltransferase dependent. However, 
continuous activation of Ras protein can result from growth factor stimulation. Lovastatin can 
inhibit Ras farnesylation and therefore, induce antiproliferative effects as a result from the 
inhibition of Ras activity (Schafer and Rine, 1992; Rowinsky et al., 1999; Johnston, 2001; 
Chatterjee and van Golen, 2011). Other intracellular targets include nuclear lamin proteins, 
lamins A and B (Farnsworth et al., 1989), modulation of the PI3-K/AKT pathway (Du et al., 
1999) or GTP-binding proteins that regulating cell adhesion or motility (Liu et al., 2000; 
Chatterjee and van Golen, 2011) are involved in this inhibition. In 1999, Du et al. showed 
that the apoptotic effects of lovastatin in Ras transformed cells and they found that lovastatin 
disrupted a signal that is crucial for survival of malignant cells, but not normal cells, if the 
PI3-K/AKT pathway is inactivated (Du et al., 1999). These results seem positive for clinical 
applications of lovastatin to induce the apoptotic responses, however there are still questions 
that need to be answered such as the biological dose, tumour cell types, stages of the disease, 
and toxcicity. 
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1.1.4.1 Interphase 3-hydroxy-3 methylglutaryl-Coenzyme A Reductase (HMG-CoA 
Reductase) Inhibitor (Lovastatin) Treatment: Ras Family Genes: Maturation and 
Activation Mechanism:  
The ras family genes have been identified as potential targets for therapeutic purposes 
because of somatic mutations in different human cancers. They are mutated in many 
cancerous cells (Downward, 2003; Graham and Olson, 2007). The enzyme 
farnesyltransferase is involved in post-translational modification of the Ras proteins by 
adding a farnesyl group to the Ras protein at C terminus. This permits the Ras protein to be 
translocated to the cell surface membrane, allowing the protein to be involved in signalling 
pathways for increased proliferation and inhibition of apoptosis. The class of 
farnesyltransferase inhibitors is designed to block farnesylation and prevent the mature Ras 
signalling and thus inhibit cell proliferation and facilitate apoptosis (Whyte et al., 1997; 
Johnson and Heymach, 2004). The association of mutant forms of Ras protein with a variety 
of human cancers has increased strong interest in therapies based on inhibiting oncogenic Ras 
signalling pathway. Attachment of Ras proteins to the plasma membrane is required for 
effective Ras signalling and this is initiated by the enzyme farnesyltransferase (Graham and 
Olson, 2007). 
 
HMG-CoA reductase is an enzyme that is responsible for the conversion of HMG-CoA to 
mevalonate to participate cholesterol biosynthesis (Alberts, 1988). Lovastatin binds to this 
enzyme and prevents the synthesis of cholesterol (Figure 1.3). Since lovastatin is specific for 
farnesylated proteins such as Ras, it is therefore expected to have less toxicity. Inhibitors such 
as lovastatin are specific for Ras converting enzyme (Rce1) and isoprenylcysteine carboxyl 
methyltransferase (ICMT), both enzymes are required for prenylation and for lamins to be 
mature and active, and expected to have more toxicity as lovastatin can modify all CAAX 
11 
 
proteins. However, Rho protein, one of Ras superfamily, might function normally under 
conditions where Rce1 and/or ICMT are blocked, making these more attractive targets for 
drugs. However, because the major limitation of lovastatin is alternative prenylation by 
geranylgeranyltransferase (Whyte et al., 1997), it has been suggested that the addition of an 
Rce1 or ICMT inhibitor might not overcome the effects of alternative prenylation. Therefore, 
a prenylated protein might be unable to be transported to the nuclear membrane in Rce1 or 
ICMT deficient cells (Michaelson et al., 2005; Malhas et al., 2007; Christiansen et al., 2011). 
Both Rce1 and ICMT are required for membrane targeting of farnesylated but not 
geranylgeranlyated GTPases and this indicate the importance of post-prenylation of CAAX 
proteins (Whyte et al., 1997; Martin et al., 2009; Christiansen et al., 2011). 
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Figure 1.3: Schematic Presentation of the Isoprenoids Pathway  
This pathway can be inhibited by Statin (Lovastatin) Treatment to inhibit HMG-CoA 
Reductase and prevent Cholesterol Synthesis, inhibit Ras Activation, and Increase Lamin B 
Expression. Other Inhibitors such as Farnesyltransferase Inhibitors (FTIs) and 
Biphosphonates can Target the Pathway at Farnesyltransferase (FT) and Farnesyl-PP 
Synthase Enzymes, Respectively.  
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1.2 Nuclear Structure and Disease: 
The eukaryotic cell nucleus is an important regulator for a variety of functions and processes, 
including gene expression, DNA replication during cell cycle, apoptosis, DNA repair, 
transcription events, ribosome assembly and maintaining the integrity of genes (Garagna et 
al., 2001; Prokocimer et al., 2006; Parnaik, 2008; Linnemann and Krawetz, 2009; Peric-
Hupkes and van Steensel, 2010). To perform these functions efficiently, the nucleus is well 
compartmentalised by nuclear structure, providing a high degree of spatial organisation 
(Cremer and Cremer, 2001; Parada et al., 2004; Malhas et al., 2007; Peric-Hupkes and van 
Steensel, 2010). These structures include the nuclear envelope, nuclear lamina, nuclear 
matrix, nucleoli, and nuclear bodies. In laminopathies (diseases caused by mutation in A-type 
and B-type lamin proteins, Section 1.2.3.6.1) and cancers, this organisation and nuclear 
functions are altered (Zink et al., 2004; Meaburn et al., 2007a; Mehta et al., 2011). These 
alterations could be important to characterise as cancer biomarkers at different stages. 
Previous studies have shown that the nuclear matrix composition, in cancerous cells, can be 
different from normal cells (Prokocimer et al., 2006). This finding has been useful in 
characterising cancer biomarkers and has helped to diagnose the disease earlier. In addition, 
these biomarkers are used for early detection and prognosis of human cancers. Thus, these 
alterations and differences in nuclear structure of the cancerous cells can be used in the 
development of new anticancer drugs (Agrelo et al., 2005; Prokocimer et al., 2006; Willis et 
al., 2008). Treatment with anticancer drugs may lead to the restoration and improvement of 
nuclear structure and a reversion of cancer phenotype thereby identifying therapeutic agents.  
 
1.2.1 The Nuclear Matrix: 
The nuclear matrix, nuclear scaffold, or nucleoskeleton is a dynamic RNA-protein complex 
and thought to be a network of fibrous proteins that consist of nuclear lamina inside the cell 
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nucleus providing structural framework for organising chromatin, nuclear structures, and 
regulating nuclear DNA metabolism (Hozák et al., 1995; Spencer et al., 2000) (Figure 1.4). It 
was first described by Berezney and Coffey in 1974 using rat liver nucleus which consists of 
nuclear matrix. This matrix is 98.2% protein, 0.1% DNA, 1.2% RNA, and 0.5% 
phospholipid. The nuclear protein matrix is composed of three acidic polypeptide fractions 
with a molecular weight range from 60–70 kDa.  (Berezney and Coffey, 1974). It is highly 
dynamic structure and involved in the regulation of gene expression and supporting major 
nuclear functions (Barboro et al., 2002; Martin et al., 2009). Different regions of the genome 
interact with the nuclear matrix and they are called matrix attachment regions (MARs). 
Telomeres and centromeres also attach to the NM. The spatial arrangements in the nucleus 
are maintained by attachments to nuclear matrix proteins (NMPs) network and RNAs (Fey et 
al., 1986; Hozák et al., 1995). The nuclear matrix binds to nuclear proteins and supports their 
assembly into functional macromolecules involved in nuclear processes such as transcription, 
RNA splicing, regulating gene expression and DNA replication (Bissell et al., 1999; 
Nickerson, 2001). Furthermore, it can participate in chromatin organisation via matrix 
attachment regions (MARs). MAR-binding proteins bind MARs and can be influenced by 
stress. The activity of MAR-binding proteins, p114, was found only in human cancers 
especially breast carcinoma and in poorly differentiated tissue rather than well differentiated 
carcinoma (Yanagisawa et al., 1996). This protein may play an important role in breast 
tumourigenesis and is effective as a diagnostic and prognostic marker. The down regulation 
and mislocalisation of genes is caused by the loss of MAR-binding protein in malignant cells 
(Woynarowski, 2004). Therefore, MARs and MAR-binding proteins are attractive therapeutic 
targets in cancer and promising for further drug discovery.  
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Figure 1.4: Mammalian Interphase Nuclear Architecture  
Cartoon of nucleus is displaying the genome organisation and nuclear structure that 
contribute to the overall interphase nuclear architecture. The figure shows an overview of 
essential nuclear substructures that contains chromosome territories (CTs) and interchromatin 
(IC) space, nuclear pore complexes (NPCs), the inner and outer nuclear membrane (INM and 
ONM), and the nuclear lamina (NL) at the nuclear periphery. In addition to, chromatin loops 
with active loci going to transcription machineries and RNA transcripts that are extended 
from chromosome territories to that share transcription sites (van Steensel and Dekker, 2010). 
A diverse set of nuclear bodies (NBs) (site for post-transcriptional and processing of RNA 
modification in the nucleus and for other nuclear functions such as apoptosis, cell cycle 
regulation, and viral infection control (Gall, 2000)), such as speckles, paraspeckles, the 
perinucleolar compartment, Cajal bodies (CBs), or PML bodies are found in the 
interchromatin space. The spatial organisation of chromosomes is regulated by 
interchromosomal contacts, intermingling, and by interactions of specific chromosomal loci 
with nuclear 'landmarks' such as the nuclear envelope (NE), nuclear matrix, and the nucleolus 
with its three main components: the fibrillar centres (FC), the dense fibrillar component 
(DFC), and the granular component (GC) (Maggi and Weber, 2005). Therefore, the nucleus 
is highly organised machinery that is required for proper nuclear functions and processes. 
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1.2.2 Nuclear Envelope (NE): 
The nuclear envelope (NE) is composed of two lipid bilayers and is made up of the nuclear 
membrane (NM) and other proteins, with an inner and an outer nuclear membrane (INM and 
ONM). The INM and ONM are studded by the nuclear pore complexes (NPCs) that mediate 
and regulate molecules movement between the nucleus and the cytoplasm and are composed 
of multiple proteins (nucleoporins) (Rout et al., 2000) (Figure 1.6). The NM encloses the 
contents of the nucleus and separates the genetic material from the cytoplasm and serving as 
a barrier to prevent macromolecules from diffusing between the nucleoplasm and the 
cytoplasm (Chi et al., 2009). The ONM is continuous with endoplasmic reticulum (ER) and 
ribosomes; and the INM faces the nuclear interior, chromatin and nuclear lamina (Aaronson 
and Blobel, 1975; Gruenbaum et al., 2005; Guttinger et al., 2009; Roux et al., 2009; Zwerger 
et al., 2010). The integral membrane proteins, found in the INM, include lamin B receptor 
(LBR), lamin associated polypeptides 1 and 2 (LAP1 and LAP2), emerin, MAN1 and the 
nesprins (Zhang et al., 2001; Roux et al., 2009; Postel et al., 2011). The interaction between 
the nuclear lamina and chromatin is mediated through these integral nuclear membrane 
proteins at the nuclear edge (Morris, 2001). The space between the INM and ONM is called 
the perinuclear space or lumen and is 10-50 nanometres (nm) wide (Rout et al., 2000; Chi et 
al., 2009; Roux et al., 2009) (Figure 1.5).  
 
1.2.2.1 The Nuclear Lamina:  
1.2.2.1.1 Introduction to Nuclear Lamins: 
The nuclear lamina is a polymeric protein meshwork of 10 nm filaments (Gerace, 1986; Lin 
and Worman, 1997). It is subjacent to the INM and is a complex network of type V 
intermediate filaments (IF) proteins, the nuclear lamins (Fisher et al., 1986; Moir et al., 
2000b). The lamina provides the mechanical and structural support for the nuclear membrane 
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(NM) and anchoring sites for chromosomes and nuclear pores (Aebi et al., 1986; Lehner et 
al., 1986; Gerace, 1988; Goldman et al., 1992; Bridger et al., 1993; Moir et al., 2000a/b; 
Malhas et al., 2007; Parnaik 2008; Martin et al., 2009; Roux et al., 2009; Kubben et al., 
2010; Peric-Hupkes and van Steensel, 2010; Dittmer and Misteli, 2011; Helfand et al., 2012). 
The nuclear lamina is composed of A-type and B-type lamins and lamins binding proteins 
(Gerace and Blobel, 1980). The interaction between lamins, chromatin and transcription 
factors at the inner nuclear membrane is more specific. The lamina forms associations with 
heterochromatin, histones and lamin binding proteins such as emerin, LAP2α and LAP2β, 
lamin B receptor (LBR, p58) and MAN1 (Figure 1.6). This interaction is important to 
regulate transcription and gene expression.  
 
1.2.2.1.2 Lamin Genes, Structures and Expressions: 
Lamin genes, found in all metazoan, are divided into A-type lamins which are regulated and 
expressed in many differentiated cells. A-type lamins are 70 and 60 kilodaltons (Gerace and 
Blobel, 1980; Goldberg et al., 2008b), are encoded by the LMNA gene located on 
chromosome 1q21.2-q21.3 (Wydner et al., 1996; Lin and Worman, 1997) and are generated 
by alternative splicing to produce different isoforms, lamins A, A∆10, C and C2, which are 
all found in different cell types (Foster and Bridger, 2005; Martin et al., 2009). Lamin C2 is 
restricted only to spermatocytes during rat spermatogenesis whereas, A∆10 is found only in a 
few carcinoma cell lines (Alsheimer and Benavente, 1996). A∆10 results from the deletion of 
exon 10 (Hutchison, 2002) and is localised at the nuclear envelope (Broers et al., 1999). The 
LMNA gene contains 12 exons. Exon 1 codes for the N-terminal head domain and the first 
part of the central rod domain of this gene. Exon 2-6 code for the central α-helical rod 
domain. Exons 7-9 code for the C-terminal tail domain for lamin A and lamin C. The nuclear 
localisation signal (NLS) is contained in exon 7. Exon 10 contains a splicing site to generate 
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lamin A and lamin C. Exon11 and 12 are specific for lamin A and coding for the CAAX box 
of pre-lamin A (Lin and Worman, 1993). In mammalian cells, lamins A and lamins C share 
the first 566 amino acids and differ by length of 98 and 6 amino acids, respectively at the C-
terminus (Gerace, 1988; Lin and Worman, 1995; Sasseville and Raymond, 1995).  
 
There are three types of B-type lamins (67 kilodaltons) in mammals: lamin B1, lamin B2 and 
lamin B3. Lamins B1 and lamins B2 are regulated and expressed in both embryonic and 
somatic cells during development whereas lamins B3 is regulated and expressed only in 
spermatocytes (Gerace and Blobel, 1980; Furukawa and Hotta, 1993; Lin and Worman, 1995; 
Alsheimer and Benavente, 1996; Furukawa and Kondo, 1998; Hutchison, 2002; Goldberg et 
al., 2008b). Lamin B1 is encoded by LMNB1 and lamin B2 and lamin B3 are encoded by 
LMNB2 genes on chromosomes 5q23.2-q31.3 and 19p13.3, respectively (Lin and Worman, 
1995; Wydner et al., 1996; Lin and Worman, 1997; Dechat et al., 2008). LMNB1 gene 
contains 11 exons. Exon 1 codes for the N-terminal head domain and the first part of the 
central rod domain of this gene. Exon 2-6 code for the central α-helical rod domain. Exons 7-
11 code for the C-terminal tail domain of lamin B. The nuclear localisation signal (NLS) is 
contained in exon 7. Exon11 contains a specific sequence for the CAAX box lamin B for 
post-translational farnesylation (Lin and Worman, 1993) (Figure 1.5).  
 
The lamins contain a central α-helical coiled-coil rod domain of 350 amino acids flanked by 
non-helical N-terminal head (4 KDa) and C-terminal tail (20-30 KDa) domain with a globular 
structure (Aebi et al., 1986; Gerace, 1986, 1988; Stuurman et al., 1998) and four subsegments 
(1A, 1B, 2A, and 2B) able to form coiled coils. These α-helical segments are separated by 
linkers, L1, L12 and L2 (Parry and Steinert, 1999; Bridger et al., 2007). This rod domain is 
responsible for the dimerisation of the lamin proteins and is also required for interactions of 
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the lamin dimers into the polymerised structure to form the nuclear lamina (Stuurman et al., 
1998). The roles of the head and tail domains IF in nuclear lamins structure, assembly and 
network formation in vivo and in vitro more systematically. N-terminal head domain 
promotes lateral association into filaments and C-terminal tail domain controls lateral 
assembly so that it terminates at 10 nm filaments level and this will participate in the 
formation of IF network through their binding to chromatin. The head to tail overlap gives 
rise to filaments thickenings (Gerace, 1988; Stuurman et al., 1998). The nuclear localisation 
signal (NLS) between the central rode and C-terminal tail domain is required for the transport 
of lamins into the nucleus (Dechat et al., 2008). Lamin dimers are stable under high pH and 
salt conditions (Gerace, 1986; Bridger et al., 2007). In addition, A-type  lamins form foci 
within the nucleoplasm that are distinct from peripheral lamina  (Bridger et al., 1993; Hozak 
et al., 1995; Goldman et al., 2002), as do B-type lamins which are associated with sites of 
DNA replication (Moir et al., 1994; Sasseville and Raymond, 1995). 
 
1.2.2.1.3 Lamins Biosynthesis and Assembly: 
Lamin classification is based on their sequence homology, expression, biochemical 
properties, and localisation during mitosis (Gerace and Blobel, 1980; Aebi et al., 1986; 
Gerace, 1988). Nuclear lamins differ from cytoplasmic IF proteins such as vimentin in their 
central α-helical rod domain which is 40-50 amino acids longer than cytoplasmic IF proteins. 
Lamins reveal strong homologies in their α-helical rod domain and contain a structural 
similar to immunoglobulin fold (Ig-fold) within their C-terminal tail domain (Herrmann and 
Aebi, 2004; Dechat et al., 2008).  
 
Pre-lamin B contains a CAAX box motif at the carboxyl-terminal (Cysteine, Aliphatic, 
Aliphatic, any of several residues) (Lutz et al., 1992) for processing and maturation, post-
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translation modifications to be more mature and active. The post-translational modifications 
and the formation of mature and active lamins through farnesylation by adding a farnesyl 
group to the cysteine residue of the C-terminal (via farnesyltransferase) (Figure 1.4) that 
promotes pre-lamin B to be associated to the nuclear membrane (Beck et al., 1990). Pre-
lamins B undergo cleavage to loose the last three amino acids by endoproteolysis on the 
AAX amino acids using Ras converting enzyme 1, Rce l (FACE2 in humans). In order for 
lamins B to be mature and active, lamins B at the C-terminus is carboxymethylated (via 
isoprenylcysteine carboxyl methyltransferase, ICMT) (Beck et al., 1990; Corrigan et al., 
2005; Prokocimer et al., 2009). After lamin Bs have completed their post-translation 
modification process then accumulated within the nucleus as isoprenylated proteins. 
 
After B-type lamin localisation, pre-lamin A undergoes the post-translational modifications 
and the formation of mature and active lamins through farnesylation by adding farnesyl group 
to the C-terminal (farnesyltransferase) (Figure 1.5). Furthermore, lamin A undergo cleavage 
to loss the last three amino acids by endoproteolysis on the AAX amino acids using 
ZMPSTE24 (FACE1 in humans). Zinc metalloproteinase (ZMPSTE24, FACE1) is involved 
in the post-translational proteolytic process of carboxy terminal residues of farnesylated pre-
lamin A to form mature lamin A. Once the farnesyl group is lost, lamin A becomes 
incorporated into the nuclear lamina. If the farnesyl group is not cleaved, the protein remains 
associated with the nuclear envelope and is not released and inserted into the nuclear lamina 
(Holtz et al., 1989). In order for lamin A to be mature and active, lamin A at the C-terminal is 
carboxymethylated (isoprenylcysteine carboxyl methyltransferase, ICMT) (Beck et al., 1990; 
Corrigan et al., 2005; Prokocimer et al., 2009).  The next stage is followed by additional 
cleavage resulting in a loss of 15 amino acids and the farnesyl group at the C-terminal using 
ZMPSTE24 (FACE1) (Sasseville and Raymond, 1995; Naetar and Foisner, 2009; Prokocimer 
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et al., 2009). This final step for post-translational modification processes is thought to be 
important for lamin A maturation and incorporation into the lamina. However, the difference 
between processing of lamins A from that of lamins B is a further endoproteolytic cleavage 
of 15 amino acids from the C-terminal (Sasseville and Raymond, 1995) (Figure 1.5). These 
steps are essential for stable association of lamins with the nuclear periphery as well as their 
role in DNA synthesis, DNA replication, RNA processing and gene expression. Moreover, 
these steps of processing and modification are important and critical for lamins localisation 
that means blocking the farnesylation, will inhibit lamins post-translation processing. 
 
Lamin C and lamin C2 do not undergo any post-translational modifications and have no 
CAAX box motifs at their C-terminus (Fisher et al., 1986; Beck et al., 1990; Vergnes et al., 
2004; Malhas et al., 2007) (Figure 1.5). Furthermore, Lamin C2 (52 KDa) shows its 
similarities with lamin C because it has a sequence identical to that of lamin C except that the 
N-terminal segment, containing the head and the alpha-helical coil 1A domains, is replaced 
with a short non-alpha-helical stretch of amino acids. In mice, lamin C2 was found to be 
specifically expressed in germ cells (Furukawa et al., 1994). 
 
Interestingly, inhibition of lamin farnesylation does not inhibit their incorporation into the 
lamina. For example, lamin C that lack 98 amino acids in their C-terminal and only have 6 
amino acids lacking a CAAX box become incorporated into the nuclear lamina (Dechat et al., 
2008). Different studies showed that pre-lamin A is modified and cleaved with a half-life of 
90-100 minutes in order for assembly into the lamina (Sasseville and Raymond, 1995). Their 
assembly starts with the formation of coiled coil dimers which is associated with head to tail 
overlap. Whether this occurs during translation or post-translation is unknown. During 
interphase, the lamins are localised in the nuclear envelope resulting in a rim at the nuclear 
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periphery and become dephosphorylated and polymerised at the nuclear periphery during 
telophase (Burke and Gerace, 1986; Foisner
 
and Gerace, 1993). During mitosis, A-type 
lamins are disassembled into monomers (Gerace and Blobel, 1980 and Prokocimer et al., 
2009) and become associated with mitotic chromosome surfaces. A-type lamins are found in 
a soluble form and have a neutral isoelectric point whereas B-type lamins are bound to 
nuclear membrane vesicles and participate in nuclear envelope assembly and disassembly 
(Gerace and Blobel, 1980; Burke and Gerace, 1986; Gerace, 1988; Georgatos et al., 1997; 
Prokocimer et al., 2009). During prophase, after the disassembly of lamins, A-type lamins 
become dispersed throughout the cytoplasm and lose their association with chromosomes. 
The lamins remain disassembled until the nuclear envelope begins to reform during early 
telophase and when they start to associate with the surface of chromosomes and this assembly 
of lamins is completed by late telophase and after the nuclear rim appearing in early G1 when 
chromatin decodensation has occurred (Gerace, 1986). The disassembly is due to 
phosphorylation and depolymerisation into a monomeric form which is a reversible process 
from dimeric or tetrameric forms (Gerace and Blobel, 1980; Georgatos et al., 1997). 
Moreover, the changes in the structure during the various phases of the cell cycle are identical 
for all cells of the same differentiated state (Blobel, 1985). These processes allow nuclear 
structure and genome to reorganise and reform in the daughter cell nuclear membranes.  
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Figure 1.5: The Structure and Biogenesis of Lamins in Normal Cells 
The steps of processing lamin B and modifications, through farnesylation by 
Farnesyltransferase, endoproteolysis by ZMPSTE24 (FACE1) or Rce1 (FACE2) and 
carboxymethylation by ICMT, are essential for activation and maturation, stable association 
of lamins with the nuclear periphery, DNA synthesis, DNA replication, RNA processing and 
gene expression, and lamins localisation into the lamina. Excluding, Lamin A again 
undergoes second cleavage that requires ZMPSTE24 to remove the last 15 amino acids 
(Dechat et al., 2008). Since lamin C lacks this CAAX motif, it does not undergo these post-
translational modifications and their localisation at the nuclear envelope depends on lamin A 
(Vaughan et al., 2001). Thus, blocking the farnesylation will inhibit lamins post-translation 
processing (Dechat et al., 2008). 
1׀=First Cleavage Site and 2׀= Second Cleavage Site.  
 
 
 
 
1.2.2.1.4 Lamin Foci and Functions: 
Lamins are not only components of the lamina but also found in the nucleoplasm. The 
nuclear A-type lamins and B–type lamins can also be found in internal foci within the 
nucleoplasm (Goldman et al., 1992; Lutz et al., 1992; Bridger et al., 1993; Moir et al., 1994; 
Prokocimer et al., 2006). Studies have shown that lamin A is found within the nucleoplasm 
during G1 phase of the cell cycle forming internal foci structures (Bridger et al., 1993; Hozak 
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et al., 1995; Sasseville and Raymond, 1995). Non-prenylated pre-lamin A accumulat in 
intranuclear foci suggesting these foci act as storage sites (Lutz et al., 1992). Lamins B foci 
are prominent in mid and late S-phase and co-localised with sites of DNA replication. Lamins 
B1 play an important role in DNA replication, cellular ageing, and stress responses (Sun et 
al., 2010).  
 
Both lamin A and lamin B do not co-localise with each other and each one has its own 
localisation (Moir et al., 1994). The role of this localisation within the nucleoplasm is 
unknown, but it may be these foci considered as sites for lamins isoprenylation, lamins 
unable to bind to the lamina or may be associated with sites for DNA replication (Stuurman 
et al., 1998). The foci can associate with transcription factories (TFs) and retinoblastoma 
(pRB) proteins to induce cell proliferation. pRB dependent E2F activity is also involved in 
organising nuclear structure, gene expression, maintaining nuclear integrity, DNA 
replication, DNA repair, apoptosis, transcription process, genome organisation, and cell cycle 
control and regulation (La Thangue, 1995; Weinberg, 1995; Garrett, 2001; Naetar and 
Foisner, 2009).  
 
Nuclear lamin A and C are present in different cell organisms can interact with 
polynucleosomes and mitotic chromosome (Lin and Worman, 1993). However, down-
regulation and instability of nuclear lamins play important roles in the infection cycles of 
viruses and some cancers (Dechat et al., 2008). Different expression between nuclear lamins 
A and lamins B support the idea of their alternative functions during development and 
differentiation. The absence of lamin A/C from undifferentiated cells is responsible for the 
deformation of the nuclei in these cells. For example, lamin A is present in late embryos but 
not expressed in blastocysts whereas lamin A/C is expressed in oocytes (Prather et al., 1989; 
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Bridger et al., 1993). Foster et al., in 2007, have shown that A-type lamins and B-type lamins 
are present at the nuclear envelope in early porcine embryos and that lamin A is also found in 
large intranuclear aggregates in two-cell to eight-cell embryos but is lacking from later 
embryonic stages (Foster et al., 2007). 
 
1.2.3 Lamins and Nuclear Functions: 
1.2.3.1 Lamins and DNA Replication: 
The precise regulation of DNA replication is fundamental to the preservation of intact 
genomes during cell proliferation. The higher order chromatin structures and the spatial 
architecture of replication sites contribute to the replication of specific regions of the genome 
at precise times of S phase (Maya-Mendoza et al., 2012). From the literature, the nuclear 
matrix, a platform for network proteins including lamins, is required for efficient DNA 
replication. The DNA is found to be associated with the nuclear matrix regions (Berezney 
and Coffey, 1975). Several enzymes which participate in DNA replication are also attached 
to the nuclear matrix such as histone transferases, DNA polymerases, nucleases, DNA 
primases, DNA helicases, single strand DNA binding proteins, and topoisotopomerases 
(Jackson and Cook, 1993; Jackson et al., 1996; Chagin et al., 2010). Other studies reveal that 
replication sites, these anchored by B-type lamins (Hassan and Cook, 1993; Hozak et al., 
1993; Hozak et al., 1994; Moir et al., 1994; Okamoto et al., 2011). This attachment to the 
nuclear matrix is important for the initiation of replication (Djeliova et al., 2001; Radichev et 
al., 2005; Chagin et al., 2010). However, origins of replication are not associated with the 
nuclear matrix throughout the cell cycle; they only associate with the structure in late G1 and 
released in early S phase (Djeliova et al., 2001). Most DNA synthesis occurs in specific 
dense structures (replication factories) attached to the nuclear matrix. These factories appear 
at the end of G1 phase and quickly become active when S phase progresses, they increase in 
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size and decrease in number. These factories are a subset of nuclear bodies; they change in 
their characteristics and contained DNA polymerase I (Ellis et al., 1997). The involvement of 
lamins in DNA replication requires correct lamins organisation. When this lamin organisation 
disrupted, it results in nuclei that do not replicate their DNA (Ellis et al., 1997; Goldman et 
al., 2002).   
 
Other studies suggest that lamins play a more direct role in DNA synthesis since the 
organisation of initiation factors was not altered by lamin disruption. This suggests that 
alteration of lamin organisation does not affect the initiation phase of DNA replication 
(Spann et al., 1997; Moir et al., 2000a). During S phase, lamins colocalise with proliferating 
cell nuclear antigen (PCNA), a factor that is required for the elongation phase of DNA 
replication, at sites of replication (Moir et al., 1995). Furthermore, the normal localisations of 
both PCNA and RFC, another factor that is required for the elongation phase of DNA 
replication, are altered when lamin organisation is disrupted (Moir et al., 2000a). Therefore, 
disruption of nuclear lamin organisation blocks the elongation phase of DNA replication 
(Spann et al., 1997; Moir et al., 2000a). Nuclear lamins may form a nucleoplasmic scaffold 
upon which the active elongation complexes required for DNA synthesis are assembled. 
However, other experiments have suggested that nuclear lamins may only be required to 
initially organise replication factors and once this occurs, lamins may no longer be required 
for DNA synthesis (Ellis et al., 1997). For understanding this hypothesis, this will require 
both the identification and characterisation of additional factors that interact with nuclear 
lamins during DNA synthesis. 
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1.2.3.2 Lamins and Transcription: 
It is important to understand that the nuclear matrix provides the foundation for transcription 
factories. RNA polymerase I and II are mediated by active transcription and attached to the 
nuclear matrix (Jackson et al., 1996; Iborra et al., 1996; Chakalova and Fraser, 2010). 
Therefore, transcriptionally active genomic regions are associated with the nuclear matrix 
while inactive regions are not (Ciejek et al., 1983; Gerdes et al., 1994). Transcription factors 
such as estrogen receptor (Alexander et al., 1987; Metzger and Korach, 1990), steroid 
hormone receptor (Barrack, 1987), and corticosteroid receptor (van Steensel et al., 1991) are 
nuclear matrix associated. Furthermore, elements required for ribosomal assembly, pre 
mRNA processing and splicing including nucleophosmins and spliceosomes, are also 
attached to the nuclear matrix (Zeitlin et al., 1987; Mattern et al., 1996). 
 
Functional nuclear matrix is required to support transcription and this process is perturbed 
when lamins are missing or mutant. The presence of mutant lamin A inhibits the activity of 
RNA polymerase II (Spann et al., 2002) whereas depleting lamin B1 disrupts RNA synthesis 
(Tang et al., 2008). In Xenopus, lamin B3 has a direct role in the assembly of a replication 
competent nucleus (Goldberg et al., 1995). Cancer cells that lose their differentiated 
phenotype express lower levels of lamin A (Venables et al., 2001). The specific function of 
lamins in transcription remains unknown. However, transcriptionally active genes and 
transcription factors have been identified in specific sites on the nuclear matrix. More 
specifically, Oct-1, a repressor of the collagenase gene, colocalises in the nuclear periphery 
with lamin B (Imai et al., 1997). The finding that the retinoblastoma protein (pRB) interacts 
with A-type lamins in vivo and in vitro supports the role of lamins in transcription regulation 
(Mancini et al., 1994; Ozaki et al., 1994; Kennedy et al., 2000). Rb represses the 
transcription of genes through its interactions with E2F (Kaelin, 1999). Interestingly, the 
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disruption of lamin organisation also alters the distribution of the TATA box binding protein, 
a component of transcription factor TFIID, which is required for polymerase II activity and 
transcription initiation. These results indicate that lamins may interact with the basal 
transcriptional machinery and provide a scaffold for the assembly or stabilisation of active 
transcription complexes. Lamin binding proteins (LAP2β) have also been implicated in 
transcription through their interaction with E2F transcription factor and chromatin (Gant et 
al., 1999). In mammalian cells, GCL, essential for germ cell formation and localised to the 
nuclear envelope, co-localises with LAP2β to the nuclear envelope and interact with the E2F 
transcription factor. This interaction can reduce the transcriptional activity of the E2F. LAP2β 
is also capable of reducing the transcriptional activity of the E2F. Co-expression of both 
LAP2β and GCL with the E2F complex resulted in a reduced transcriptional activity equal to 
that produced by the pRB protein (Gant et al., 1999; Nili et al., 2001). The binding between 
LAP2β proteins that are reduced E2F activity during cell cycle and B-type lamins that are 
involved in DNA replication, thus LAP2β might also be involved in DNA replication either 
directly or indirectly by affecting lamina assembly during cell cycle (Foisner, 2003). 
 
The interaction of lamins, lamin binding proteins, and transcription factors raises the 
possibility of a common defective mechanism in diseases and cancers. This mechanism could 
be the regulation of gene expression, which is normally dependent on correct interactions 
between transcription factors, chromatin and proteins of the nuclear envelope. 
 
1.2.3.3 Lamins and DNA Repair: 
The nuclear matrix is thought to act as a platform for the regulation of cell cycle progression 
and DNA repair. In addition, its role in chromatin modelling, replication and transcription. 
DNA repair occurs at the nuclear matrix where homologous recombination proteins are 
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anchored such as Rad51. Spatial organisation of the genome represents an important role in 
the regulation of nuclear functions. Mutations in the LMNA gene or changes in its expression 
are associated with defects in DNA replication, transcription and repair, as well as alterations 
in epigenetic modifications of chromatin (Hutchison and Worman, 2004). Defects in A-type 
lamins are associated with a whole variety of degenerative disorders, premature ageing 
syndromes and cancers and this supports the hypothesis that these proteins are considered as 
the guardian of the genome. A-type lamins control transcription and degradation of proteins 
with important roles in cell cycle regulation and DNA double strand breaks (DSBs) repair 
(Warren and Shanahan, 2011) by non-homologous end-joining (NHEJ) and homologous 
recombination (HR). Importantly, the proteins that are binding by A-type lamins such as RB 
family members and BRCA1 accelerate tumour suppressor functions and their loss is 
associated with cancer susceptibility (Redwood et al., 2011). Repair of damaged DNA is 
critical for maintenance of genomic stability. DSBs are harmful to the genome, leading to 
mutations, loss of genomic material, and translocations if not properly repaired. 
 
1.2.3.4 Lamins and Apoptosis: 
Apoptosis (programmed cell death) is a process that is required for the normal development 
and homeostasis of tissues and can also be activated in response to cancer, viral infection, or 
stress (Gruenbaum et al., 2000). Apoptosis is characterised by reduction in nuclear size and 
chromatin condensation which is accompanied by chromatin fragmentation. The nucleus 
fragments into small parts containing highly condensed chromatin. Interestingly, lamin 
assembly may also be involved in triggering apoptosis, as inhibition of the assembly of lamin 
B induces cell death (Steen and Collas, 2001). The nuclear lamins are the first proteins 
identified as caspase targets which begins before DNA cleavage or chromatin condensation 
are detected (Gruenbaum et al., 2000) and the cleavage of the lamins is used as a marker for 
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caspase activation and the induction of apoptosis. The single caspase cleavage site of lamin A 
was mapped to aspartic acid 230 (Takahashi et al., 1996). This residue lies in the 2B region 
of the central rod domain, which is one of the most highly conserved regions in all known 
intermediate filament proteins. This domain is critical for polymerisation of IF proteins into 
higher order structures (Stuurman et al., 1998). The cleavage of lamins by caspases probably 
serves to disassemble the lamina during apoptosis and this disassembly may be essential for 
nuclear apoptosis to be completed successfully (Okinaga et al., 2007). Lamin degradation 
appears to play a critical role in shutting down vital nuclear processes during apoptosis. 
 
1.2.3.5 Lamins and Viral Infection: 
There is increasing evidence that lamins play a role in viral infection. The replication cycle of 
cytomegalovirus (CMV) and herpes simplex virus type-1 (HSV-1). Both members of the 
Herpesviridae family, assemble their capsids and encapsidate their DNA in the nucleus, 
while the final steps in the maturation of virions takes place in the cytoplasm (Mettenleiter et 
al., 2006). The nucleocapsids exit from the nucleus in a two-step process involving primary 
envelopment at the INM and fusion of their primary membrane with the ONM to facilitate 
their movement into the cytoplasm. In order to gain access to the INM, the nuclear lamina has 
to be destabilised by phosphorylation and disassembly of the lamins specifically in locations 
where viruses are accessing the INM (Radsak et al., 1991). Lamin A and its binding proteins 
(BAF, LAP2α, and emerin) have also been implicated in viral infections. BAF is involved in 
the incorporation of retroviral cDNA into the genome of host mammalian cells (Segura-
Totten and Wilson, 2004) and LAP2α stabilises this association. Emerin is required for the 
efficient integration of viral cDNA into the host genome in HIV1 infections in primary 
macrophages (Jacque and Stevenson, 2006). It is obvious that lamins and several of their 
binding proteins are involved in distinct processes of the infection cycles of various viruses. 
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1.2.3.6 Lamins and Diseases: 
Mutation or mis-organisation in lamin and other binding protein genes disturbs the nuclear 
activities and functions and may lead to laminopathies such as X-linked Emery-Dreifuss 
Muscular Dystrophy (X-EDMD) and some cancers. Mutations in B-type lamins are 
considered to be lethal and very few defects have been reported in the expression. In mice, 
the expressed mutated lamin B1 have more severe effects and they die from respiratory 
failure and prenatal lethality in addition to abnormalities in other organs (Vergnes et al., 
2004; Martin et al., 2009; Chi et al., 2009). This supports the idea that lamin B1 is required 
during development and associated with sites of DNA replication in early S-phase and not G1 
(Moir et al., 1994; Vergnes et al., 2004; van Steensel and Dekker, 2010). Lamin B is required 
to anchor peripheral chromosomes and any disruption of this interaction may lead to 
chromosomal relocation and up regulation of genes expression on these chromosomes during 
interphase (Malhas et al., 2007). In the central nervous system, lamin B1 expression is crucial 
for oligodendrocyte development and myelination (Lin and Fu, 2009). Mutations in LMN 
genes lead to genetic diseases that affect a number of different tissues such as muscle, 
adipose, and neuronal tissues. The interactions of lamins with INM proteins, chromatin, and 
various regulatory factors are considered to be the basis of the role of lamins in cellular 
processes and tissue specific signalling pathways (Parnaik, 2008). 
 
1.2.3.6.1 Laminopathies: 
Diseases caused by mutations in genes encoding nuclear lamins or lamin binding proteins are 
termed “laminopathies”. They are diverse range of tissues specific diseases. LMNA gene can 
have different mutations in different regions resulting in different laminopathies, this 
highlights the variety of processes and functions that A-type lamin are involved in disease 
include Emery-Dreifuss Muscular Dystrophy (EDMD) that is caused by mutations in lamin A 
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and emerin and affects skeletal muscles, tendons and heart whereas, Progeria is caused by 
mutations in lamin A and also affect similar tissues skin, hair, fat, muscle, bone and 
cardiovascular system (Gruenbaum et al., 2005). Mutations in emerin can cause Limb-Girdle 
muscular dystrophy (Hutchison et al., 2001; Dechat et al., 2008). Heterozygous MAN1 
(LEMD3) mutations cause osteopoikilosis, Buschke-Ollendorff syndrome, and 
melorheostosis, characterised by increased bone density (Hellemans et al., 2004). This 
pathological effect may result from impaired MAN1 regulation of Smad signalling, which is 
important for bone development. With respect to lamin B regulation, the over-expression of 
B-type lamin knock-out mice die soon after birth (Vergnes et al., 2004). The over-expression 
of B-type lamins cause autosomal dominant leukodystrophy (Barraquer Syndrome) (Padiath 
et al., 2006). LBR, that regulates sterol reductase, also binds lamin B and is required for 
correct nuclear shape and reorganises chromatin in differentiating neutrophils (Hoffmann et 
al., 2002). Heterozygous LBR mutations cause Pelger-Huet anomaly, a benign autosomal 
dominant syndrome characterised by abnormal nuclear shape and chromatin organisation in 
blood granulocytes (Hoffmann et al., 2002). Greater loss of LBR protein correlates with more 
severe phenotypes, including developmental delay, epilepsy, and skeletal abnormalities 
(Hoffmann et al., 2007). Mutations that significantly reduce the sterol reductase activity of 
LBR are linked to autosomal recessive Greenberg’s skeletal dysplasia, characterised by lethal 
skeletal and visceral anomalies (Waterham et al., 2003). 
 
1.2.3.6.2 Summary of Diseases that are Associated with LMNA Mutations:  
Some of the examples of laminopathies with preferential involvement of skeletal and cardiac 
muscle, range from muscular dystrophies to cardiac defects such as in Emery-Dreifuss 
muscular dystrophy (EDMD), Muscular dystrophy limb-girdle type 1B (LGMD1B), and 
Cardiomyopathy dilated 1A (CMD1A); lipodystrophies, which specifically affect adipose 
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tissues such as familial partial lipodystrophy (FPLD);  neuropathy disorders, which affect the 
motor and sensory neurons of the peripheral nervous system such as Charcot-marie-tooth 
disease (CMT); systemic laminopathies, which are heterogeneous disorders involving 
multiple tissue systems such as mandibuloacral dysplasia (MAD), Restrictive Dermopathy 
(RD), Heart-Hand syndrome, and mutations associated with premature ageing disorders. 
Mutations affecting amino acids 1 to 566 affect both lamin A and C isoforms, whereas 
mutations found in the carboxy-terminal 566 to 664 amino acids are specific to the lamin A 
isoforms such as Hutchinson-Gilford progeria syndrome (HGPS) and a typical Werner 
syndrome (WRN)  (Dittmer and Misteli, 2011).  
 
1.2.4 Lamin Binding Proteins: 
The roles of lamins are mediated by interactions with numerous lamin binding proteins both 
at the nuclear periphery and/or in the nucleoplasm. There are many inner nuclear membrane 
(INM) proteins bind to lamins either directly or indirectly. For example, lamins bind in vitro 
to INM proteins: emerin, MAN1, LBR, LAP1, LAP2β, nesprin, otefin, and SUN1 (Foisner, 
2003). Lamins can also bind non integral proteins including chromatin, histone (H2A/H2B) 
(Höger et al., 1991), transcription factors (E2F), RNA polymerase II transcription machinery 
(Mattout-Drubezki and Gruenbaum, 2003), pRb (Dorner et al., 2007), BAF (Barrier to 
Autointegration Factor) (Furukawa, 1999), LAP2α, extracellular signal-regulated kinase 
(Erk), nuclear actin, and proteins of the nuclear pore complex such as nucleoporin (Nup153) 
(Vlcek et al., 2001; Mattout-Drubezki and Gruenbaum, 2003; Dechat et al., 2008; Olins et 
al., 2010). The actual in vivo interactions between lamins, DNA, chromatin and the INM 
remain unclear. However, interaction must be specific and reversible to allow nuclear growth 
and disassembly during mitosis. After mitosis and during interphase, the reorganisation of 
nuclear lamina and its assembly at the nuclear periphery is elicited by the IMPs. Most of 
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these proteins can bind directly to lamin A, lamin B or both (Wilson and Foisner, 2010) 
(Figure 1.6).  
 
1.2.4.1 Lamin Associated Proteins (LAP): 
Several integral membrane (IMPs) proteins known as lamin binding proteins are found at the 
nuclear periphery and this include Lamin Associated Proteins 1 and 2 (LAP1 and LAP2).  
LAP1 (LAP 1A, 1B, and 1C) are found at the nuclear membrane and require high 
concentrations of monovalent salts and nonionic detergents to extract them from nuclei 
(Senior and Gerace, 1988; Foisner and Gerace, 1993). They arise by alternative splicing, and 
interact with the genome (Foisner and Gerace, 1993; Pyrpasopoulou et al., 1996). LAP1C has 
a transmembrane domain and is localised in the nucleoplasm (Martin et al., 1995). LAP2α 
lacks a transmembrane domain, localises to the nuclear interior and specifically binds lamin 
A (Harris et al., 1994). LAP2β has the specificity to bind B-type lamins and heterochromatin 
as well as to different other histones, such as HP-1 (Foisner and Gerace, 1993; Harris et al., 
1994; Bridger and Bickmore, 1998). This binding is responsible for attaching the nuclear 
lamina to the INM. LAP2α has N-terminal nucleoplasmic domain containing 
phosphoacceptor sites for CDC2 kinase and a C-terminal hydrophobic domain which codes 
for transmembrane segments. The physiological role of LAP2α and lamin A complexes bind 
directly to pRB and are involved in the pRB activity of E2F/pRB target gene (Furukawa, 
1994; Wilson and Foisner, 2010). LAP2β has N-terminal domain residing in the nucleoplasm 
and C-terminal domain localised in the lumen between the INM and the ONM. This protein 
can bind HA95 which is a chromatin protein involved in DNA replication (Martins et al., 
2003; Wilson and Foisner, 2010). LAP2 has critical roles in genetic disorders and 
hematopoietic malignancies. LAP2 is widely over-expressed in diverse digestive tract cancers 
and this increase the motility of cancer cells. LAP2β is over-expressed in gastric cancer 
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tissues. Knockdown of LAP2β did not affect the proliferation of most digestive tract cancer 
cells except pancreatic cancer cells whereas; over-expression of LAP2β increased motility of 
gastric and pancreatic cancer cells (Kim et al., 2012) (Figure 1.6). 
 
1.2.4.2 Lamin B Receptor: 
 Lamin B Receptor (LBR or p58, 58 kDa) is an integral membrane protein of the interphase 
nuclear envelope with a structural function interacting with chromatin and lamins, and an 
enzymatic function as a sterol reductase (Worman et al., 1990; Ye and Worman, 1994). It has 
eight transmembrane receptors with functional domains. The LBR required high KCl/Triton-
X-100 to be extracted from the nuclear envelope (Worman et al., 1990; Ye and Worman, 
1994; Meier and Georgatos, 1994; Ye and Worman, 1996; Wydner et al., 1996; Silve et al., 
1998; Olins et al., 2010). It is a receptor to lamin B. Human LBR contains 615 amino acids 
(aa), the N-terminus (~208aa) resides in the nucleoplasm binding to both lamin B and 
heterochromatin with these interactions disrupted during mitosis. The N-terminal region also 
contains three DNA-binding motifs that are found in gene regulatory proteins and histones, 
suggesting that the LBR may additionally play a role in gene regulation and/or chromatin 
organisation (Worman et al., 1990). While the C-terminus (~407aa) resides within the inner 
nuclear membrane, it remains connected with B-type lamins during mitosis, exhibits sterol 
Δ14-reductase activity and is involved in the conversion of 7-dehydrocholestrol to cholestrol 
(Ye and Worman, 1996; Silve et al., 1998; Olins et al., 2010). LBR is a substrate for several 
protein kinases including p34 and p58 kinase (Ye and Worman, 1994). LBR, LAP1A and 1B 
and LAP2 bind to lamin B whereas LAP1A and 1B again bind both to lamin A. LBR also 
binds directly to heterochromatin (HP1α and HP1γ); which is thought to participate in gene 
silencing and play important role in nuclear membrane-chromatin interaction as well as its 
interaction with HA95, LAP2β, and emerin (Ye and Worman, 1994; Pyrpasopoulou et al., 
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1996; Ye and Worman, 1996; Olins et al., 2010) (Figure 1.6). Heterozygous LBR mutations 
cause nuclear hyposegmentation in neutrophils (Pelger Anomaly), while homozygous 
mutations cause prenatal death with skeletal defects and abnormal sterol metabolism 
(Greenberg Dysplasia). It has remained unclear whether the lethality in Greenberg dysplasia 
is due to cholesterol defects or altered nuclear morphology (Hoffmann et al., 2002; 
Waterham et al., 2003; Clayton et al., 2010). Therefore, LBR mutations can affect sterol 
reductase activity, causing lethal Greenberg dysplasia but not Pelger anomaly. These findings 
separate the metabolic from the structural function and indicate that the sterol reductase 
activity is essential for human intrauterine development. In addition, LBR mutation can lead 
to other abnormalities including alopecia and hydrocephalus (Shultz et al., 2003; Clayton et 
al., 2010). In cancer, the lack of LBR at the NM in papillary thyroid carcinoma might be 
linked to LBR gene mutation or alterations in the expression of LBR (Fischer et al., 1998). 
 
1.2.4.3 Emerin:  
Emerin was first identified from the gene mutation on chromosome Xq28 causing X-linked 
recessive disease Emery-Dreifuss muscular dystrophy (X-EDMD). The emerin gene encodes 
a 254 amino acid type II integral membrane protein. Structural analysis predicts that emerin 
contains a transmembrane region at the C-terminus and a large hydrophilic N-terminal 
domain with multiple putative phosphorylation sites (Bione et al., 1994). In addition, emerin 
contains the LEM (LAP2, Emerin, and MAN1) domain that is common to a number of 
integral membrane proteins of the inner nuclear membrane, INM (Vaughan et al., 2001). 
Emerin is an IMP that has some homology to LAP2. It binds to transcription factors such as 
E2F/RB, actin, nesprin and also binds to lamin A and lamin C (Figure 1.6). In cells lacking 
functional A-type lamins, emerin is mislocalised to the endoplasmic reticulum (Sullivan et 
al., 1999; Burke and Stewart, 2002; Holaska et al., 2002; Dahl et al., 2008). Thus, its correct 
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nuclear localisation requires A-type lamins. Emerin colocalises with lamin proteins in vitro 
and in vivo (Hutchison et al., 2001; Vaughan et al., 2001). The specificity of this binding 
depends on its phosphorylation by CDC2 kinases during interphase and mitosis (Haque et al., 
2006).  
 
1.2.4.4 MAN1: 
The “MAN antigens” are polypeptides recognised by autoantibodies from a patient with a 
collagen vascular disease and localised to the nuclear envelope. MAN1 is a 82.3 kDa protein. 
The MAN1 (LEM3) gene is located on human chromosome 12q14 (Lin et al., 2000). A 
number of experiments show that MAN1 is an IMP of the INM and shares the LEM domain 
with LAP2β and emerin (Hellemans et al., 2004; Mansharamani and Wilson, 2005). The 
protein sequence analysis reveals that MAN1 shares a conserved globular domain of 
approximately 40 amino acids, associated with other inner nuclear membrane proteins, lamin 
A, lamin B1, LAP2β, and emerin (Lin et al., 2000; Mansharamani and Wilson, 2005). MAN1 
is located in the nuclear membrane and has a short C-terminus. MAN1 serves as a membrane 
anchor and play roles in nuclear positioning by connecting the nuclear membrane with the 
cytoplasm as well as its interaction with Smad proteins to regulate bone development (Haque 
et al., 2006). Over-expression of MAN1 results in inhibition of R-Smad phosphorylation, 
nuclear translocation, and repression of transcriptional activity of transforming growth factor 
beta (TGF-β) (Pan et al., 2005; Ishimura et al., 2006). It has been shown to regulate TGF-β 
by interacting with receptor-associated Smads. However, the in vivo roles of MAN1 have not 
been fully characterised. In 2006, Ishimura and his co-workers showed that MAN1 regulates 
vascular remodeling by analysing MAN1-deficient embryos lacking the Smad interacting 
domain. MAN1-deficient embryos die at midgestation because of defects in embryonic 
vasculation. They have revealed a novel role for MAN1 in angiogenesis and provided the 
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first evidence that vascular remodeling can be regulated at the INM through the interaction 
between MAN1 and Smad proteins (Hellemans et al., 2004; Lin et al., 2005; Mumm et al., 
2007)  (Figure 1.6). 
 
1.2.4.5 LEM Domain Proteins: 
LEM complex (belong to LAP, Emerin and MAN1 domain family) is important in the 
interaction with chromatin and/or lamins and other proteins to regulate signalling 
transcription. LEM interacts directly with BAF (dsDNA binding protein, 10 kDa) and lamin 
A and/or lamin B and thus mediates chromatin interactions. Thus, BAF is required to 
segregate and enclose chromosomes within the nuclear envelope and assemble the nuclear 
lamina (Furukawa, 1994; Margalit et al., 2005).  LEM is a group of proteins which share a 
motif of ~40 amino acids in length (Lin et al., 2000). There is a large family of proteins 
called nesprins which is a part of LEM complex family and interact with heterochromatin 
regions of the genome as well as SUN1 proteins in the lumen that connect the cytoplasm and 
the nucleoplasm (Broers et al., 2006). Lamin A but not lamin C, lamin B1 or lamin B2 
interacts with SUN1/2 in the lamina while in the cytoplasm; nesprin is thought to bind to 
actin. This interaction creates nesprin-SUN complexes connecting the cytoskeleton to nuclear 
components (Haque et al., 2006; Roux et al., 2009) (Figure 1.6). 
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Figure 1.6: Dynamic Connections of Nuclear Envelope Proteins, Nuclear Lamina and 
Lamin Binding Proteins to Chromatin and the Nuclear Matrix 
The figure displays the nuclear envelope (NE) that consists of inner nuclear membrane 
(INM), outer nuclear membrane (ONM), and the nuclear lamina which is a filamentous 
scaffold structure underneath the INM. The lamina consists of A-type lamins and B-type 
lamins and integral nuclear membrane proteins (IMPs) such as lamin B receptor (LBR), 
MAN1, emerin, and various isoforms of lamina-associated polypeptides 1 (LAP1, A, B, and 
C) and LAP2 (β, ε, δ, and γ). Lamins, LAP2, emerin and LBR interact with DNA and/or 
chromosomal proteins such as histones, BAF, HP1 and HA95, and provide a complex 
dynamic link between the peripheral lamina and nucleoplasm structures and chromatin fibers 
for chromatin organisation and gene expression. In addition, components of nuclear pore 
complexes (NPCs), such as Nup153 and translocated promotor region (Tpr), link the nuclear 
envelope to the nuclear interior and involved in mRNA transport and transcription repression 
of telomeric genes. Furthermore, intranuclear complexes of A-type lamins and LAP2α are 
likely involved in higher order chromatin organisation throughout the nucleus. Moreover, 
lamin A associate directly with retinoblastoma protein (pRb), which binds E2F and represses 
transcription of S-phase-specific genes during cell cycle. These interactions are regulated in a 
spatial manner during the cell cycle and are responsible for the dynamic nuclear and 
chromatin structure organisation, in DNA replication, gene transcription, cell cycle 
progression, and apoptosis. This figure is adapted from Foisner, 2003 (Foisner, 2003). 
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1.3 Genome Organisation:  
1.3.1 Chromatin Loops are Selectively Anchored Using Scaffold/Matrix-Attachment 
Regions: 
It is clear that the nuclear envelope, specifically nuclear lamins, forms part of a major 
important nuclear structure which is the nuclear matrix (Figures 1.4 and 1.6). The nuclear 
matrix is composed of two main nuclear parts; the interior nuclear matrix and peripheral 
nuclear lamins (Nickerson, 2001). Numerous modifications of biochemical pathways start 
signal transductions for accurate physiological conditions, therefore the term nucleoskeleton 
(Jackson and Cook, 1988). The visualisation of chromatin attached to the nucleoskeleton 
initiated the discovery of looped DNA at least 10-30 µm long or 30-90 kilobases which are 
responsible for correct replication and transcription (Cook and Brazell, 1975; Paulson and 
Laemmli, 1977) as it is where RNA polymerases cluster and loop the DNA (Cook, 2002). 
Therefore, it considered to be the active site for replication, repair, transcription, organisation, 
and integrity. 
 
The biological significance of nuclear scaffold/matrix-attachment regions (S/MARs) remains 
a subject of interest. Understanding S/MAR behaviour relies on the physical functions and 
chromatin loop anchors. In 2004, Heng et al. found that S/MARs functioned as the mediators 
of loop attachment and they were used in a selective and dynamic fashion (Heng et al., 2004). 
The genome interacts with the nuclear matrix proteins at specific DNA sequences known as 
matrix attachment regions (MARs). These proteins include nuclear lamins, A-type and B-
type lamins, are involved in associations and interactions of the nuclear matrix proteins and 
the genome. A-type lamins have been shown to associate with telomeres (Raz et al., 2006). 
The loss of these proteins disrupts telomere localisation and maintenance (Gonzalez-Suarez 
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et al., 2009).  However, many of these regions are discovered but still they are poorly 
characterised (Bode et al., 2000).  
 
 1.3.2 The Network of the Nuclear Lamina Proteins Bind to Chromatin and Histones: 
The dynamic nature of the NE is well illustrated at mitosis when the NE breaks down and 
reassembles around daughter chromosomes in interphase. Disassembly of the NE at prophase 
correlates with phosphorylation of proteins of the chromatin, nuclear membranes and lamina, 
leading to soluble lamin A/C form while B-type lamins remain in a membrane-bound form 
(Gerace and Blobel, 1980). In telophase, lamins are dephosphorylated and repolymerised 
(Ottaviano and Gerace, 1985). Proteins of the INM, lamina and chromosomes are extensively 
and strongly interconnected. LBR and LAP2β also bind chromatin via interactions with 
heterochromatin protein HP1 (Ye and Worman, 1996) and the small DNA-binding protein 
BAF (Furukawa, 1994). LAP2α also interacts with lamins A/C (Dechat et al., 1998) while 
H2-type histones bind lamins A/C and B in vitro (Goldberg et al., 1999). Thus, the chromatin 
provides multiple anchoring sites for the NE. HA95, also called HAP95 or NAKAP95, is a 
novel nuclear protein (Orstavik et al., 2000; Seki et al., 2000; Westberg et al., 2000). HA95 
exhibits high homology to the human nuclear A-kinase (PKA) anchoring protein, AKAP95 
(Eide et al., 1998) and like AKAP95, HA95 harbors two zinc fingers (Orstavik et al., 2000) 
and co-localises with AKAP95 in interphase and at mitosis. To support this view, 
HA95/HAP95 was recently shown to interact with RNA helicase A and enhance expression 
of the constitutive transport element (CTE), an RNA element involved in nuclear export of 
retroviruses and DNA replication (Westberg et al., 2000). Furthermore, HA95 is a chromatin 
and nuclear matrix associated protein implicated in the regulation of NE-chromatin 
interactions. HA95 directly interacts with the lamina and with a subset of integral proteins of 
the INM for chromatin condensation and assembly of nuclear membranes. However, HA95 is 
42 
 
a central element of the chromatin and the nuclear matrix implicated in regulating NE-
chromatin interactions during the cell cycle. 
 
Both lamins and lamin binding proteins bind directly to chromatin, histones, DNA 
polymerase II, transcription factors, and DNA (Zink et al, 1999). Peripheral chromatins are 
considered to be epigenetically silent and inactive (Mattout-Drubezki and Gruenbaum, 2003). 
These interactions are thought to be the basis of a tethering mechanism that direct specific 
chromosomes or chromosome regions to the periphery. However, there is a problem with this 
study; that lamins and lamin binding proteins (lamin A and LAP2α) can be found within the 
nucleoplasm. LAP2α-lamins A/C complexes in the nucleoplasm have been implicated in the 
regulation of gene expression. They bind chromatin proteins and chromatin modifying 
enzymes, and can thus participate in epigenetic control pathways. Furthermore, binding of 
lamins A/C complexes to specific transcription factors and repressors may directly affect 
their transcriptional activity. LAP2α-lamins A/C also regulate pRB/E2F and influence cell 
cycle progression and differentiation, which could have important implications for molecular 
mechanisms of laminopathic diseases (Dorner et al, 2007). To investigate these interactions, 
researchers have identifed the specificity of this binding and they found that some histone 
such as H2A and H2B sub-types and chromatin bind specifically to the coiled-coil rod 
domain. The tail domains of mammalian lamins C, B1, and B2 also bind to chromatin and 
histones. This lamin-histone interaction could be involved in specifying the high avidity 
attachment of chromatin to the nuclear envelope in vivo (Höger et al., 1991; Taniura et al., 
1995) (Figure 1.6).  
 
The lamins and the lamin binding proteins, LAP2β and LBR have been described to bind to 
DNA or to interact with chromatin via histones, BAF, and HP1 chromodomain proteins, 
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respectively, and may provide anchorage sites for chromatin fibers at the nuclear periphery 
(Gotzmann and Foisner, 1999; Foisner, 2003). Nuclear envelope proteins also bind 
chromatin; LBR binds lamin B, heterochromatin via histones H3/H4 as well as HP1α and 
HP1γ (Pyrpasopoulou et al., 1996) as well as binds LAP2β through BAF. BAF is a soluble 
protein that can also bind to histones and DNA and plays a role in the higher order structure 
of nucleoproteins (Olins et al., 2010). BAF has specificity of interaction with histones (H1) 
as well as its association with NE through LAP2α. Based on its interactions with histones and 
DNA, it is suggested that BAF might bind nucleosomes in vivo (de Oca et al., 2005; Greer 
and Shi, 2012) (Figure 1.6). It is clear this binding of NE proteins with chromatin is 
important and required for NE assembly after mitosis. It is interesting that emerin and LBR 
appear to assemble at different positions on mitotic chromosomes suggesting that some of 
interphase chromatin organisation has affinity interaction at the end of mitosis. In addition, 
MAN1 binds directly to the DNA through its carboxyl terminal domain whereas LAP2β 
binds to chromatin proteins HA95 to restrict its association with the nuclear envelope 
(Martins et al., 2000 and 2003). Several nuclear envelope proteins not only bind to chromatin 
but also bind chromatin modification enzymes such as LBR-specific kinase and histone 
deacetylase (HDAC3) for H4 deacetylation and can bind LAP2β (Pyrpasopoulou et al., 1996; 
Somech et al., 2005). Emerin binds directly to HDAC3 and recruits HDAC3 to the nuclear 
periphery. This binding stimulates the catalytic activity of HDAC3 and inactivates H4K5 
acetylation, protein involved in chromatin formation at the nuclear periphery (Demmerle et 
al., 2012). Therefore, nuclear lamina and chromatin are supposed to provide mechanical 
stability for nuclear structure to form a platform for most metabolic nuclear processes and to 
organise chromatin within the nucleoplasm and thus regulate gene expression at the 
chromatin structure and spatial levels. 
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1.3.3 Spatial Genome Organisation is Tissue Specific: 
Genomes are organised into individual chromosomes and each chromosome occupies a 
territory in cell nuclei. This non-random positioning of territories is according to their gene 
density or the cell’s transcriptional or differentiation status (Foster and Bridger, 2005). Gene 
density is highlighted by the positions of HSAs 18 and 19 territories has been observed (Croft 
et al., 1999; Boyle et al., 2001). These chromosomes are similar in DNA content (86 Mb and 
72 Mb, respectively) and 2.6 % and 2 % of the physical length of the genome, respectively 
(Tanabe et al., 2002) but have contrasting functional and structural characteristics such as 
they differ in their gene content and replication timing (Croft et al., 1999). Most of HSA19 
chromatin belongs to G-light bands, which is gene dense and replicates early during S phase, 
are located toward the nuclear interior whereas HSA18 chromatin represents G-dark bands, 
which consists of gene poor chromatin and replicate later, are located close to the nuclear 
periphery (Croft et al., 1999; Boyle et al., 2001; Zink et al., 2004; Bolzer et al., 2005; Foster 
and Bridger, 2005). Our knowledge about the structural and functional genome organisation 
of the cell nucleus is limited and the position of a chromosome territory is determined by its 
DNA contents and transcriptional status. The nuclear functions are highly organised and 
localised within the cell nucleus as well as chromatins are organised in loops, containing 
active areas of the genome (Figure 1.4) within the nuclear matrix (van Driel et al., 1991). 
This organisation and arrangement of chromatin is responsible for the regulation of gene 
expression.  
 
The location of a gene within the nucleus is responsible for specific nuclear function such as 
transcription and splicing (Parada and Misteli, 2002). Heterochromatin contains few genes, 
replicates during late S-phase, is enriched in specific nuclear proteins and has the ability to 
suppress the transcriptional activity of active genes. It is believed that the heterochromatic 
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rich regions of the nuclear periphery are stable. Therefore, the majority of transcription 
machinery is also found peripherally to regulate the gene expression activity (Deniaud and 
Bickmore, 2009). Spatial genome organisation is tissue specific (Cremer and Cremer, 2001; 
Parada et al., 2004; Malhas et al., 2007). For example, human chromosome 5 was 
preferentially found towards the centre of the nucleus in liver cells, but was predominantly 
peripheral in lung cells and was located in an intermediate position in lymphocytes (Parada et 
al., 2004). Furthermore, most cell types shared positioning of some but not other 
chromosomes. For example, lung cells and liver cells shared the position of chromosomes 12 
and 14 but not chromosomes 5 and 6. Furthermore, lymphoblasts and myeloblasts differ in 
the positioning of HSA 5 (Parada et al., 2004). There is also preferential position of all 
chromosomes in spermatogenesis. The positioning of sex chromosomes are highly organised 
at the nuclear edge in primary spermatocytes, whereas, in spermatids, the sex chromosomes 
with a preferential location in the central region (Foster et al., 2005). This explains the 
repositioning of chromosome territories in testes sections during spermatogenesis. Moreover, 
the radial positioning of HSA 12 and 16 was also observed during adipocyte differentiation. 
There is a close association between HSA 12 and 16 in differentiated adipocytes, an 
association not observed in preadipocytes. This suggests the translocation of chromosomes 12 
and 16 might play a key role in human liposarcomas (Kuroda et al., 2004).  
 
It could be hypothesised that specific chromosomes and/or gene loci would change their 
nuclear location before or after changes in regulation associated with cell differentiation 
because it is tissue specific. However, no changes in human chromosomes positioning were 
observed in both skin fibroblasts and lymphoblasts with the exception of two chromosomes, 8 
and 21 (Boyle et al., 2001). Porcine chromosomes have also been demonstrated to change 
nuclear location during adipogenesis, using mesenchymal stem cells, derived from porcine 
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bone marrow. These chromosome territories (SSC4, SSC6, SSC12, SSC13, SSC15, and 
SSC17) were found to alter their nuclear position during the in vitro adipogenesis, from the 
nuclear periphery towards the nuclear interior and found that during in vitro adipogenesis 
chromosome territories decondensed (Szczerbal et al., 2009). The same model was used to 
assess the chromosome territories during normal spermatogenesis (Foster et al., 2005). This 
is supporting model of the involvement of spatial genome repositioning in regulating gene 
expression and the nuclear interior is being an important region of the nucleus for 
transcriptional activity. 
 
Foster et al., in 2012, have assessed the interphase genome behaviour using porcine cells and 
tissues. They have positioned individual whole chromosomes in different cell types such as 
embryonic fibroblast cell line (ESK4), ex vivo lymphocytes and ex vivo bone marrow 
Mesenchymal stem cells (MSCs). They found that chromosomes occupy similar interphase 
nuclear positions regardless of in vitro or in vivo conditions. The comparisons between 
chromosome positioning of chromosomes 5, 13, 17 and X in cultured nuclei (during S-phase) 
and nuclei within ex vivo tissue sections, revealed that chromosomes 5, 13 and X occupy 
peripheral positions, whereas chromosome 17 is localised at more internal nuclear locations. 
That means nuclear chromosomes 5, 13, 17 and X share nuclear positions between in vitro 
cultured nuclei and in vivo nuclei (Foster et al., in 2012). 
 
We can conclude that the positioning of chromosomes within interphase nuclei is tissue 
specific in the formation of chromosome arrangements among tissues. However, the 
functional properties of tissue specific spatial genome organisation in gene expression and 
gene silencing during cell differentiation remain unclear. 
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1.3.4 Chromatin, Chromosome Territories and Gene Loci within Interphase Nuclei: 
Since the human chromosomes are positioned non-randomly during interphase, the genome is 
well organised and re-organised after mitosis for the correct nuclear functions. Nuclear 
structure and genome organisation are involved in organising and co-ordinating interphase 
chromosome positioning and gene loci regulation and expression. Nuclear architecture 
interacts with itself and anchors the genome. Mis-organisation or perturbing of this nuclear 
architecture can lead to aberration or alteration in regulating normal chromosome behaviour 
and increases the cells possibility to diseases such as cancer. 
 
Understanding of chromosome territories behaviour in the interphase nucleus increases the 
understanding of the differences between cancerous and normal cells. The changes in the 
nuclear architecture of cancer cells are used in tumour diagnosis for over 140 years. The first 
patient biopsy was examined in 1860; this led to improvement in understanding these 
changes. However, diagnosis still relies on the analysis of cell morphology. Specific nuclear 
markers of cancer include changes in nuclear size and shape, nucleolar alterations, changes in 
chromatin organisation, aberrant nuclear lamina and alterations to PML (Zink et al., 2004). 
Nuclear morphological changes in shape are observed in papillary thyroid carcinomas (Fisher 
et al., 1998) and enlarged nucleoli are associated with small-lung carcinoma (Zink et al., 
2004). Moreover, these were some changes observed to heterochromatic foci in cancer and 
usually associated with gene repression (Hahn et al., 2010). The changes to heterochromatic 
foci found in knockdown mice lacking the tumour suppressor gene BRAC1 resulted in loss of 
foci from the nuclear periphery leading to a more diffuse state of foci throughout the nucleus. 
BRAC1 binds H2A at satellite repeat to maintain heterochromatin structure (Zhu et al., 
2011). It is important to understand whether changes in chromatin structure or location cause 
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deregulation of genes and thus drive cancer. These studies suggest that the loss of a tumour 
suppressor gene can lead to aberrant chromatin changes then induce cancer.  
 
Specific areas of the genome that are tethered to the nuclear lamina or the nucleolus have 
been characterised during interphase chromatin (Lodén and van Steensel, 2005; Woodcock, 
2006; van Steensel and Dekker, 2010; Fudenberg et al., 2011). In the past decade, there is 
increased debate in the idea of effects of the gene positioning and organisation. Now it is 
reasonable to accept the theory of organisation is in fact non-random (Figure 1.7), tissue 
specific and that individual chromosome occupy discrete regions (territories) (Parada et al., 
2004). This explains the idea of genes activities may be affected by its location on 
chromosomes in the nucleus. Repositioning of chromosome territories (CTs) has been 
observed in different tissue types. This has also been seen during differentiation (Foster et al., 
2007). Interestingly, a recent study showed that the nuclear periphery, a zone of 
transcriptional repression, gene-poor and inactive chromatin, has an active role in some 
mammalian genes. This regulation and activation is affected by gene expression level and 
through their association with different genomic regions and proteins associated with the 
nuclear pore complexes thus different genome functions (Deniaud and Bickmore, 2009).  
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Figure 1.7: Chromosome Territories 
The figure shows that 24-Colour 3D FISH chromosome territories are organised in non-
random positions in a human fibroblast interphase nucleus (Bolzer et al., 2005). 
 
 
1.3.4.1 Genome Interactions with Lamina and Nuclear Pore Complex: 
The nuclear envelope provides anchoring sites for interphase chromosomes and participates 
in genome organisation inside the nucleus through two main structures, nuclear lamina (NL) 
and nuclear pore complexes (NPCs). Both the NL and NPCs are involved in anchoring sites 
for interphase chromosomes (Blobel, 1985) (Figure 1.6). Different studies have supported 
this idea. Some genomic loci are preferentially located close to the nuclear envelope, while 
other loci are found in the nuclear interior (Takizawa et al., 2008; Fedorova and Zink, 2009). 
Recent genome-wide mapping techniques have begun to provide more global insights into the 
molecular interactions of chromosomes with components of the nuclear envelope. 
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Interactions of the genome with the NL have been mapped in Drosophila by fusion of the NL 
to DNA adenine methyltransferase (Dam) from E. coli. When expressed in cells, this 
chimaeric protein is incorporated into the NL. Thus, DNA that is in molecular contact with 
the NL in vivo becomes methylated by the tethered Dam. By this approach, NL interactions 
have been mapped in detail in Drosophila, mouse and human cells (Guelen et al., 2006; 
Pickersgill et al., 2006; Peric-Hupkes et al., 2008). In all three species, interactions with the 
NL involve large genomic domains, rather than focal sites. Human genomes have more than 
1,000 lamina-associated domains (LADs) with a median size of ~ 0.5-10Mb. LADs are 
relatively gene-poor, they harbour thousands of genes and most of these genes are 
transcriptionally inactive (Guelen et al., 2006; van Steensel and Dekker, 2010). The reason 
could be of a repressive role of the NL in gene regulation. Lamin B in Drosophila causes 
repression of some NL-associated genes such as testis-specific gene cluster (Shevelyov et al., 
2009). Moreover, the NL can cause the down-regulation of some endogenous genes, although 
this may depend on its genomic integration site (Reddy et al., 2008; Finlan et al., 2008). 
Furthermore, during differentiation hundreds of genes show altered interactions with NL. 
 
Interactions of the genome with NPCs have been studied by both DamID and Chromatin 
Immunoprecipitation (ChIP). These techniques employ cross-linking of protein-DNA 
interactions with formaldehyde, followed by mechanical fragmentation of the DNA and 
immunoprecipitation using antibodies against NPC proteins (Nups). Genome-wide 
microarrays were used to identify the immunoprecipitated DNA sequences. In yeast, 
Drosophila and human cells, hundreds of genes are associated with various Nups (Brown et 
al., 2008a). 
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1.3.4.2 Genome Interactions with Nucleolus: 
The nucleolus is an important organelle to study genome activity, since all RNA polymerases 
(pol I, II, and III) are involved in the dynamic and regulation of ribosome biogenesis process, 
which is its main function. The high proliferation activity of tumour cells with high ribosome 
biogenesis activity exposes the nucleolus as a promising target in cancer biology (Drygin et 
al., 2009). In addition, cell-type and function-dependent nucleolar localisation of tumour 
suppressor proteins, such as p53 and MDM2 indicates the role of the nucleolus in 
carcinogenesis (Sirri et al., 2008). A number of other biological processes such as 
senescence, RNA modification, cell cycle control and stress are also regulated in the 
nucleolus and connect it to several functional networks of the cell (Sirri et al., 2008). 
Furthermore, high chromatin density is found at nucleoli or nuclear periphery, and disruption 
of nucleoli increases motility of chromatin domains, indicating the role of the nucleolus in 
chromatin arrangement (Chubb et al., 2002; van Steensel and Dekker, 2010). It was thought 
that this nuclear compartment harbors only the rRNA-encoding genes, which are transcribed 
by RNA polymerase I. In order to find other sequences that may interact with nucleoli, a 
recent study isolated nucleoli from human cells. The associated DNA was then characterised 
and identified genomic regions named nucleolus-associated domains (NADs). NADs are 
large genomic segments (median size 750 kb, 97 chromosomal regions) that are highly 
enriched in centromeric satellite repeats and specific inactive gene clusters, which is 
consistent with the preferential localisation of centromeres around nucleoli (Stahl et al., 1976 
and Németh et al., 2010). Interestingly, the 5S and tRNA genes, which are transcribed by 
RNA Polymerase III, also preferentially associate with the nucleolus (Németh et al., 2010; 
van Steensel and Dekker, 2010), suggesting that nucleolar interactions may help to coordinate 
the expression of specific gene sets. These results demonstrated and confirmed that 
chromosomal regions interact specifically with the nuclear lamins, NPCs and nucleoli. The 
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nucleolus can therefore be considered as a model system to investigate functional genome 
organisation. However, that alteration in the nucleolus might be linked to multiple forms of 
human disease, including cancer and viral infections. Moreover, multiple genetic disorders 
have been mapped to genes that encode proteins located in nucleoli under specific conditions 
such as Werner’s syndrome (Marciniak et al., 1998) and fragile X (Tamanini et al., 2000). 
 
1.3.5 Interphase Chromosome Positioning in Cancer: 
During disease, the spatial organisation of the genome can be altered. Chromosomal 
aberrations are the most characteristic of tumour cells. The aberration of genetic material 
from two or more chromosomes will lead to the cells transformation that acts as a cause of 
tumourgenesis by fusion or mis-regulation of genes, this is termed chromosomal 
translocation. This formation is processed by double strand breaks (DSB) and failure in repair 
mechanisms to eliminate DSBs can lead to mis-position of specific chromosomes (Kanaar et 
al., 1998; Meaburn et al., 2007b). In addition, the distribution of centromeres and telomeres 
can be altered in specific cancer cells (Poddighe et al., 1992). Furthermore, chromosome 
aberrations and type of tumour are considered the most important for diagnosis and prognosis 
of cancer with chromosomal abnormalities. A number of studies were performed in order to 
understand the deferential positioning in chromosomes interphase nuclei. Abnormal 
relocation of chromosome 18 from the nuclear periphery to the interior has been documented 
in several types of tumour cell lines (Cremer et al., 2003), including melanoma-derived cell 
line, cervix carcinoma, colon carcinoma, Hodgkin-derived cell line and colon carcinoma 
metastasis cells (Cremer et al., 2003). Moreover, report supports the idea of the functional 
correlation between non-random positioning and formation of translocation, for example 
HSAs 9 and 22 in chronic myeloid leukaemia (CML), (Lukasova et al., 1997) as well as the 
correlation between tissue specific spatial organisation and tissue specific translocation 
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(Parada et al., 2004). Furthermore, the nuclear location of chromosomes 10, 18 and 19 were 
assessed in normal thyroid tissue and compared to adenomatous goiters, papillary carcinomas 
and undifferentiated carcinomas. There was no difference in chromosome position in the 
normal and goiter tissue with chromosomes 10 and 18 positioned towards the nuclear 
periphery; and chromosome 19 in a central location. However, in the papillary carcinoma 
tissue chromosome 19 was located centrally as in normal cells. Furthermore, in 
undifferentiated carcinomas all the chromosomes assessed were mislocalised. These findings 
indicate that alteration of chromosome positioning could be related to DNA amplification and 
abnormal chromatin features (Murata et al., 2007). Marella et al., in 2009, used normal 
human WI38 lung fibroblast and MCF10A epithelial breast cells and identified that similar 
levels of associations were found in the normal cell lines WI38 and MCF10A for 
chromosomes 1, 4, 11, 12, 14, and 16 whereas a 2-fold increase of chromosome 4 and 16 
associations in a malignant breast cancer cell line (MCFCA1a) compared to the related 
normal epithelial cell line (MCF10A) was found. This demonstrates that chromosome 
associations are cell type specific and undergo alterations in cancer cells (Marella et al., 
2009).  
 
Furthermore, Wiech et al., 2005 analysed chromosome 8 positions in wax embedded 
pancreatic cancer tissue samples. Their results obtained from non-neoplastic pancreatic cells 
of randomly selected individuals indicated that the radial arrangement of the chromosome 8 
territories as well as their shape (roundness) did not significantly differ between the 
individuals. In pancreatic tumours, the radial distance indicated the repositioning of 
chromosome 8 to the nuclear periphery and the decreased roundness of CTs found may 
reflect the genomic and transcriptional alterations in carcinoma. There were considerable 
differences between pancreatic tumour and non-neoplastic cells. In non-neoplastic ductal 
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epithelium of the breast there was a larger distance in the positioning of the centromere 17 
and HER2 domains between individuals. In neoplastic epithelial breast cells, the distances 
between centromere and gene domains were smaller than in non-neoplastic cells. They 
demonstrated repositioning of the centromere on chromosome 17 to a more internal location 
(Wiech et al., 2005; Timme et al., 2011). A study by Wiech et al., in 2009 reported 
repositioning of chromosome 18 during cell differentiation of cervical squamous epithelium 
towards the nuclear centre whereas, in cervical squamous carcinomas showed a positioning 
of chromosome 18 towards the nuclear periphery (Wiech et al., 2009).   
 
1.3.6 Interphase Gene Positioning in Cancer: 
Nuclear architecture and chromatin structure are important features for the regulation of gene 
expression and can be altered in cancer. Altered chromosome positioning has been associated 
with numerous types of cancer in which altered gene expression that lead to malignant 
transformation of the cell. Individual gene loci are also repositioned during early 
tumorigenesis (Ferrai et al., 2010). In vitro studies of tumourigenesis in early breast cancer 
showed altered positioning of cancer-associated genes such as AKT1, BCL2, ERBB2, and 
VEGF loci although no correlation was found between radial redistribution and gene activity 
level (Meaburn and Misteli, 2008). However, translocation occurs in specific type of cancers 
that contribute to nuclear positioning of the loci involved (Roix et al., 2003). Furthermore, 
the intermingling between specific pairs of chromosomes correlates with the frequency of 
translocations between the same chromosomes that observed after ionizing radiation (Branco 
and Pombo, 2006). Analyses of single genes close to or at translocation sites have also shown 
that their nuclear positioning is closer in cell types in lymphoma associated with t(2;5) 
translocations (Roix et al., 2003).  
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Meaburn et al., in 2009 studied the repositioning of genes in the nuclei that are involved in 
breast cancer. From 11 normal human breast and 14 invasive breast cancer tissue specimen, 
they identified eight genes (HES5, ERBB2, MYC, FOSL2, HSP90AA1, AKT1, TGFB3, and 
CSF1R) that have altered their position when they compared their spatial organisation in 
cancerous tissue and normal, suggesting that the changes are gene specific. It was shown this 
alteration did not reflect large scale changes in global genome organisation. The repositioning 
of these genes was not due to genome instability as the genes analysed in this study had no 
changes in copy number and are cancer type specific (Meaburn et al., 2009). Furthermore, 
this study is supported by the results of Weich et al, 2005 who identified BCL2 repositioning 
to the periphery in BCL2 cervical squamous cell carcinomas but not in BCL2 cervical 
squamous epithelial cells (Weich et al, 2005).  
 
In breast cancer, the position of a specific gene, HES5, a transcriptional repressor that 
regulates cell differentiation, could distinguish between a cancerous tissue and a healthy one 
with almost 100 percent accuracy. Alteration or repositioning of this gene has been associated 
with tumourgenesis and was identified in several types of breast cancer. This could prove a 
useful diagnostic tool (Meaburn et al., 2009; Cukierski et al., 2012). The gene repositioning 
occurs at an early stage of tumourgenesis, however, the gene repositioning did not affect 
transcription levels (Meaburn and Misteli 2008). Chromatin rearrangement is pivotal 
mechanism for the control of transcription (Kosak et al., 2002). These finding was observed 
when Ig heavy (H) and Igκ loci were preferentially positioned at the nuclear periphery in 
hematopoietic progenitors and pro-T cells but are centrally located in pro-B nuclei. To find 
out the relationship between position and transcription, the inactive loci at the periphery do 
not associate with centromeric heterochromatin and their localisation away from the nuclear 
periphery in pro-B cells, suggested that the IgH locus appears to influence by other factors 
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such as tissue type. They suggest that this positioning is regulated by transcription and 
recombination of IgH and Igκ loci during lymphocyte development (Kosak et al., 2002). In 
addition to gene repositioning in cancer, it was also observed during viral infection.  
 
Therefore, changes in the radial position of specific gene loci in cancer cells could contribute 
to tumourgenesis but further investigation is still needed. These observations strongly support 
the idea that the genomic regions influenced by states of gene activity and cell-type specific 
genome architecture, this can predispose translocations that are characteristic to specific cell 
types and cancers due to changes in gene expression placing genes in a new location. 
 
1.3.7 Lamins and Cancers: 
Alterations to the nuclear lamina are thought to be involved in malignant transformations and 
cancer processes because of their role as guardian of the genome, their role in regulating 
basic nuclear activities that are implicated in tumourgenesis, their interactions with cancer 
gene pathways and their role in chromosomal territories and reorganisation. Thus, lamin 
expression in cancer cells may serve as a biomarker for diagnosis, prognosis and surveillance. 
In small cell lung cancer cell lines, lamins A and C levels decreased whereas in non-small 
cell lung cancer cell lines were both clearly detected. However, levels of B-type lamins were 
equal in both cell lines (Kaufmann et al., 1991; Broers et al., 1993). Studies in 
gastrointestinal neoplasms have found reduced or no expression of lamins A and C, and B1 
(Moss et al., 1999; Willis et al., 2008). Further, reduced or no expression of lamins A and C 
in basal cell carcinoma of the skin was found whereas B-type lamins were expressed in all 
these cells (Venables et al., 2001). Evaluation of lamin expression in prostate cancer was also 
been assessed and reduced expression of lamins A, C, and B1 was found (Moss et al., 1999). 
In contrast, there was a significant increase in lamin B1 and no change in lamins A and C in 
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prostate cancer, the increase in lamin B1 was strongly correlated with the prognostic status of 
the patient (Coradeghini et al., 2006). In cervical and utrine cancers, lamin A and C were not 
detected whereas lamins B1 expression was reduced (Moss et al., 1999). There was increased 
expression of lamins A and C in ovarian cancer from 30 patients and 30 healthy individuals 
(Hudson et al., 2007). In papillary thyroid carcinoma there was no change found in the 
expression or localisation of lamins A, C, and B1 or LAP2 and LBR (Fischer et al., 2001). In 
breast cancer, there was reduced expression in lamins A, C, and B1 (Moss et al., 1999). 
Moreover, the expression level of lamin B1 correlated positively with tumour stages, tumour 
sizes, and number of nodules and is clinically useful biomarker for early stages of 
hepatocellular carcinoma in tumour tissues and plasma (Sun et al., 2010). In this thesis and 
for the first time, my work evaluated the expression of lamins and lamin binding proteins in 
normal breast (MCF-10A cell lines) and cancer (T-47D, BT-474, GI-101, and Sk-Br-3) cell 
lines. Differential aberrations in the presence and distribution of lamins A, C, B1, and B2, 
LAP2α, LAP2, MAN1, emerin, and LBR whereas, co-localisation was found between lamins 
and some nuclear proteins such as PML, nucleolin, LBR, and Ki67 (Chapter 4). 
 
1.3.7.1 Lamins and Cancer Pathways: 
Tumour suppressor genes such as pRB are in one of the pathways that are involved in the 
control of tumourgenesis. The nuclear lamins are involved in tumour suppressive pathways 
that trigger apoptosis or senescence and thus yielding an anti-cancerous effect through 
protecting this pathway. Lamin alterations allow cancer cells to change the normal control of 
cell proliferation and cell death yielding a pro-cancerous effect (Vogelstein and Kinzler, 
2004). Moreover, the epigenetic silencing of the lamins A and C gene by hypermethylation to 
CpG island promoter is responsible for the loss of expression of A-type lamins in leukemia 
and lymphoma (Agrelo et al., 2005). LAP2α and A-type lamins both participate in pRB 
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dependent E2F repression and loss of LAP2α or A-type lamins in fibroblasts results in 
accelerated S-phase entry, through loss of pRB activity. Lamin A causes up-regulation of T-
plastin which can lead to down regulation of E-cadherin. Plastins are a family of actin 
binding proteins that implicated in invasion and metastasis (Foran et al., 2006). This is 
confirmed by Willis et al., in 2008 where they found that the expression of A-type lamins 
within a tumour was a highly significant risk indicator of tumour related mortality. 
Expression of lamin A in colorectal cancer (CRC) cell lines promoted invasiveness via up-
regulated expression of the actin, which in turn gives rise to down-regulated expression of the 
cell adhesion molecule E-cadherin. They concluded that expression of A-type lamins in CRC 
promotes tumour invasiveness through reorganisation of the actin cytoskeleton (Willis et al., 
2008). Furthermore, pre-lamin A and mature lamin A have been implicated in regulation of 
cell cycle control and DNA repair mechanisms whereby they activate a proliferative arrest 
(Varela et al., 2005; Shalev et al., 2007). The Wnt/β-catenin signalling cascade has been 
implicated in multiple stages of hematopoietic development. It was proposed that Wnt 
signalling controls the auto-renewal of hematopoietic stem cells (HSCs). Aberrant of β–
catenin signalling during thymocyte development has been found in various epithelial and 
haematological tumours due to aberrant thymocyte development and reduction in T-cell 
receptor β rearrangements (Guo et al., 2007). Thus, alterations in composition of lamins 
within cell nuclei result in loss of proliferative control and hence may be involved in tumour 
progression (Venables et al., 2001; Burke and Stewart, 2006). The interaction between lamins 
and chromatin is mediated through other proteins at the lamina, these include lamina 
associated polypeptide-2 (LAP-2), emerin and MAN1 (LEM), nesprin, barrier to 
autointegration factor 1 (BAF1) as well as lamin B receptor (LBR) (Morris, 2001; Ostlund 
and Worman, 2003). These interactions might be involved in heterochromatin formation at 
the nuclear periphery. Alterations of nuclear structure are often associated with altered 
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organisation or even loss of heterochromatin. Changes in the nuclear lamina and nuclear 
shape may affect chromatin territories organisation and gene position, respectively (Zink et 
al., 2004). This may result in chromosome aberrations and alteration of gene expression and 
transformation of the cell nucleus. 
 
Table 1.1: Different Nuclear Lamins Expression in Different Cancerous Tissues: 
Tissue Lamins A/C  Lamins B Reference 
(1) Lymphoma No Yes Stadelmann et al., 1990 
(2) Non-Small cell Lung 
Cancer 
Yes Yes Kaufmann et al., 1991 
and Broers et al., 1993  
(3) Small cell Lung Cancer No Yes Kaufmann et al., 1991 
and Broers et al., 1993 
(4) Gastrointestinal 
Neoplasms 
No No Moss et al., 1999 
Willis et al., 2008 
(5) Cervical Cancer No Yes Moss et al., 1999 
(6) Skin Cancer  No Yes Venable et al., 2001 
(7) Prostate Cancer No Yes Coradeghini et al., 2006 
(8) Ovarian Cancer Yes -* Hudson et al., 2007 
(9) Colorectal Cancer Yes -* Willis et al., 2008 
(10) Gastric Carcinoma No -* Wu et al., 2009 
(11) Liver Cancer -* Yes Sun et al., 2010 
-* = Nothing Mentioned 
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1.3.8 Changes in Nuclear Structure during Cancer: 
The architecture of cell nuclei is often altered in cancerous cells. The types of cancers are 
associated with characteristic changes and these may provide an important diagnostic feature. 
Different studies showed that much debate about changes in the cell nucleus structure in 
cancer diagnosis. One of these changes was observed in nuclear structure variation. This was 
followed by cytoplasmic features of the cells. These include changes in nuclear lamina and 
nuclear matrix. These alterations can be characteristic of cancer type and its stage which is 
might be related to the altered functions of cancer cells (Zink et al., 2004).  
 
1.3.9 The Nuclear Matrix and Cancer:  
Since the nuclear matrix is the dynamic scaffold through which cell nucleus is structurally 
and functionally organised, some of nuclear matrix proteins (NMPs) are restricted to cancer 
cells or to stages of cancer progression. The NMPs are tissue and cell type specific as well as 
reflecting the state of cell differentiation and transformation. They can serve as biomarkers 
for malignant phenotype (Getzenberg et al., 1996). These proteins are tumour specific, for 
example PC-1, which is only active in the nuclear matrix of prostate cancerous cells and 
inactivated in normal and benign prostate tissues (Partin et al., 1997). The relationship 
between NMPs activity and cancer progression has also been reported in acute promyelocytic 
leukaemia (APL) due to chromosomal translocation (Sukhai et al., 2004) and bladder cancer 
(van Le et al., 2004). Moreover, NMP66 and c-erbB2 promotors bind nuclear matrix protein 
present in human breast cancer cells and they induce mitogenesis (Ya-Ian et al., 2005). A 
number of studies showed that the nuclear matrix interacts with steroid receptors to help 
modulate cell function (Khanuja et al., 1993). Therefore, the changes in nuclear matrix in 
cancer cells may affect DNA organisation, DNA replication, gene expression and other 
nuclear functions. 
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1.3.10 The Nuclear Lamina and Cancer: 
The nuclear lamina is thought to be a principal determinant of the nuclear shape. The nuclear 
lamina and nucleoplasmic lamin networks are organised in an interconnected domains. These 
domains have different functions in chromatin organisation and gene regulation (Goldman et 
al., 2002). The nuclei of most normal cells have regular shape, structures and functions but an 
irregular nuclear shape, structures and functions are observed in cancerous cells (Zink et al., 
2004). These changes are characteristics of different cancer types. For examples, small-cell 
lung carcinomas lack the proteins of lamin A whereas lamin B expression varied between 
normal and cancer cells (Broers et al., 1993) and lack of expression of A-type lamins in 
lymphoma and leukemia has been reported, demonstrating that the lamin A/C gene encoding 
these central components of the nuclear lamin undergoes transcriptional silencing by 
promoter CpG island hypermethylation (Agrelo et al., 2005). However, lamin A/C proteins 
are positively involved in malignant behaviour of prostate cancer cells through the 
PI3K/AKT/PTEN pathway. Lamin A/C may represent a new oncogenic factor and a novel 
therapeutic target for prostate cancer (Kong et al., 2012). Therefore this may contribute to the 
structural changes observed in the lamina. However, changes in lamina proteins or nuclear 
shape, involved in the process of cancer transformation, remain unclear. Chromatin is 
attached to the inner surface of the nuclear lamina (perinuclear heterochromatin) and the 
lamina may be involved in transcriptional repression of gene loci (Brown et al., 1997).  
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1.4 Conclusion: 
The nuclear envelope and integral nuclear membrane proteins, A-type and B-type lamins and 
their binding proteins have a role in maintaining the correct functions of the nucleus and 
genome organisation. Diseases and cancers can arise from aberrant forms of these proteins 
and changes in protein amount. Since the genome organisation is disorganised in a number of 
diseases and cancers, it is important to understand how, why and when this occurs and 
whether it has an effect on gene expression. My thesis addresses nuclear structure and 
genome organisation in breast cancer which have revealed interesting findings. Clearly, there 
is a need for better understanding, diagnosis and treatment of this cancer and how it is 
important to understand the nucleus for disease control. Understanding the progress would 
enable the designing of novel therapies and avoid side effects. In addition, the study will help 
in the fundamental understanding of this cancer. 
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Chapter 2: Chromosome Territories and 
Gene Position in Human Breast Cancer 
Cell Nuclei 
 
 
 
 
 
 
Manuscript in Preparation: Hassan Ahmed M., Karteris E; Harvey A; 
Bridger JM.   
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2.1 Introduction: 
The spatial organisation of the genome alters during physiological processes such as 
differentiation and development (Foster and Bridger, 2005). In addition, large scale 
alterations to spatial organisation of the genome also occur in cancer conditions (Zink et al., 
2004; Meaburn et al., 2009) and between quiescence and proliferation (Mehta et al., 2010a).  
 
2.1.1 The Role of Nuclear Envelope (NE) in Genome Organisation, Gene Expression 
and Genome Stability: 
Nuclear architecture is important, since it is capable of maintaining genome organisation, 
stability, and regulating gene expression. Numerous genes relocate from the nuclear 
periphery to the nuclear interior upon activation and are hypothesised to interact with pre-
assembled sites of transcription (Brown et al., 1997). In contrast to the nuclear interior, the 
nuclear periphery is considered as less transcriptionally active (Shaklai et al., 2007; Van de 
Vosse et al., 2011). This is reflected by the preferential association of heterochromatin and 
gene poor areas of the genome with the NE (Guelan et al., 2008). However, some activated 
genes in yeast are recruited to the nuclear periphery through interactions with nuclear pore 
complexes (NPCs), and NPC proteins are capable of preventing the spread of silent 
chromatin into regions of active chromatin, leading to the idea that NPCs may facilitate the 
transition of chromatin between transcriptional sites. Thus, the NE might be considered as a 
discontinuous platform that promotes both gene activation and repression (Van de Vosse et 
al., 2011). Indeed, some human genes when targeted to the NE still transcribe (Finlan et al., 
2008). Many diseases are frequently associated with alterations in the NE. Therefore, the 
effects of the NE and its effects on chromatin organisation, gene expression, and stability 
could be the causative agents for many cancers and other diseases such as laminopathies, 
where the nuclear lamina is aberrantly affected by mutant lamina proteins. The nuclear 
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lamina is thought to provide an anchoring site for interphase chromosomes and have a role in 
gene regulation and expression. Recent genome mapping studies and functional experimental 
data strongly support these roles for the nuclear lamina (Peric-Hupkes and van Steensel, 
2010).  
 
2.1.2 The Relationship between Chromosome Territories (CTs), Transcription Sites, 
and Gene Expression:  
There is a functional link between chromatin structure at the level of the nucleosome and 
gene expression (Jenuwein and Allis, 2001). However, the functional significance of higher-
order chromatin structures in transcription remains unclear. Hence, it has been proposed that 
transcription and RNA processing might occur in a space between territories 
(interchromosome domain, ICD) compartment in which transcription, RNA processing, RNA 
transport and splicing of mRNA occur (Verschure et al., 1999; Cremer and Cremer, 2001). In 
support of this model, specific gene transcripts and components of the splicing machinery 
have been reported to be found at the border of chromosome territories (CTs) (Zirbel et al., 
1993). If transcription occurs close to the surface of chromosome territories, genes should 
preferentially be found there, and non-coding sequences should be more internal. Kurz et al., 
1996, found that coding DNA is found preferentially at the periphery of chromosome 
territories, whereas a non-coding genomic locus was found predominantly in the interior of 
the territory. It has been shown that the gene-rich major histocompatibility complex (MHC) 
lies on large chromatin loops that extend away from the surface of chromosome 6 territory 
when activated (Volpi et al., 2000). Therefore, most active genes lie on the surface of 
chromosome territories. However, both early and late replicating DNA that are usually 
equated with gene-rich and gene-poor domains, respectively, as well as RNA and splicing 
factors appear to be distributed throughout chromosome territories (Visser et al., 1998). 
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Similarly, the most GC-rich fraction of the human genome (which has a high gene density) is 
also distributed throughout the territories (Tajbakhsh et al., 2000). Chromatin fibres 
containing transcriptionally active DNA may be decondensed at the surface of these sub-
domains or extended into the interchromatin spaces and newly synthesised RNA accumulates 
in the interchromatin spaces inside and around chromosome territories (Verschure et al., 
1999). However, it has been found that most expressed genes are indeed located at the 
surface of chromosome or on loops. It seems there is clear correlation between chromosome 
territory sub-domains and the expression of tissue specific genes.  
 
As has been discussed in the Introduction; chromosomes and genes are non-randomly 
positioned in interphase nuclei (Croft et al., 1999; Boyle et al., 2001; Szczerbal et al., 2009; 
Mehta et al., 2010a). These positions can change in differentiation and disease leading to 
changes in gene expression (Bourne et al., 2013).  
 
The goal of this chapter is to assess the global spatial genome organisation within cancerous 
cells during interphase. This is done by determining nuclear positions of human 
chromosomes and genes. This work demonstrates that chromosomes (7, 10, 11, 14, and 17) 
and genes (EGFR, PTEN, CCND1, AKT1, HSP90AA1, and ERBB2/HER2) in normal breast 
(MCF-10A) and breast cancer (T-47D, GI-101, BT-474, and Sk-Br-3) cell lines are 
positioned non-randomly but in different locations to publish normal chromosome positions 
and the control cell line. Interestingly, my results showed that HER2 gene position was 
altered in all the cancer cells studied which was similar to the work by Wiech et al., in 2005 
and Meaburn and Misteli, in 2008. They both found that HER2 gene changes location in 
neoplastic breast epithelial cells (Wiech et al., 2005). In addition, Meaburn and Misteli, in 
67 
 
2008, demonstrated that gene position (including HER2) had altered in the cancer cells 
(Meaburn and Misteli, 2008).  
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2.2 Material and Methods: 
2.2.1 Cell Culture:  
The five human breast cell lines either immortalised (MCF-10A) or transformed (T-47D, BT-
474, Sk-Br-3, and GI-101) were obtained from Dr. Amanda Harvey at Brunel University, 
London. They were grown and cultured in medium (GIBCO) which is described in tables 1, 
2, and 3, supplemented with 10 % fetal calf serum (FCS) and antibiotics at 50 mg⁄ml 
concentration (Stock: 100X: 10,000 u/ml penicillin, 10,000 µg streptomycin, and 29,2 mg/ml 
L-Glutamine in a 10 mM citrate buffer (for pH stability)) and maintained in a humidified 
environment at 37ºC with 5% CO2. The cells were passaged therize time weekly and the 
normal cells were passaged twice weekly. For passaging, cells were washed twice with 1X 
Dulbecco’s Phosphate Buffer Saline (DPBS). Cells were harvested by incubation in 0.5% 
Trypsin-ethylenediaminetetraacetic acid (1X EDTA) phenol red (Ivitrogen) for 3-10 minutes 
in a humidified environment at 37ºC with 5% CO2. The trypsin was neutralised by the 
addition of equal volume of fresh medium. The cellular suspension was distributed into 
flasks. For indirect immunofluorescence, cellular suspensions were prepared and cells were 
seeded in 13 mm glass coverslips on plastic petri dishes. The table below summarises the 
general characteristics and properties of the different cell lines. The cell lines were not tested 
for Mycoplasm infection as this organism can modify the cell physiology and no bacterial or 
fungal contamination was observed during this study. This test is essential for quality control 
in tissue culture laboratory every three month. The cell lines were selected for this study on 
the basis of several criteria as described below:  
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(1) MCF-10A cell line: 
The human mammary epithelial cell line MCF-10A is non-tumorgenic and immortalised. It is 
derived from human fibrocystic mammary tissue. This cell line can be engineered using 
molecular manipulation techniques to allow future studies of malignent progression changes 
and mechanisms especially signal transduction pathways such as Ras pathway to increase 
malignancy. These cells are "normal" breast epithelial cells as they are relatively stable and 
have nearly diploid karyotype (Data not Shown) and are dependent on different growth 
factors for proliferation. MCF-10A cell line is an excellent model system for understanding 
epithelial cell biology. The cells were grown in Dulbecco’s Modified Eagles Medium 
(DMEM/Ham’s F12 ((+) L-Glutamine, GIBCO) and supplemented with 10% fetal calf serum 
(FCS), 5 ml PSQ antibiotics at 50 mg⁄ml concentration (Stock: 100X: 10,000 u/ml penicillin, 
10,000 µg streptomycin, and 29,2 mg/ml L-Glutamine in a 10 mM citrate buffer (for pH 
stability)) and 1.25 ml (µg/ml) Insulin, 500 µl (1 µg/ml) Hydrocortisone (HC) and 20 µl (10 
µg/ml) Epithelial Growth Factor (EGF). This cell line was sub-cultured and was split 1:2. 
Cells were grown on 75cm
2 
flasks.  
 
(2) T-47D cell line: 
The human ductal breast epithelial tumour cell line T-47D is derived from an invasive ductal 
carcinoma cell line. The cells were grown in RPMI 1640 medium, developed in 1966 by 
Moore et al. as a modification of McCoy’s 5A medium at Roswell Park Memorial Institute 
(www.atlantabio.com), ((-) L-Glutamine, GIBCO) and supplemented with 10% fetal bovine 
serum (FBS) and antibiotics 5 ml PSQ antibiotics at 50 mg⁄ml concentration (Stock: 100X: 
10,000 u/ml penicillin, 10,000 µg streptomycin, and 29,2 mg/ml L-Glutamine in a 10 mM 
citrate buffer (for pH stability)). This cell line was sub-cultured and was split 1:4. Cells were 
grown on 25cm
2 
flasks. 
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(3) GI-101 cell line: 
The human breast carcinoma cell line GI-101 is derived from a metastasic ductal 
adenocarcinoma cell line. The cells were grown in RPMI 1640 medium ((-) L-Glutamine, 
GIBCO) and supplemented with 10% fetal bovine serum (FBS), some additives 625 µl 
(µg/ml) Insulin, and antibiotics 5 ml PSQ antibiotics at 50 mg⁄ml concentration (Stock: 100X: 
10,000 u/ml penicillin, 10,000 µg streptomycin, and 29,2 mg/ml L-Glutamine in a 10 mM 
citrate buffer (for pH stability)). This cell line was sub-cultured and was split 1:4. Cells were 
grown on 75cm
2 
flasks. 
 
(4) Sk-Br-3 cell line: 
The human breast adenocarcinoma carcinoma cell line Sk-Br-3 is a poorly differentiated 
adenocarcinoma and hypertriploid cell line. Its name came from the Memorial Sloan-
Kettering Cancer Centre where it was isolated. The cells were grown in RPMI 1640 medium 
((-) L-Glutamine, GIBCO) and supplemented with 10% fetal bovine serum (FBS) and 
antibiotics 5 ml PSQ antibiotics at 50 mg⁄ml concentration (Stock: 100X: 10,000 u/ml 
penicillin, 10,000 µg streptomycin, and 29,2 mg/ml L-Glutamine in a 10 mM citrate buffer 
(for pH stability)). This cell line was sub-cultured and was split 1:4. Cells were grown on 
25cm
2 
flasks. 
 
(5) BT-474 cell line: 
The human ductal breast carcinoma cell line BT-474 is derived from a solid, invasive ductal 
carcinoma cell line. The cells were grown in RPMI 1640 medium ((-) L-Glutamine, GIBCO) 
and supplemented with 10% fetal calf serum (FCS) and antibiotics 5 ml PSQ antibiotics at 50 
mg⁄ml concentration (Stock: 100X: 10,000 u/ml penicillin, 10,000 µg streptomycin, and 29,2 
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mg/ml L-Glutamine in a 10 mM citrate buffer (for pH stability)). This cell line was sub-
cultured and were split 1:4. Cells were grown on 75cm
2 
flasks. 
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2.2.1.1 Tables 2.1-2.3 Display the Characteristics of Cell Lines: 
Table 2.1: Characteristics of Cell Lines I: 
 T-47D Cell Line** MCF-10A Cell Line*** 
Species Human, Female (54 Years) Human, Female (36 Years) 
Morphology Epithelial Cells Epithelial Cells 
Tissue Breast Breast 
Tumour Invasive Ductal 
Carcinoma 
Non-tumourgenic, Immortalised 
(Normal) and arose 
spontaneously in culture 
Culture Medium RPMI 1640 media, 10% 
FBS, and 5 ml PSQ* 
DMEM/Ham’s F12 media, 10% 
FCS, 5 ml PSQ*, and  (Insulin, 
Hydrocortisone and Epithelial 
Growth Factor) 
Split Ratio 1:4 1:2 
Properties Tp53
+
, PR
+
, ER
+
, and 
Her2
+
. Model of Apoptosis 
and Drug Resistant**.  
Nearly Diploid, and Adherent in 
growth. Responds to insulin, 
HC, and EGF. Cialmucin
+
, ER
-
, 
PR
- 
and normal expression to 
p53
+
 and normal Her2
+
 
expression***  
*PSQ antibiotics at 50 mg⁄ml concentration (Stock: 100X: 10,000 u/ml penicillin, 10,000 µg 
streptomycin, and 29,2 mg/ml L-Glutamine in a 10 mM citrate buffer (for pH stability)). 
**(http://icbp.lbl.gov/breastcancer/list_data.php?id=1, July 2009). 
***(http://icbp.lbl.gov/breastcancer/viewline.php?id=37, July 2009). 
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Table 2.2: Characteristics of Cell Lines II: 
 GI-101 Cell Line** Sk-Br-3 Cell Line*** 
Species Human, Female (57 Years) 
Passed Through a Mouse  
Human, Female (43 Years) 
Morphology Epithelial Cells Epithelial Cells 
Tissue Breast Breast 
Tumour Metastasis Ductal 
Adenocarcinoma  
Poorly Differentiated 
Adenocarcinoma 
Culture Medium RPMI 1640 media, 10% 
FCS, 5 ml PSQ*, and 
Insulin  
RPMI 1640 media, 10% 
FCS, and 5 ml PSQ* 
Split Ratio 1:4 1:4 
Properties ER
-
, Does not respond to 
Estradiol, Model for 
Metastases mechanisms 
and Therapy**. 
Hypertriploid cells 
Overexpression of Fatty 
Acid Synthase (FAS) and 
Overexpresses Her2/c-erb-
2 gene Product, p53
-
, PR
-
, 
ER
+
, and Her2
+
. Model for 
FAS mechanism***. 
*PSQ antibiotics at 50 mg⁄ml concentration (Stock: 100X: 10,000 u/ml penicillin, 10,000 µg 
streptomycin, and 29,2 mg/ml L-Glutamine in a 10 mM citrate buffer (for pH stability)). 
**( http://www.freepatentsonline.com/5693533.html, July 2009). 
***(http://icbp.lbl.gov/breastcancer/viewline.php?id=53, July 2009). 
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Table 2.3: Characteristics of Cell Lines III: 
 BT-474 Cell Line** 
Species Human, Female (60 Years) 
Morphology Epithelial Cells 
Tissue Breast 
Tumour Solid, Invasive Ductal 
Carcinoma 
Culture Medium RPMI 1640 media, 10% 
FCS, and 5 ml PSQ* 
Split Ratio 1:4 
Properties Adherent Patches of cells, 
Form Nodules, Aneuploid 
and some Chromosomes 
are absent (11, 13 and 
22)**. Tp53
+
, PR
-
, ER
-
, 
and Her2
+
. 
*PSQ antibiotics at 50 mg⁄ml concentration (Stock: 100X: 10,000 u/ml penicillin, 10,000 µg 
streptomycin, and 29,2 mg/ml L-Glutamine in a 10 mM citrate buffer (for pH stability)). 
**(http://icbp.lbl.gov/breastcancer/viewline.php?id=6, July 2009). 
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2.2.2 Bacterial Artificial Chromosomes (BACs):  
Bacterial Artificial Chromosomes (BACs) were selected using The University of California 
Santa Cruz (UCSC) Genome Browser website and obtained from Invitrogen. Different BACs 
were stored at -80ºC. 
 
2.2.2.1 BAC Preparation:  
BACs containing EGFR, CCND1, PTEN, AKT1, HSP90AA1 and ERRBB2/HER2 genes, were 
streaked on a Luria-Bertani (LB) agar plate (1% NaCl, 1% Tryptone, 0.5% Yeast Extract, 
1.5% Agar Technical, and 12.5% Chloramphinicol). Each plate was incubated at 37ºC 
overnight. Single colonies from a plate was used to inoculate 10 ml of LB broth (1% NaCl, 
1% Bactotryptone, 0.5% Yeast Extract and 12.5% Chloramphinicol) and then incubated at 
37ºC overnight with shaking. In order to make glycerol stocks of BACs clones, 0.5 ml of 
bacterial culture was placed in specific tubes (used for low temperature) with 0.5 ml glycerol. 
They were mixed and stored at -80ºC. 
 
2.2.2.2 BACs DNA Extraction: 
The rest of culture (9.5 ml) was added to 90 ml LB broth medium and incubated at 37ºC 
overnight. 100 ml suspension was centrifuged at 1300 rpm for 10 minutes. The supernatant 
was discarded and the pellet was resuspended in 6 ml P1 solution using vortex (P1=15 mM 
Tris (pH8) (Fisher Scientific), 10 mM EDTA (Fisher Scientific), and 100 µg/ml RNase A 
(Sigma-Aldrich)). 6 ml P2 solution was added to this mixture (P2= 0.2 M NaOH (BDH, 
AnalaR) and 1% SDS (Fisher Scientific)). The suspension containing the DNA was incubated 
at RT for 5 minutes and followed by addition of 6 ml P3 solution drop by drop with gentle 
mixing (P3= 3 M CH3COOK, (Sigma-Aldrich)). This suspension was incubated on ice for 10 
minutes followed by centrifuge at 9,500 rpm for 10 minutes at 4ºC. The supernatant that 
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contained the DNA was transferred to another tube and 16 ml of ice-cold isopropanol was 
added. These tubes were incubated at -20ºC overnight to allow DNA precipitation. After 
overnight incubation, these tubes were centrifuged at 9,500 rpm for 15 minutes at 4ºC. The 
supernatant was discarded and the pellet was resuspended with 10 ml ice-cold 70% ethanol. 
Again this was centrifuged at 9,500 rpm for 5 minutes at 4ºC. The supernatant was discarded 
again and the pellet were left to dry at RT. 2 ml of ddH2O was added to the pellet DNA and 
then transferred to small eppendroff tubes to be stored at -20ºC.  
 
2.2.2.3 Nick Translation for Labelling the Genes: 
This is a labeling technique for DNA labeling of FISH probes. This allows the incorporation 
of a modified nucleotide conjugated with either biotin, Biotin-16-dUTP, (Invitrogen, red) or 
digoxigenin, Digoxigenin-11-dUTP, (Roche, green). 
 
Table 2.4: The Concentration of Each BAC Clone and Its Location on Human 
Chromosomes: The concentration for each gene was measured in ng per 1 µl using nano-
drop machine: 
Genes HSAs BACs ID Concentration (ng/1 µl) 
(1) ERRBB2/HER2 17q12 CTD-2251J22 78.1 
(2) CCND1 11q13.3 RP11-266K14 104.7 
(3) EGFR 7p11.2 CTD-2151I21 321.3 
(4) AKT1 14q32.33 CTD-3022N7 78.7 
(5) PTEN 10q23.31 CTD-2553L21 2993.6 
(6) HSP90AA1 14q32.31 RP11-367F11 3984 
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2.2.2.3.1 Biotin Labeling: for all six genes and five chromosomes, biotin labeling by nick 
translation was performed using BioNick
TM
 Labeling System (Invitrogen) and the method as 
followed: firstly, these concentrations should be transferred into µg to know how many µls 
that we need (for example 78.1 ng/1 µl = 0.0781 µg/1 µl or 1 µg/X µl and X is the volume of 
probe). Then, 5 µl 10X dNTP Mix was added to (1) 15 µl, (2) 12 µl, (3) 5 µl, (4) 15 µl, (5) 1 
µl and (6) 1 µl DNA from these BACs, respectively then followed by addition of 25 µl, 28 µl, 
35 µl, 25 µl, 39 µl and 39 µl ddH2O, respectively to make it 45µl. 5µl 10X enzyme mix was 
added to this mixture and then incubated at 16ºC for 2 hours. These tubes were incubated at -
20ºC untill the next use.  
 
2.2.2.3.2 Digxogenin labeling: for AKT1, HSP90AA1, and ERBB2/HER2 genes, digxogenin 
labeling was performed using the method as followed: 1 µg of template DNA was used. 
Then, 13 µl, 1 µl, and 13 µl (respectively) was added to 3 µl, 15 µl, and 3 µl ddH2O to make 
it 16 µl. 4 µl of Dig-Nick Translation Mix (Roche) was added to the mixture to make it 20 µl. 
The mixture was then incubated at 15ºC for 90 minutes. The labeled genes were stored at -
20ºC and were ready for the next use.  
 
2.2.3 2-Dimensional Fluorescence In Situ Hybridization (2D-FISH):   
2.2.3.1 Harvesting Cells and Fixation (methanol: acetic acid, 3:1): 
After the cells were harvested during cell culture, the cells were placed in an equal volume of 
medium and spun at 1000 rpm for 5 minutes in the bench centrifuge. The supernatant was 
removed and the pellet resuspended using hypotonic solution (0.075 M KCl) at room 
temperature (RT) for 15 minutes. The hypotonic solution was added drop wise with constant 
agitation. The cells were spun again at 800 rpm RT for 5 minutes in a bench centrifuge. The 
pellet was resuspended in the remaining supernatant. Then fixation was initiated by adding 
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methanol: acetic acid, 3:1 drop wise with gentle shaking by hand. The cells with fixative 
solution were placed on ice for 1 hour and spun at 800 rpm for 5 minutes. The pellet was 
resuspended again with methanol: acetic acid (3:1) and spun again at 800 rpm for 5 minutes. 
The fixation procedure was repeated at least 6 times. The cells were checked with light 
microscopy to determine when the nuclei were free of cytoplasm. 
 
2.2.3.2 Degenerated Oligonucleotide Primer-Polymerase Chain Reaction (DOP-PCR):  
2.2.3.2.1 Whole Chromosome Paints Template DNA without Labelling and Labelled 
with Biotin using DOP-PCR: 
The protocol for Degenerated Oligonucleotide Primer-Polymerase Chain Reaction (DOP-
PCR) was followed to generate two different rounds of amplifications: the first, the primary 
amplification products without labeling of different chromosomes 7, 10, 11, 14, and 17. The 
second, the secondary amplification products were labeled with 20 µl biotin-16-dUTP (1 
mM, Roche) was also performed.  
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Table 2.5: The Master Mix Components for DOP-PCR: This technique was performed on 
PCR master mix using the DOP primer as follows: 
 Without Biotin With Biotin 
10X DOP PCR Buffer 10 µl 10 µl 
dACGTP (2µM) 10 µl 10 µl 
dTTP (2µM) 10 µl 4 µl 
DOP-PCR Primer (20 µM) 10 µl 10 µl 
Sterilised Water 57 µl 35 µl 
DNA Template 2 µl 10 µl 
Biotin-16-dUTP (1 mM) - 20 µl 
Taq-KAPA HIFI 1 µl 1 µl 
Total 100 µl 100 µl 
 
 
Table 2.6: The Cycling Conditions for DOP-PCR Programme: The PCR was performed 
on a thermocycler machine. The two rounds of amplification were performed. Cycling 
conditions for DOP-PCR programme were as follows:   
Phase Step (Cycle) Temperature (ºC) Time (Minutes) 
Initial Denaturation 1  94 3  
Denaturation  
30  
94 1  
Annealing 62 1  
Extension 68 1.5  
Final Extension 1  68 8  
For Collection  4 ∞ 
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2.2.3.2.2 Confirmation of Amplified DNA Products by Agarose Gel Electrophoresis: 
Agarose gel electrophoresis was performed using 1% agarose gel (1 g agarose in 100 ml 1X 
TBE, Tris, Boric Acid, and EDTA (Appendices)) to check that the DNA amplification had 
occurred. After heating the agarose, 2 µl ethidium bromide (10 mg/ml) was added to the 
warm gel. The gel was poured into the gel tank with comb and left to set. Then 1X TBE was 
poured into the tank to cover the gel. The samples were prepared for loading as well as the 
control (sterilised water instead of DNA). Each sample contained 3 µl of the PCR products, 1 
µl sterilised water, and 1 µl loading dye. The DNA ladder (marker, 3 µl) (1 Kb, 50 µg/ml, 
BioLabs) was loaded into the first lane on the gel. The gel electrophoresis apparatus was run 
at 80 volts for 40 minutes. Images were captured using the UV Transilliminator to visualise 
the products. The unlabelled and labeled DOP-PCR products were stored at -20ºC until use. 
 
2.2.3.3 Probe Preparation: 
The template probes labeled with biotin (HSAs 7, 10, 11, 14, and 17) were prepared and 
amplified using DOP-PCR technique and stored at -20ºC. In order to prepare probes for 2D-
FISH, 8 µl of probe template or 25 µl of DNA template (200-400 µg of chromosome paint or 
gene, respectively) was added to 7 µl of C0t-1 DNA (1 µg/1 µl), and 3 µl of salmon herring 
sperm DNA, in 1.5 ml eppendroff tube. 1/10
th
 of the volume of 3M Na Acetate and 2 
volumes ice-cold 100% ethanol were added. This mixture was incubated at -80ºC for at least 
30 minutes. After incubation, the probe was centrifuged at 13,000 rpm for 30 minutes at 4ºC. 
After centrifugation, the excess liquid was removed and the DNA pellet was washed with 200 
µl of ice-cold 70% ethanol. This was centrifuged again at 13,000 rpm at 4ºC for 15 minutes 
and the excess liquid was removed carefully. The pellet was then dried at 37ºC on the hot 
block or oven until it became transparent. 12 µl of hybridisation buffer was added to the dried 
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pellet and allowed to dissolve for 2 hours at 50ºC with gentle tapping every 15 minutes or left 
overnight at RT.  
 
2.2.3.4 Slide Cell Preparation: 
In order to prepare slides, they were made damp or steamed. The cells in fixative solution 
were spun and resuspended in fresh methanol: acetic acid, 3:1 and one drop of cell 
suspension was placed onto a damp slide to spread the cells. These cells were checked with 
the light microscope and then incubated for 2 days at RT or 1 hour at 70ºC before denaturing.  
 
2.2.3.5 Probe Denaturation: 
The probes that were stored at -20ºC were spun and incubated at 75ºC for 10 minutes on a 
heat block. Then the probes were placed in a water-bath at 37ºC for 30 minutes - 2 hours for 
reannealing.  
 
2.2.3.6 Slide Denaturation: 
After ageing the slides, they were subjected to an ethanol row 70% ethanol, 90% ethanol and 
100% ethanol for 5 minutes each. The slides were then dried on the hot block. After this 
dehydration, the slides were warmed in an oven at 70ºC for 5 minutes. Meanwhile, 
formamide solution (70% formamide in 2XSSC, pH 7.0) was placed in a water-bath and 
heated to 70ºC. The dried slides were placed in the formamide solution (70%) for 2 minutes 
at 70ºC. Then, slides were immediately placed in ethanol ice-cold 70% for 5 minutes, 90% 
and 100% ethanol solutions at RT for 5 minutes each to be ready for hybridisation with the 
probe.  
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2.2.3.7 Hybridisation: 
After preparation and denaturation of probes and slides, hybridisation was performed by 
adding 10 µl of probe on the slide. This probe was covered with a warmed coverslip and 
sealed with rubber glue. The probe and the slide were allowed to hybridise in a humidified 
chamber for 2 days before washing.  
 
2.2.3.8 Washing and Mounting on Slides for 2D-FISH: 
Buffer A and B (appendices section) were pre-warmed at 45ºC and 60ºC, respectively. Then 
the slides were removed from the hybridisation chamber one by one. The rubber glue was 
removed carefully using forceps and the slides with coverslips were placed in wash buffer A 
(50% Formamide and 2X sodium saline citrate (SSC), pH 7.0) at 45ºC for 15 minutes with 3 
changes of the buffer. Then buffer B (0.1X SSC, pH 7.0) pre-warmed at 60ºC was 
immediately transferred to water-bath at 45ºC and the slides washed for 15 minutes with 3 
changes of buffer. The slides were placed immediately into 4X SSC at RT for 5-10 minutes 
to cool down. 100 µl of 4% bovine serum albumin (BSA) (Sigma-Aldrich) solution in 
4XSSC was added onto the slides and covered with parafilm for blocking for 10 minutes at 
RT. 100 µl of Cyanine 3 (Cy3) conjugated streptavidin (Amersham Life Sciences) solution in 
1% BSA in 4XSSC (1:200 dilution) was placed on the slide in order to detect the labeled 
probe.  
 
For dual colour FISH, streptavidin-cyanine 3 was mixed with anti-dixogenin antibody 
(Roche) (diluted 1:50, in 1% BSA in 4XSSC). Then, the slides were incubated at 37ºC in a 
dark place (oven) for 30 minutes. The slides were washed in 4X SSC with 0.5% Tween-20 
(Appendices) for 15 minutes with 3 changes at 42ºC. This was followed by washing the 
slides again in ddH2O to remove the excess of 4X SSC-Tween-20. The slides were mounted 
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in counterstain, Vectashield medium (Vector Laboratories) with 4`, 6-Diamidino-2-
Phenyindole (DAPI, 1.5 µg/ml) and covered by glass coverslips. Then mounted slides were 
visualised and images captured by fluorescence microscopy. DAPI excites at 360 nm and 
emits at 460 nm when bound to DNA producing a blue fluorescence. The slides were placed 
on a dark box at 4ºC. 
 
2.2.3.9 Evaluation and Detection by Capturing Images using Microscopy: 
Fluorescence microscopy was performed with a microscope (Olympus BX41 with 
Smartcapture3 Software). All slides were examined under 100X immersion oil (Immersol)™ 
objective lens and images of genes, chromosomes and both were captured with a camera and 
previewed on Macintosh Apple Computer (MAC) operated with SmartCapture3 software 
programme. The slides were stored in a black dark box at 4ºC. 
 
2.2.3.10 Image Analysis for Chromosomes, Genes, and Both:  
Images were randomly selected in IPLab Spectrum Software. To analyse chromosome and 
gene position using the erosion script analysis programme. This programme divides the 
nucleus (DAPI stain) into 5 shells of equal area. 1
st
 shell is peripheral and 5
th
 shell is interior 
(Figure, 2.1). The script determines the pixel intensity of DAPI, chromosomes and gene in 
these five shells. This intensity of the probe signal was normalised by dividing the percentage 
of probe signal by the percentage of DAPI signal in each shell. For at least 50 nuclei, the 
normalised intensity was calculated for the 5 shells, the standard error bars of the mean were 
measured and graphs made using Microsoft Excel software. 
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Figure 2.1: Erosion Script Analysis: The Erosion Script Analysis for Positioning of 
Chromosome Territories and Intensity Measurement 
The cell nuclei were fixed with methanol: acetic acid (3:1) and 2D-FISH was performed for 
whole chromosome paints (Green) or gene signals (Red). Images were captured and analysed 
using erosion script (Croft et al., 1999). The erosion script programme divides the nucleus 
into 5 shells of equal area, 1
st
 shell is peripheral and 5
th
 shell is interior. The script measures 
the signal intensities of probe and DNA in each shell. These probe measurements were 
normalised.  
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2.3 Results  
From previous studies it is known that the genome is positioned non-randomly during 
interphase (Bridger and Bickmore, 1998), chromosomes are positioned according to their 
gene density (Croft et al., 1999; Bridger et al., 2000) or their size (Bolzer et al., 2005).  
 
In this chapter, the work investigated the spatial positioning of chromosomes 7, 10, 11, 14, 
and 17 in normal breast (MCF-10A) and breast cancer (T-47D, GI-101, Sk-Br-3, and BT-
474) cell lines, as well as the positioning of specific genes of interest (EGFR, PTEN, CCND1, 
AKT1, HSP90AA1, and ERBB2/HER2). These chromosomes were chosen because they 
accommodate the genes of interest that are involved in breast cancer progression. These cell 
lines were chosen as a model system because they represent different stages of breast cancer. 
There are no previously published data about chromosome and gene positions in these cell 
lines.  
 
To assess the positions of these chromosomes and genes in the breast cancer cell line, 2D-
FISH was performed, digital images captured and analysed, the data analysed and displayed 
as histograms with error bars. 
 
2.3.1 Chromosome Territories and Gene Loci in Breast Cancer Cells by 2D-
Fluorescence In Situ Hybridisation (2D-FISH):  
The localisation of human chromosomes within the different cell lines was assessed and 
representative images are shown in Figure 2.2. It can be seen that not all chromosomes have 
two chromosome territories many of them have more than one. Gene loci were delineated by  
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2D-FISH and specific BACs as probes and representative images are shown in Figure 2.3. 
Again in some cells there are more than the normal two gene loci. 
Figure 2.2: (A) Chromosomes Positioning: 2D-FISH was used to analyse the position of human
chromosomes 7, 10, 11, 14, and 17 in normal breast (MCF-10A, A-E) and cancer (T-47D (F-J), GI-
101 (K-O), Sk-Br-3 (P-T), and BT-474 (U-Y)) cell lines. DNA has counterstained using DAPI (Blue)
whereas; chromosome signals can be seen in Red (Cy3-streptavidin) and then converted into green
colour to facilitate their analysis. Magnification = X100; Scale Bar = 10µM.
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EGFR               PTEN            CCND1              AKT1          HSP90AA1   ERBB2/HER2
Figure 2.3: (B) Genes Positioning: Using 2D-FISH to analyse the positioning of specific genes
EGFR, PTEN, CCND1, AKT1, HSP90AA1, and ERBB2/HER2 of interest in breast normal MCF-
10A (A-F) and cancer T-47D (S-X), GI-101 (Y-D*), Sk-Br-3 (G-L), and BT-474 (M-R) cell lines.
DNA has been counterstained using DAPI (Blue) whereas; gene signals can be seen in Red (Cy3-
streptavidin) and then converted into green colour to facilitate their analysis. Magnification = X100;
Scale Bar = 10µM .
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2.3.2 Position Analysis for both Chromosomes and Genes 
The images collected of the different chromosomes and gene loci were subjected to the 
erosion analysis script (Croft et al., 1999) Histograms were plotted with individual 
chromosomes and the genes they host for all the different cell lines (Figure 2.4). 
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Figure 2.4: Images Analyses for Genes and Chromosomes using 2D-FISH 
These histograms show the nuclear localisations of human genes EGFR, PTEN, CCND1, 
HSP90AA1 and AKT1, and ERRBB2/HER2 and chromosomes 7, 10, 11, 14 and 17 in normal 
breast (MCF-10A) and breast cancer (T-47D, GI-101, Sk-Br-3, and BT-474) cell lines. Their 
positions were assessed by 2D-FISH and analysed by simple erosion analysis. Error bars was 
measured from the standard error of the mean (SEM). Y Axis = % of Chromosome and Gene 
Signal / % of DAPI Signal whereas X Axis = the position from periphery to interior (1 to 5).  
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2.3.3 Statistical Analysis of using Student’s t-test: 
The Student’s t-test with Excel Software Programme was used to statistically compare the 
positions of genes and chromosomes within BT-474, GI-101, T-47D, and Sk-Br-3 cells with 
the normal MCF-10A immortalised cells that were statistically different from each other. The 
probability-value (p-value) in the test was known; p<0.5 was considered significant and any 
less than 0.05 that means there is a significant difference in position and indicated with star 
and more than 0.5 that means no significant difference in position. 
 
2.3.3.1 Statistical Analyses for Chromosome Position: 
Statistical analyses with the Student’s t-test were also performed for the cancer cell lines 
compared to the control cell line. All the cell lines show chromosomes in different nuclear 
locations to the control cells.  The chromosome that is most unaffected is HSA 10.  
 
 (1) HSA 7: 
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(2) HSA 10: 
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(3) HSA 11: 
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(4) HSA 14: 
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(5) HSA 17: 
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2.3.3.2 Statistical Analyses Comparing Cancer Cells with the Control Cells for Gene 
Position: 
In order to determine if gene position had changed from the control cells (MCF-10A) in the 
cancer cells statistical analysis was performed on the data generated for gene loci position. 
The results are shown in the following charts. Black signifies no significant difference 
whereas green and red do show differences. Interestingly, most of the genes that haven’t 
changed location are in T47D cells when compared to control cells.  
 
 (1) EGFR: 
 BT-474 GI-101 T-47D Sk-Br-3 
Area 1 0.406016 0.048312 0.04407 0.003366 
Area 2 0.354978 0.061717 0.028622 0.392051 
Area 3 0.335405 0.156527 0.282418 0.433687 
Area 4 0.335341 0.070113 0.195944 0.004823 
Area 5 0.174483 0.025945 0.009932 0.002676 
 
 
(2) PTEN: 
 BT-474 GI-101 
 
T-47D 
 
Sk-Br-3  
Area 1 0.000567 0.411599 3.34E-16 0.036888 
Area 2 0.176814 0.10788 0.002687 0.011173 
Area 3 0.10339 0.002676 0.000152 0.001436 
Area 4 0.222305 0.337347 0.001447 0.077467 
Area 5 0.363993 0.000318 0.005446 1.17E-08 
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(3) CCND1: 
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(4) AKT1: 
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(5) HSP90AA1: 
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Area 1     
Area 2     
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(6) ERBB2-HER2: 
 BT-474 GI-101 
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Sk-Br-3  
Area 1     
Area 2     
Area 3     
Area 4     
Area 5     
 
The Key: 
Black = Indicates no significant difference between the positions with the p-value >0.5 
Green = Indicates significant difference between the positions with the p-value <0.5 
Red = Indicates significant difference between the positions with the p-value <0.05 
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From this analysis, it can be seen that the positions of chromosome 7 in T-47D and MCF-
10A cells was located at the periphery whereas, it was interior in BT-474, GI-101 and Sk-Br-
3 cells. The positions of chromosomes 10 in MCF-10A, T-47D, and BT-474 cells were 
located at the periphery and at the nuclear interior in Sk-Br-3 and GI-101 cells. The position 
of chromosomes 11 in MCF-10A cells was intermediate but at the periphery in GI-101, T-
47D and BT-474 cells, and in the interior in Sk-Br-3 cells. The positions of chromosomes 14 
in T-47D, MCF-10A, GI-101, and Sk-Br-3 cells was located at the periphery whereas, BT-
474 cells showed an intermediate localisation. The positions of chromosomes 17 in MCF-
10A, Sk-Br-3 T-47D, BT-474 and GI-101 cells was located at the interior (Figure 2.4 and 
Table 2.4, A). 
 
The position of EGFR gene was located at the nuclear periphery in all cell lines except GI-
101 cells were located interiorly. PTEN gene was located in the nuclear interior in MCF-10A, 
GI-101 and Sk-Br-3 cells whereas, at the periphery in T-47D, BT-474 cells. CCND1 gene 
was positioned interiorly in MCF-10A, GI-101, and Sk-Br-3 cell lines whereas it was at the 
periphery in T-47D, BT-474 cells. Furthermore, HSP90AA1 gene was positioned interiorly in 
BT-474, GI-101, and Sk-Br-3 cell lines whereas it was at the periphery in MCF-10A and T-
47D cells. Moreover, AKT1 gene was localised in the interior in MCF-10A, GI-101, and Sk-
Br-3 cells but at the periphery in T-47D and BT-474 cells. ERRBB2/HER2 gene was located 
in the interior in MCF-10A and GI-101 cells but at the periphery in T-47D, BT-474, and Sk-
Br-3 cells (Figure 2.4 and Table 2.4, B). 
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Table 2.7 (A and B): Summary of Locations of Human Chromosomes (HSA 7, 10, 11, 
14, and 17, Table A) and Genes (EGFR, PTEN, CCND1, AKT1, HSP90AA1, and 
ERBB2/HER2, Table B) in Interphase Nuclei of Normal and Abnormal Breast Cell 
Lines: The tables below (A and B) display the position of human genes EGFR, PTEN, 
CCND1, AKT1, HSP90AA1, and ERBB2/HER2 that are located and resided on human 
chromosomes 7, 10, 11, 14 and 17 territories in Sk-Br-3, GI-101, T47-D and BT-474 breast 
cancer cell lines occupy altered localisations during interphase nuclei when compared to 
MCF-10A normal but immortalised breast cell line. 
A:  
HSA MCF-10A T-47D BT-474 GI-101 Sk-Br-3 
7 Periphery Periphery Interior Interior Interior 
10 Periphery Periphery Periphery Interior Interior 
11 Intermediate Periphery Periphery Periphery Interior 
14 Periphery Periphery Intermediate Periphery Periphery 
17 Interior Interior Interior Interior Interior 
 
 
B: 
Gene MCF-10A T-47D BT-474 GI-101 Sk-Br-3 
EGFR Periphery Periphery Periphery Interior Periphery 
PTEN Interior Periphery Periphery Interior Interior 
CCND1 Interior Periphery Periphery Interior Interior 
AKT1 Interior Periphery Periphery Interior Interior 
HSP90AA1 Periphery Periphery Interior Interior Interior 
ERBB2/HER2 Interior Periphery Periphery Interior Periphery 
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2.3.4 Two Colour FISH for Both Gene and Chromosome Positioning: 
From the findings, it was seen that all genes were in the same compartment as their host 
chromosome as shown in table 2.4 (A and B) in all cell lines except PTEN and AKT1 in 
MCF-10A, ERBB2/HER2 in T-47D, EGFR and ERBB2/HER2 in BT-474, CCND1, AKT1, 
and HSP90AA1 in GI-101, and EGFR and ERBB2/HER2 in Sk-Br-3 cell lines. In these cells 
the genes were not in the same compartment as their chromosome because they must be away 
from chromosomes on chromatin loops. Therefore, two colour FISH experiments were 
performed to assess the position of both gene and chromosome in the same nuclei to 
determine if the genes were colocalised or at a distance from their chromosomes (Figure 2.5 
and Table 2.5). 
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2.3.4 Two Colours FISH for Both Gene and Chromosome Positioning
HSA14/ AKT1 HSA14/ HSP90AA1 HSA17/ ERRBB2.HER2
MCF-10A
T-47D
BT-474
Figure 2.5: Spatial Reorganisation of both Genes and Chromosomes in Breast Cancer
and Normal Cell Lines: These images are demonstrating the positions of both human
chromosomes (red, Cy3-streptavidin) and genes (green, FITC). These genes were chosen to
see their location on/away from chromosomes. They were detected by dual colour FISH
technique in normal breast (MCF-10A, G-I) and cancer (T-47D, A-C and BT-474, D-F) cell
lines. Nuclei were counterstained with DAPI (blue). Magnification = X100; Scale Bar =
10µM.
A
E F
G
B C
D
IH
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Table 2.8: Gene Loci at A Distance from Their Host Chromosomes: The spatial 
organisation of both genes on/away from chromosomes in breast cancer and normal breast 
cell lines was assessed. The percentages of copy number of genes (AKT1, HSP90AA1, and 
ERBB2/HER2) that located onto chromosomes (HSA 14 and 17) or found at a distance from 
their home chromosomes were counted in T47-D, BT-474, and MCF-10A cell lines (Figure 
2.5).  
 
(1) T47-D Cell Lines: 
 On 
Chromosome 
At a Distance from 
Chromosome 
AKT1, HSA 14 60% 40% 
HSP90AA1, HSA 14 38% 62% 
ERBB2/HER2, HSA 17 40% 60% 
 
 
(2) BT-474 Cell Lines: 
 On 
Chromosome 
At a Distance from 
Chromosome 
AKT1, HSA 14 100% 0% 
HSP90AA1, HSA 14 86% 14% 
ERBB2/HER2, HSA 17 17% 83% 
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(3) MCF-10A Cell Lines: 
 On 
Chromosome 
At a Distance  from 
Chromosome 
AKT1, HSA 14 75% 25% 
HSP90AA1, HSA 14 57% 43% 
ERBB2/HER2, HSA 17 40% 60% 
 
The T47D cell line displayed two genes with over 50% of their loci away from their home 
chromosome. Whereas the other two cell lines, BT474 and MCF10A, had only one gene 
away from the host chromosome in more than 50% of the cells. This was the same gene in 
both cell lines; ERBB2/HER2 which is interesting considering how important this gene is in 
breast cancer progression.  
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2.4 Discussion: 
To study the organisation of the genome in the nuclei of breast cancer cells, chromosomes 
and genes were delineated with labeled FISH probes and their nuclear distribution and 
position assessed.  
 
Figure 2.4 displays the position of human genes EGFR, PTEN, CCND1, AKT1, HSP90AA1, 
and ERBB2/HER2 that are accommodated on human chromosomes 7, 10, 11, 14 and 17 
territories in Sk-Br-3, GI-101, T47-D and BT-474 breast cancer cell lines. These territories 
were found in different nuclear locations interphase nuclei when compared to MCF-10A 
normal immortalised breast cell line. This alteration and difference in position was significant 
and indicated by green (p-value <0.5) and red (p-value <0.05) colour in the statistical analysis 
tables. The significance of this alteration and changes in most genes positioning within breast 
cancer cells requires further investigation. However, the re-positioning of genes in these cells 
indicates the disruption of genome organisation. These differences in position raise several 
questions; why are certain chromosomes and genes were affected while others are not? Is this 
due to involvement of other factors such as transcription factors activity? Or this is cell type 
dependent? Most importantly has this change in gene position within nuclei affected gene 
expression profiles? 
 
Whole chromosome territory positions are generally maintained during interphase and these 
territories have individual loci that can move rapidly over large distances (Mehta et al., 
2010a). These results indicate that an aberrant gene position was seen in breast cancer cells 
when compared to the normal cells. In this study, I found that HSA11 accommodating 
CCND1, occupies an intermediate location in normal cell nuclei whereas CCND1 was 
interiorly positioned in the same cell line which is similar result to the work done by Meaburn 
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et al., 2008; Mehta et al., 2010a. The position of genes was assessed by investigation the 
position either on or away from chromosomes. In T-47D cells, 60-62% of cell nuclei showed 
the position of HSP90AA1 and ERBB2/HER2 genes was away from their chromosomes and 
60% of cell nuclei showed the position of AKT1 gene on chromosome. In BT-474 cells, all 
cell nuclei showed that AKT1 gene position on chromosome (100%) whereas HSP90AA1 
gene positioned on chromosome in 86% of nuclei and only 17% of nuclei showed 
ERBB2/HER2 gene position on chromosome. In MCF-10A cells, 25% of nuclei showed that 
AKT1 gene was position away from chromosomes whereas 43% of nuclei showed the 
position of HSP90AA1 gene away from chromosome and 40% of nuclei showed 
ERBB2/HER2 gene was positioned on chromosome. Regarding, the position of genes away 
from their chromosomes this could suggest that in these cells, the gene loops away from 
home chromosome. The change in gene position may be due to specific internal nuclear re-
organisation and this indicates a change in the activity of the cells and their transcription 
status.  
 
Often upon transcriptional activation a locus will decondense and move until it associates 
with PML bodies to maximise transcriptional output or some loci on chromosomes move into 
large distances to interact with transcription factories to regulate their transcription and 
expression whereas, some of chromosomes and genomic regions associated with specific 
structures (nuclear matrix, nuclear lamina, and nucleoli) and then determined their movement 
(Eskiw et al., 2003; Elcock and Bridger, 2010).  
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2.4.1 The Concept of Chromosomes Kissing and Gene Regulation in Genome 
Organisation:  
Eukaryotic chromosomes occupy distinct territories in the cell nucleus. These territories 
interact with other chromosomes to make several interactions between different chromosomal 
loci via cis contacts which have been investigated in a phenomenon called “chromosome 
kissing” (Cavalli, 2007). These contacts are due to preferential chromosome neighbourhoods 
and of sharing of transcriptional machineries while others seem to have regulatory functions. 
Moreover, these contacts are modulated by specific chromatin features of each locus, and 
they play important roles in the regulation of gene expression. Chromosome kissing events 
may also be at the origin of chromosomal rearrangements (Cavalli, 2007). Furthermore, gene 
expression can influence by cis-regulatory elements (on the same chromosome) or trans-
regulatory elements (on different chromosome) that affect gene function (therefore, it might 
be involved in mechanisms of gene activation or silencing) as well as transcription factors 
and chromatin-histone complexes. However, the correlation of these components of the 
nucleus is unclear. Technical advances are now identifying the relationships, locations, and 
interactions of genes and these regulatory elements in the nucleus are revealing that there is a 
network within and between chromosomes and genes but to which this network organisation 
affects gene function is still unclear (Fraser and Bickmore, 2007). Recent studies show that 
genes on the same chromosome or even on different chromosomes can come together in the 
nuclear space via loops. It has been hypothesised that functionally related genes 'kiss' at 
transcription factories to coordinate their expression and discover this romantic concept of 
nuclear architecture (de Laat, 2006). Figure 2.3 displays the position of multiple copies of the 
gene at the same place or at the transcription machinery to regulate their expression and 
activity. 
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2.5 Conclusion:  
Interestingly, there are differences in chromosomal and gene locations between different cells 
(Figure 2.4 and Table 2.4). The results showed chromosomes 14 and 17 with clear 
differences with respect to position between cells as well as AKT1, HSP90AA1, and 
ERBB2/HER2 genes within MCF-10A, T-47D, and BT-474 cell lines. 
 
When analysing the nuclear positioning of specific genes and their chromosomes in breast 
cancer cell lines, it is found that the important genes that involved in breast cancer 
progression are positioned in different localisations as compared to controls. These changes 
will affect chromatin organisation and gene expression. If this alteration is consistent as seen 
in Meaburn’s studies then it may be extremely useful as a diagnostic biomarker.  
 
Understanding the nuclear behaviour of breast cancer cells will aid in the goal to investigate 
new pathways involved in expression of interested genes in cancer. The results from this 
study emphasise the genome organisation and its importance to genomic stability. New 
directions of monitoring genomic instability could impact on cancer biology, genetics, 
diagnosis and efficiency of treatment response in medicine. However, the development in 
molecular and cytogenetic techniques allows us to understand how the nucleus is well 
organised and how it functions although the mechanistic basis by which alterations in 
genome organisation, and function lead to cancer is an exciting new area of study.  
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Chapter 3: Expression of Specific Genes in 
Human Breast Cancer Cell Lines 
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3.1 Introduction: 
Studies have shown that individual chromosomes have preferential neighbouring territories 
and the organisation appears to be cell type specific (Nagele et al., 1999; Parada and Misteli, 
2002; Parada et al., 2004; Bolzer et al., 2005; Foster and Bridger, 2005; Branco and Pombo, 
2006; Meaburn and Misteli, 2008). The arrangement of these chromosome territories (CT)   is 
based on the transcriptional activity. Croft et al., in 1999 and Bridger et al., in 2000, studied 
the gene rich chromosome 19 and gene poor chromosome 18 and showed the morphology of 
chromosome territories is linked to their transcriptional status. The eukaryotic cells 
demonstrate variable ranges in gene expression, because of variable rates in kinetics of gene 
activation, transcription, and translation. This demonstration has been linked to gene position 
via spatial variation in the induction, regulation and activation of transcription factors, 
nucleosomes, and chromatin remodeling complexes (Batenchuk et al., 2011). However, 
different studies of gene expression in yeast have failed to display this idea (Newman et al., 
2006). Moreover, chromosome position can influence the transcriptional activity of genes 
within it and this will affect their expression (Volpi et al., 2000). Several mechanisms or 
factors can alter the position of genes for example non-allelic homologous recombination, 
movement of chromosomes, movement of genes, and movement of nuclear sub-structures 
such as nucleolus, chromatin fibres, and PML bodies (De and Babu, 2010). These events can 
contribute to cause specific disease such as cancer.    
 
Individual genes, as well as chromosomal regions, occupy preferential, distinct radial 
locations within interphase nuclei (Bridger and Bickmore 1998). Transcriptionally active 
genes can be found at the periphery of chromosome territories (Kurz et al., 1996), within the 
chromosome territory (Mahy et al., 2002), and they can also loop out from the chromosome 
territory (Branco and Pombo, 2006) where they can access to the transcriptional machinery. 
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Moreover, the preferential location of the ANT2 and ANT3 genes at the edge of X 
chromosome territories (Dietzel et al., 1999) suggest a non-random and function-related 
distribution of genomic regions. In order to understand the relationship between chromosome 
architecture and its gene activity, Volpi et al., 2000 studied genomic regions of human 
chromosome 6 during interphase and assessed their responses to transcriptional activation. 
They used two cell types, fibroblasts and B-lymphoblastoid cells, which express the major 
histocompatibility complex (MHC) genes upon regulation by interferon-gamma (IFNγ) to 
assess the effect of transcriptional activation.  They found that the MHC genes came out on 
loops away from chromosome 6 when activated to transcribe. This is what we believe 
happened to the genes seen away from their home chromosome in chapter 2.                          
 
Changes in nuclear position of genes are induced by many factors such as transcriptional 
status of genes and stress. Upon activation, genes can move away from a CT to a site that is 
enriched in gene expression machinery. However, gene activation is not always accompanied 
by movement, as positioning is determined by many factors, including gene structure and the 
local genomic environment (Mekhail and Moazed, 2010; Geyer et al., 2011). Finlan et al., in 
2008 investigated the role of gene position and transcriptional suppression at the nuclear 
periphery in mammalian cells. They relocated two different human chromosomes via the 
interaction of Eschericia coli (E.coli) lac operator (lacO) to the nuclear periphery with lac 
repressor (lacI) that is fused to the integral INM protein LAP2β. They found that reduction in 
the expression of some genes close to the lacO sites and some other genes that away from 
lacO also appear to be down-regulated by relocalisation of these chromosomes toward the 
nuclear periphery and this is due to histone deacetylases (HDACs) inactivity. Their data 
suggest that, during development and differentiation, re-position of genes to the nuclear 
periphery could be used as a mechanism to modulate the expression of specific genes without 
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changing expression of their neighbours in vertebrates. Szczerbal et al., in 2009 provide 
evidence that genes that are to be expressed in adipogenesis move towards the nuclear 
interior and some move back again when their transcription has ceased. These data and others 
(Bourne et al., 2013) strongly suggest that the position of a gene in the cell nucleus is 
involved in regulating gene expression.  
 
The aim of this chapter focuses on the expression of specific genes that are involved in breast 
cancer susceptibility and progression but they can also play a role in other types of cancer, 
such as colorectal, ovarian, or prostate. These are the genes that have changed nuclear 
location in the breast cancer cell lines compared to normal control cells (Chapter 2). These 
genes showed variant expression within normal breast (MCF-10A) and breast cancer (T-47D, 
GI-101, BT-474, and Sk-Br-3) cell lines when assessed by qRT-PCR (Figure 3.1). Their 
expression characteristics are compared to their nuclear position.     
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3.2 Material and Methods: 
3.2.1 Gene Primer Design: 
To design primers, the steps were followed using the Invitrogen website: 
www.Invitrogen.com → Nucleic Acid Amplification and Expression Profiling → 
Invitrogen™ Custom Oligonucleotides → Primer Designer Tools → Oligo Perfect™ 
Designer → Country → Gene Name, Researcher Name, and PCR Detection (mRNA 
Sequence was copied) → Submit. The primer size was chosen between 18-25 bp and the 
GC% of primer was chosen between minimum 40 and maximum 60 (Appendices). 
 
3.2.2 Genes Assessed in Breast Cancer Cell Lines: 
3.2.2.1 EGFR (Epidermal Growth Factor Receptor Gene): 
Gene Symbol Gene Location Gene Description 
EGFR; ERBB1; 
HER1 in 
humans  
located on 
7p11.2 (OMIM) 
It is a cell surface receptor for members of the 
epidermal growth factor family (EGF-family) of 
extracelluar protein and is a transmembrane 
glycoprotein that constitutes one of four members of 
the ERBB family of tyrosine kinase receptors (EGFR 
(ERBB1), HER2 (ERBB2), HER3 (ERBB3) and 
HER4 (ERBB4)). Binding of EGFR to its ligands 
leads to phosphorylation of receptor tyrosine kinase 
and activation of signal transduction pathways that are 
involved in regulating cellular proliferation, 
differentiation, motility, survival, and tissue 
development (Wang et al., 2004). Although is present 
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in normal cells, EGFR is over-expressed in a variety 
of tumour cell lines (breast, head and neck (HNC) and 
lung cancers) and has been associated with poor 
prognosis and decreased survival. Mutations affecting 
EGFR expression or activity could result in cell 
proliferation and cancer. PML and p73 are involved in 
the regulation of EGFR expression (Herbst, 2004; 
Klanrit et al., 2009). 
 
 
 
3.2.2.2 PTEN (Phosphatase and Tensin Homology): 
Gene Symbol Gene Location Gene Description 
PTEN gene located on 
10q23.31 
(OMIM) 
This gene is identified as a tumour suppressor that is 
mutated in a large number of cancers at high 
frequency. Mutations in this gene have been linked to 
various tumours including renal, glioma, melanoma, 
endometrial, breast, prostate, lung, bladder, and 
thyroid (Li and Sun, 1998). It encodes a major lipid 
phosphatase that antagonises the phosphatidylinositol-
triphosphate kinase (PI3K) signaling pathway through 
its lipid phosphatase activity, resulting in the 
inhibition of the AKT proto-oncogene and mTOR 
pathway and induces G1 cell cycle arrest and 
apoptosis (Eng, 2003). This phosphatase activity 
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negatively regulates the mitogen-activated protein 
kinase (MAPK) pathway. Inactivation or loss of PTEN 
function results in an increased cell survival and 
uncontrolled cellular proliferation, growth, migration, 
and survival mediated by these pathways and resulting 
in neoplasia (Cowden disease) (Katso et al., 2001; Yin 
and Shen, 2008). PTEN is believed to be an active 
protein; its activity is dependent on its levels 
(Blumenthal and Dennis, 2008). Despite this fact, 
PTEN has significant roles in regulating the cell cycle, 
implicated in apoptosis processes, maintaining of cell 
size (Huang et al., 1999), maintaining chromosome 
integrity and stability through the interaction with 
centromeres and control of DNA repair suggesting 
that PTEN acts as a guardian of genome integrity 
(Shen et al., 2007), differentiation (Zheng et al., 
2008), and in the malignant transformation associated 
with carcinogenesis. Relatively little is known about 
the mechanisms that control transcriptional regulation 
for PTEN expression (Pezzolesi et al., 2007). 
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3.2.2.3 CCND1 (Cyclin D1): 
Gene Symbol Gene Location Gene Description 
CCND1 gene located on 
11q13.3 
(OMIM) 
It is regulatory subunit of a holoenzyme that 
phosphorylates and inactivates the pRB and promotes 
progression through the G1-S phase of the cell cycle 
dependent on cyclin-dependent kinases, CDKs. In 
addition, CCND1 has a number of cell cycle and 
CDK-independent functions. CCND1 associates with 
and regulates transcription factors, ac as co-activator, 
and co-repressor that controls histone acetylation and 
chromatin remodeling proteins. CCND1 has also roles 
in cellular growth, metabolism, and cellular 
differentiation. Amplification or over-expression of 
CCND1 plays pivotal roles in the development of 
several human cancers, including parathyroid 
adenoma, breast cancer, colon cancer, lymphoma, 
melanoma, and prostate cancer (Fu et al., 2004). 
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3.2.2.4 AKT1 (V-Akt Murine Thymoma Viral Oncogene Homolog 1): 
Gene Symbol Gene Location Gene Description 
serine-threonine 
protein kinase 
encoded by the 
AKT1 gene 
located on 
14q32.33 
(OMIM) 
It is inactive in serum-starved primary and 
immortalised fibroblasts. It was shown that the 
activation occurs through phosphatidylinositol 3-
kinase (PI3K). PI3Ks generate specific inositol lipids 
implicated in the regulation of cell growth, 
proliferation, survival, differentiation, and cytoskeletal 
changes. One of the targets of PI3K lipid products is 
the protein kinase AKT, or protein kinase B (PKB) 
(Vanhaesebroeck and Alessi, 2000). In the developing 
nervous system, AKT is a critical mediator of growth 
factor-induced neuronal survival. Survival factors can 
suppress apoptosis in a transcription-independent 
manner by activating the serine/threonine kinase 
AKT1, which then inactivates components of the 
apoptotic machinery. 
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3.2.2.5 HSP90AA1 (Heat-Shock Protein, 90-KD, Alpha, Class A, Member 1): 
Gene Symbol Gene Location Gene Description 
HSP90AA1 gene located on 
14q32.31 
(OMIM) 
It is encoded for HSP90 proteins which are highly 
important molecules that have key roles in signal 
transduction, protein folding, protein degradation, and 
morphologic evolution. HSP90 proteins normally 
associate with other molecules and play important 
roles in producing newly synthesised proteins or 
stabilising denatured proteins after stress. The genome 
analyses revealed that the human HSP90 family 
includes 17 genes that fall into four classes. These 
classes are HSP90AA, HSP90AB, HSP90B, and 
TRAP and contain 7, 6, 3, and 1 genes, respectively 
(Chen et al., 2005). There are 2 major cytosolic 
HSP90 proteins, HSP90AA1, an inducible form, and 
HSP90AB1, a constitutive form. Other HSP90 
proteins (HSP90B1 and TRAP1) are found in 
endoplasmic reticulum (ER) and mitochondria (Chen 
et al., 2005 and Nagahori et al., 2010). 
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3.2.2.6 ERBB2/HER2: 
Gene Symbol Gene Location Gene Description 
V-ERB-B2 
AVIAN 
Erythroblastic 
Leukemia Viral 
Oncogene 
Homolog 2 
(ERBB2) 
Neuroblastoma- 
or Glioblastoma 
(Neu) 
Tyrosine 
Kinase-Type 
Cell Surface 
Receptor 
(HER2)  
The oncogene 
originally called 
NEU 
located on 
17q12 (OMIM) 
It was derived from rat neuro/glioblastoma cell lines. 
It encodes a tumour antigen, p185, which is 
serologically related to EGFR. It is a cell surface 
receptor of the tyrosine kinase gene family named 
HER2 and its sequence is very similar to the EGFR.  
Therefore, its name came from the Human EGF 
Receptor, HER2 (Coussens et al., 1985). In 1986, 
Akiyama et al., raised antibodies against a synthetic 
peptide and they precipitated the ERBB2 gene product 
from adenocarcinoma cells and its size estimated to be 
a 185 kDa glycoprotein with tyrosine kinase activity 
(Akiyama et al., 1986). Di Fiore et al., in 1987, 
indicated that NEU and HER2 are both the same as 
ERBB2. In addition, the chromosomal location of the 
V-ERBB oncogene for this protein is similar with the 
NEU oncogene, which suggests that the two 
oncogenes may be identical (Coussens et al., 1985). 
 
 
 
 
 
120 
 
3.2.2.7 β-Actin (ACTB): 
Gene Symbol Gene Location Gene Description 
Beta-actin gene 
(ACTB) 
located on 
7p22.1 (OMIM) 
It is one of the six different actin isoforms (OMIM) 
which have been identified in humans and is one of 
the two non-muscular actins. They are highly 
conserved proteins (Hanukoglu et al., 1983) that are 
involved in cell motility, structure and integrity. Alpha 
actins are a major protein of the contractors. 
Mutations in this gene have been associated with B-
cell Lymphoma (Lohr et al., 2012). Beta-actin is 
usually used as a control or housekeeping gene to 
measure the integrity of cells and protein degradation 
in PCR and Western Blots experiments. 
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Table 3.1: The List of Primers EGFR, PTEN, CCND1, AKT1, HSP90AA1, HER2, and β-
Actin Genes for qRT-PCR: Forward and reverse primers as well as melting temperature 
used for each set of primer are displayed in the table below: 
 
Primer Name Primer Sequence (5` → 3`) Product 
Length 
(bp) 
%GC Tm (°C) 
EGFR (F) CAGCGCTACCTTGTCATTCA 195 50.00 60.01 
EGFR (R) TGCACTCAGAGAGCTCAGGA  55.00 60.01 
PTEN (F) CATAACGATGGCTGTGGTTG 106 50.00 59.99 
PTEN (R) CCCCCACTTTAGTGCACAG  55.00 60.03 
CCND1 (F) GAGGAAGAGGAGGAGGAGGA 237 60.00 59.88 
CCND1 (R) GAGATGGAAGGGGGAAAGAG  55.00 60.01 
AKT1 (F) AGAAGCAGGAGGAGGAGGAG 139 60.00 60.09 
AKT1 (R) CCCAGCAGCTTCAGGTACTC  60.00 60.01 
HSP90AA1 (F) AGACCCAGTCTTGTGGATGG 120 55.00 59.96 
HSP90AA1 (R) ACTCCCCTTTCCCCCTAAAT  50.00 60.01 
HER2 (F) ACAGTGGCATCTGTGAGCTG 148 55.00 60.06 
HER2 (R) CCCACGTCCGTAGAAAGGTA  55.00 59.99 
β-Actin (F) AAGAGAGGCATCCTCACCCT 216   
β-Actin (R) TACATGGCTGGGGTGTTGAA    
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3.2.3 Primer Dilution: 
Primers were diluted according to their concentration and each stock was prepared to a final 
concentration of 1 µg/1 µl. Dilutions were prepared again for each primer (10 µl/100 µl in 
nuclease free water, Ambion) and then all primers were stored at -20ºC. 
 
3.2.4 Cell Culture:  
The five human breast cell lines either immortalised (MCF-10A, normal) or cancerous (T-
47D, BT-474, GI-101, and Sk-Br-3) were investigated. They were grown and cultured as in 
Chapter 2.  
 
3.2.5 RNA Extraction: 
Total RNA was extracted from different cell lines, using the GenElute
TM
 Mammalian Total 
RNA Miniprep Kit (Sigma-Aldrich), according to the manufacturer’s instructions. Before 
starting, 60 ml of absolute ethanol was added to wash solution 2 and 10 µl 2-mercaptoethanol 
(2-ME) was mixed with 990 µl lysis solution. The cells were then washed once with pre-
warmed 1X PBS then 1 ml of lysis solution/2-ME was added to the flask with gentle rocking 
for 2 minutes to ensure all cells come into contact with the lysis mixture. The lysed cells were 
pipetted into GenElute Filtration Columns (blue) and centrifuged at maximum speed 16000 
rpm for 2 minutes. The filtration columns were discarded and 500 µl of 70% ethanol solution 
were added to the 2 ml tubes and then vortexed. 700 µl of that mixture (lystae/ethanol) was 
taken and added to the GenElute Binding Columns and then centrifuged for 15 seconds at 
16000 rpm maximum speed. The liquid that came through was discarded and the binding 
columns were returned to tubes. 500 µl of wash solution 1 was added to the binding columns 
and then they were centrifuged at maximum speed for 15 seconds. The liquid that passed 
through was discarded. The columns were transferred to fresh new collection tubes. 500 µl of 
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diluted wash solution 2 was added to the columns and then they were centrifuged at 
maximum speed for 15 seconds. The liquid was discarded and another 500 µl of diluted wash 
solution 2 was added to the columns and then centrifuged for 2 minutes at maximum speed. 
The columns were centrifuged again for 1 minute at maximum speed to dry after discarding 
the excess liquid. The binding columns were transferred to a fresh 2 ml collection tubes and 
then 50 µl of the elution solution were added into the binding columns, again these tubes 
were centrifuged at maximum speed for 1 minute. This process of elution was repeated. 
Isolated RNA from each sample was maintained on ice at all times. However, there was no 
addition or treatment of DNase I solution for this isolated RNA to avoid any genomic 
contamination but later on these samples showed high validity and integrity. 
 
3.2.6 RNA Analysis (Nano-drop): 
The amount of RNA in each sample was measured and quantified by spectrophotometry 
using nano-drop machine. 1 µl of RNA extraction was added to the pin head on the nano-
drop 2000c machine (Thermo Scientific) to measure the quality and concentration of the 
RNA samples. RNA concentration (ng/µl) was measured and the ratio 260/280 was 
automatically calculated. Accurate ratio reading is between 1.9 and 2.1. The isolated RNAs 
were stored at -80ºC until further use for cDNA synthesis and qRT-PCR. MCF-10A cell line 
showed low cell number and this could be of growth activities such as passage number, 
confluence, viability, and cell morphology therefore, this could affect the RNA levels in this 
cell lines. 
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3.2.7 Complementary DNA (cDNA) Synthesis: 
Two master mix groups (1 and 2) were prepared and RNA standardisation was calculated for 
each cell line (Appendices). Master Mix 1 was composed of 1 µl random primers 
(oligonucleotides of every possible combination), 1 µl dNTPs mix (10 mM), and 10 µl of 
both RNA and water solution as calculated on the table below to make up standardised RNA 
amount in ng. Master mix 2 was composed of 4 µl of 5X first strand buffer (250 mM Tris-
HCl, pH 8.3, 375 mM KCl, and 15 mM MgCl2), 1 µl of molecular grade water, and 2 µl of 
0.1 M DTT (Dithiothreitol). This was followed by adding 1 µl of Superscript
TM
 II reverse 
transcriptase enzyme (200 unit/1 µl, Invitrogen).  
 
In order to perform the cDNA synthesis, 2 µl of master mix 1 was added to each sample tube 
followed by adding dH2O then mixed. This mixture was heated for 5 minutes at 65ºC on 
heating block, then centrifuged and placed quickly onto ice. This was followed by the 
addition 7 µl of master mix 2 to each of the sample tubes with mixing. These tubes were left 
for 2 minutes at room temperature. Then 1 µl of Superscript
TM
 II reverse transcriptase 
enzyme was added to each tube, and left at RT for 10 minutes. These tubes were incubated at 
42ºC for 50 minutes followed by heating for 15 minutes at 75ºC. The tubes were stored at -
20ºC. 
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Table 3.2: RNA Standardisation Calculation: 
The RNA concentrations from each sample were used as shown on the table below. Large 
samples can use up to 500 ng RNA for cDNA synthesis; smaller concentrations can use 100 
ng for cDNA synthesis: 
 
Cell Lines  Concentration 
of RNA (ng/ µl) 
Standard 
Amount (ng) 
RNA 
Required (µl) 
H2O  
Required (µl) 
 X Y Y / X 10 – (Y / X) 
(1) T-47D 420.2 500 1.18 8.82 
(2) BT-474 284.8 500 1.75 8.25 
(3) GI-101 389.8 500 1.28 8.72 
(4) Sk-Br-3 718.1 500 0.69 9.31 
(5) MCF-10A 59.3 500 8.43 1.57 
 
 
3.2.8 Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR): 
It is considered as the standard method for accurate, sensitive and fast measurement of gene 
expression (Derveaux et al., 2010). The qPCR reactions for each template were done in small 
Optical 96-Well Fast Thermal Cycling Plates in triplicate under the standard conditions. The 
comparative method was used to determine gene expression changes in each sample, using β-
Actin as a reference control (Applied Biosystems). All the qPCR mixtures or components 
were prepared and distributed to 0.2 ml wells. Then the plates were centrifuged before 
amplification by qPCR machine (ABI machine). All 7 genes and the house keeping gene (β-
Actin) were amplified using the cDNAs (samples) generated by reverse transcriptase. The 
Power SYBR
®
 Green PCR Master Mix was used to perform RT-PCR Assays (Applied 
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Biosystems). A number of different primers were employed. The component of each reaction 
(master mix) can be seen on the table below.  
 
Table 3.3: The qPCR Reaction Components Used to Amplify EGFR, PTEN, CCND1, 
AKT1, HSP90AA1, HER2, and β-Actin Genes: The Mixture was used to Measure their Fold 
Change in Expression in Different Cell Lines as Manufacturer’s Instructions (Applied 
Biosystems): 
 
Component from Power SYBR
®
 Green 
PCR Master Mix 
Total Volume in a 20μl Reaction 
PCR Grade Water (Nuclease Free) 7 µl 
2X  Power SYBR
®
 Green PCR Master Mix 10 µl 
Forward Primer (100nM) 1 µl 
Reverse Primer (100nM) 1 µl 
cDNA Template 1 µl (end) 
 
 
The cDNAs were diluted using nuclease free water (1:10) before the experiment started. Then 
master mix was prepared for each gene and maintained on ice. 19 μl of qPCR master mix was 
added into each well. 1 μl of cDNA sample or water (negative control) was added to the side 
then the plate was centrifuged for a few seconds in a micro-centrifuge to collect the cDNA 
sample into the reaction master mix. β-Actin was used as an internal or endogenous control to 
ensure cDNA quality and loading accuracy. The expression of each gene was assessed in 
triplicate. The plate was placed in the qPCR machine with specific programme parameters. 
The qPCR cycles required for amplification are 40 cycles with annealing temperature 58ºC. 
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The cycling conditions for relative quantification were: 95°C for 10 minutes; 95°C for 15 
seconds, and 58°C for 1 minute for 40 cycles whereas; the cycling conditions for absolute 
quantification were: 95°C for 15 seconds, 60°C for 15 seconds, and  95°C for 15 seconds for 
40 cycles. Specificity of the qPCR products has confirmed by analysis of the dissociation 
curve. The plates were stored in the fridge for further analyses by agarose gels to verify the 
band size of each gene and to ensure the quality and integrity of product amplification. The 
expected size and the absence of nonspecific products were confirmed by analysis of the 
products on 2% agarose gels.  
 
3.2.9 Confirmation of Amplified Gene Primer Products by Agarose Gel Electrophoresis: 
Agarose gel electrophoresis was performed using 2 % agarose gel (2 g agarose in 100 ml 1X 
TAE, Tris, Acetic Acid, and EDTA, (Appendices)). After heating the agarose gel, 5 µl 
ethidium bromide (10 mg/ml, Sigma-Aldrich) was added to the warm gel. The gel was 
poured into a sealed gel container with comb and left to set. When the gel had set, it was 
placed inside a tank. Then the gel running buffer (1X TAE, Appendices) was poured on the 
tank to cover the gel. The samples were prepared for loading into the wells as well as to the 
negative control (sterilised water instead of DNA sample). Each sample contained 15 µl of 
the qPCR products, and 5 µl 5X loading dye. The DNA ladder or marker, have 12 bands, (15 
µl plus and 5 µl 5X loading dye, Appendices) (100 bp, 50 µg/ml, BioLabs) was loaded onto 
the first lane of the gel then followed by loading other samples (T-47D, BT-474, GI-101, Sk-
Br-3, and MCF-10A). The gel electrophoresis apparatus was connected to the power and was 
run at 100 volts for 60-90 minutes. This is followed by capturing images with the BIO-RAD 
gel document system to visualise the products and bands on the gel were revealed on a UV-
transluminator and were identified with the expected band size using IPLab software 
(Appendices). 
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3.3 Results: 
Chromosomes territory (HSA 7, 10, 11, 14, and 17) and gene positioning (EGFR, PTEN, 
CCND1, AKT1, HSP90AA1, and HER2) in human normal breast (MCF-10A) and cancer (T-
47D, BT-474, GI-101, and Sk-Br-3) cell lines were determined using 2D-FISH (Chapter 2). 
Alterations in chromosome and gene position can lead to changes in gene expression. 
Understanding the signalling pathways of these genes and their involvement in breast cancer 
progression is an important goal (Chapter 1). Difference in position of chromosomes where 
these genes resided was observed between different cell lines. Chapter 2 demonstrates the 
aberrant nuclear positioning of chromosomes as well as some important genes. These are 
studied in this chapter by qRT-PCR to ascertain their relative change in expression. 
 
It is important to understand the functional relevance of these differential positions of 
chromosomes and to assess whether the positions of these chromosomes are linked to gene 
expression and transcription profiles of genes involved in breast cancer progression. 
Furthermore, these positions were compared with normal but immortalised MCF-10A cell 
line, for example, ERBB2/HER2, resided on HSA 17, is located at the nuclear periphery in T-
47D, BT-474, and Sk-Br-3 breast cancer cell lines whereas the same gene is positioned in the 
interior in MCF-10A normal breast and GI-101 cancer cell lines. Chromosome 17 is 
positioned in the interior in T-47D, BT-474, and Sk-Br-3 breast cancer cell lines whereas the 
same chromosome is positioned in the interior in MCF-10A normal breast and GI-101 cancer 
cell lines (referring to chapter 2 to compare the positions of other genes and other 
chromosomes). Thus, any change in position could lead to change in gene expression. 
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3.3.1 qRT-PCR Analysis for Selected Genes from Different Cells: 
The two most commonly used methods to analyse data from quantitative RT-PCR 
experiments are absolute quantification (AQ) and relative quantification (RQ). Absolute 
quantification determines the copy number, usually by relating the PCR signal to a standard 
curve. Relative quantification is measured by relating the PCR signal of the target group of 
sample to that of untreated sample such as an untreated control. The 2
(-Delta Delta C
T
)
 method is a 
prefered way to analyse the relative changes (fold change or RQ) in gene expression from 
quantitative RT-PCR experiments (Livak and Schmittgen, 2001).   
 
In figure 3.1, the graphs show the percentage of relative quantification of gene expressions by 
fold changes in expression for each gene using qRT-PCR. The levels of expression of all 
genes studied here are calculated from 2
-ΔΔC
t or relative quantification (RQ) using RQ 
Manager and Microsoft Excel software.  
The equations are:  
ΔCt = Ct (target) – Ct (housekeeping gene) 
ΔΔCt = ΔCt (sample) – ΔCt (normal or calibrator) 
RQ = 2
-ΔΔC
t
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3.3.2 qPCR Analysis for Gene Expression in Breast Cell Lines: 
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Figure 3.1: Expression Levels of EGFR, PTEN, CCND1, AKT1, HSP90AA1, HER2, and 
β-Actin Genes mRNA of Breast Cell Lines using qRT-PCR 
These histograms show the percentage of relative quantification (RQ%) of different genes in 
present of β-actin as a housekeeping gene with no supplement set as 1 (100%) (A-F). The 
fold changes in different gene expression were assessed between cell lines (MCF-10A, T-
47D, BT-474, GI-101, and Sk-Br-3) using RQ Manager and Microsoft Excel Software. 
Different mRNA levels showed a two-fold increase or decrease change in the gene 
expression. The expression over 100% is up-regulated and below this percentage is down-
regulated. Error bars represent the Standard Error of the Mean (SEM) of three replicates. 
 
 
 
3.3.3 Agarose Gels from qPCR Products: 
Figure 3.2 shows the detection of specific gene qPCR products and their molecular sizes 
(Figure 3.2 and Appendices) by agarose gel electrophoresis. These products are shown after 
40 cycles of amplification to evaluate the quality and integrity of these primers. 
 
(1) EGFR (195 bp):     (2) PTEN (106 bp): 
  M   1    2     3    4     5    6     7    8    9   10          
   
 
 
100 bp 
200 
300 
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(3) CCND1 (237 bp):     (4) AKT1 (139 bp): 
   
 
 
(5) HSP90AA1 (120 bp):   (6) HER2 (148 bp):  
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(7) β-Actin (216 bp): 
 
 
Figure 3.2: Representative Images of Gels Showing the Identification and Specificity of 
7 Selected Genes of Interest in Breast Normal and Cancerous Cell Lines, Either Treated 
or Untreated Cells 
Complemetry DNA (cDNA) was synthesised from RNA samples obtained from different cell 
lines. qRT-PCR experiments were performed using specific primers for each of the 7 target 
genes as well as to the β-actin as a reference gene. For amplification of each gene, qPCR was 
also performed in triplicate for positive and negative control at the same time on 96-well 
plate. To confirm and ensure this amplification has worked properly, the amplicons from 
each experiment were run on 2% agarose gel. The table above showed the size of the band for 
each product. Moreover, the dissociation curve (DC) can also confirm this accuracy, 
efficiency, specificity, and validity of the cDNA (Data not shown). *The Key: M= Marker 
(100 bp Ladder, BioLabs), 1=T-47D, 2=BT-474, 3=GI-101, 4=Sk-Br-3, 5=MCF-10A, 6=T-
47D (12uM/48hours), 7=MCF-10A (12uM/48hours, lovastatin), 8=MCF-10A 
(24uM/48hours, lovastatin), 9=BT-474 (12uM/48hours, lovastatin), and 10=-ve Control 
(H2O). Note: Lanes 6-9 include cells treated with lovastatin (see Chapter 5). 
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3.4 Discussion: 
Both chromosomes and genes are organised in a non-random position in interphase nuclei 
(Croft et al., 1999 and Cremer and Cremer, 2001). Non-random positioning of chromosomal 
domains relative to each other and to nuclear components is a common feature of eukaryotic 
genomes. Different studies showed that this organisation of the genome within the nucleus is 
specific, non-random, dynamic, and changes during cell life span (Bridger et al., 2000 and 
Meaburn et al., 2007a). This spatial organisation of the genome has been suggested to be the 
controller of all nuclear processes and functions (Lanctôt et al., 2007).  
 
The distribution of gene loci relative to the nuclear periphery has been linked to both 
transcriptional activation and repression. Nuclear pores and integral nuclear membrane 
proteins are key players in the dynamic organisation and regulation of the genome in the 
nucleus as well as recent advances in our understanding of the molecular networks that 
organise and regulate genomes at the nuclear periphery led to a further role for non-random 
locus positioning in DNA repair, remodeling, nuclear function and stability (Mekhail and 
Moazed, 2010). 
 
In most cells the peripheral chromatin, which includes a large fraction of the 
heterochromatin, is associated with the nuclear lamina. Previous studies showed that lamin B 
associates with the chromatin in mammalian cells and control their localisation and gene 
expression (Malhas et al., 2007). In Drosophila cells the centromeres, telomeres, and 
heterochromatin are almost always associated with the nuclear lamina (Sáez-Va´squez and 
Gadal, 2010). In addition, in both Drosophila and mammalian cells the B-type lamins interact 
in higher frequencies with gene-poor regions of the genome (Sáez-Va´squez and Gadal, 
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2010). The mechanisms that control gene activation at the nuclear pore are not well 
understood.  
 
The hypothesis in this chapter is that the gene expression is changed by alteration of the 
spatial position of the genes in the cancer cells as compared to the control. Chapter 2 studied 
the chromosomes and gene positioning which are differentially localised in breast cancer and 
normal cell lines (Chapter 2). Since the alteration in position of these chromosomes and 
genes are observed with different cells, together the selection of genes on chromosomes was 
studied by dual colour FISH and found that some genes were localised on their chromosomes 
and some are on loops and away from their chromosomes (Chapter 2). In order to study the 
expression levels of these genes, the transcriptional activity of each gene was assessed by q-
PCR as shown in figure 3.1.  
 
Table 3.4: To summarise the comparison and correlation between EGFR, PTEN, CCND1, 
AKT1, HSP90AA1, and HER2 gene positions and their change in expression in each cell line 
(T-47D, BT-474, GI-101, and Sk-Br-3) when compared with normal cell line (MCF-10A): 
 
 MCF-10A T-47D BT-474 GI-101 Sk-Br-3 
EGFR Peripheral Peripheral Peripheral Interior Peripheral 
PTEN Interior Peripheral Peripheral Interior Interior 
CCND1 Interior Peripheral Peripheral Interior Interior 
AKT1 Interior Peripheral Peripheral Interior Interior 
HSP90AA1 Peripheral Peripheral Interior Interior Interior 
HER2 Interior Peripheral Peripheral Interior Peripheral 
The Key:  = up-regulated                 = down-regulated 
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With respect to the hypothesis there are nine situations where genes in the interior are up-
regulated as compared to the control and four situations where genes at the periphery are 
down-regulated. Against the hypothesis there are also nine situations where genes are 
positioned at the nuclear periphery and are up-regulated with two situations where genes in 
the interior are down-regulated. So it seems in cancer cells that spatial positioning of genes 
does not fit with the hypothesis that genes at the nuclear periphery are down-regulated and 
ones in the interior are up-regulated. In the literature there are a number of examples that 
show genes in normal cells being down-regulated at the nuclear periphery and vice versa for 
the interior (Bourne et al., 2013). Three genes are up-regulated in all cancer cell lines, HER2, 
HSP90AA1 and AKT1. All genes were up-regulated in GI-101 cells.  
 
The spatial organisation of the genome can influence gene expression in normal cells. 
However, cancer cells may be more difficult to fit gene position with expression since there is 
a more chaotic distribution of the genome.  Thus more analysis is required to investigate the 
link between the position of the gene and its expression in cancer. From these results, the 
location of genes and chromosomes within different cells might be due to changes in the 
interaction of chromosomes and genes with the nuclear components (the nuclear lamina, 
transcription factories, splicing speckles, PML bodies, nucleoli, and Cajal bodies) 
Chromosomes found at the nuclear periphery and the genes on these chromosomes might be 
located on the inner site of these chromosomes and away from the nuclear periphery or on 
loops extending away from their chromosomes into the nuclear interior. It is possible that 
these changes in position are either of a global re-organisation of chromosomes in breast 
normal, and cancer, cells or due to other re-positioning events. Other factors may participate 
in transcriptional activity, regulation, and spatial organisation of the genome such as 
epigenetic modification.  
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Transformed and tumour cells exhibit alterations in nuclear morphology as well as in the 
distribution of genes and regulatory factors. The functional relationships of nuclear structure 
and gene expression is found to be more related and linked to tumour modifications in 
nuclear organisation and gene regulation during the progression of cancer (Stein et al., 2000). 
The finding that changes in gene position are correlated with changes in gene expression 
mean that if gene position can be controlled then perhaps gene expression can be controlled 
as well which would open up a whole new field of treatments for cancer patients. The cells in 
this study do have changes in nuclear morphology and this may lead to a re-organisation of 
the genome. In diseases of the nuclear lamina nuclei are mis-shapened and genome 
organisation is affected (Mehta et al., 2011). The next step would be to analyse nuclear 
structures such as the nuclear lamina to see if they are affected in these cells. 
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3.5 Conclusion: 
In conclusion, my data show that a change in gene positions in breast cancer cells is 
correlated with a change in gene expression. This alteration in expression is most noticeable 
in T-47D and BT-474 cell lines in comparison to MCF-10A normal cell lines. The correlation 
between gene position and expression could probably uncover many of the secrets of non-
random genome organisation and its role in gene regulation and expression, genome stability 
and disease such as cancer.  
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Chapter 4: Aberrant Distribution and 
Presence of Nuclear Envelope Proteins in 
Breast Cancer Cell Lines 
 
 
 
 
 
 
Manuscript in prep 2: Hassan Ahmed M; Harvey M; Bridger JM.  
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4.1 Introduction: 
The nuclear envelope, which forms the border of the nucleus in eukaryotic cells, restricts 
nuclear metabolism activities and helps to organise nuclear structure (Hetzer, 2010). Genetic 
and cell biological studies indicate that the nuclear lamina, part of the nuclear envelope, is a 
structural scaffold that provides mechanical strength to the nucleus and helps to maintain 
nuclear shape. The lamina is also involved in tethering chromatin to the nuclear envelope and 
therefore this implicates the lamina in the regulation of gene expression. The importance of 
the lamina in cells is emphasised by recent work showing that over 20 inherited human 
diseases "laminopathies" are caused by mutations in lamins. Many laminopathies target 
specific tissues, such as skeletal muscle and heart, adipose tissue, or bone and connective 
tissue and therefore, these mutations target nuclear envelope proteins (lamins) and affect 
many cell types (Prokocimer et al., 2009). 
 
Transmembrane proteins of the inner nuclear membrane (INM) are also involved in 
chromatin regulation and nuclear envelope (NE) function. For example, lamin B receptor 
(LBR) protein in mammals binds to HP1 which is involved in heterochromatin formation. 
Moreover, LAP2β, emerin, and MAN1 proteins have LEM domain. This LEM domain binds 
BAF which is involved in chromosome organisation and nuclear assembly. Indeed, multiple 
INM proteins, including LEM domain proteins, have been found to directly bind to 
transcriptional regulators. These proteins have roles in signal transduction at the nuclear 
envelope (Holaska, 2002). 
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4.1.1 Lamin B1 is Required for RNA Synthesis and Gene Expression in Human Cells: 
A study from Goldman and colleagues provides data to link the organisation of the lamin 
network to gene expression in somatic mammalian cells (Spann et al., 2002). The loss of 
lamin B1 is also correlated with a loss of transcriptional activity (Dechat et al., 2008; Malhas 
et al., 2009). During the early stage of lamin B1 depletion, pre-rRNA synthesis in nucleoli 
was unaffected. However, at later stages, pre-rRNA synthesis was inhibited and changes in 
nucleolar morphology seen. This indicates that lamin B1 is required for assembly of active 
sites of RNA synthesis (Tang et al., 2008). In contrast, reducing the level of lamin A/C had 
no obvious effects on transcription by either RNA polymerase I or II (Vergnes et al., 2004). 
Moreover, it is the loss of lamin B1 but not lamin B2 resulted in transcriptional inhibition 
(Tang et al., 2008). 
 
4.1.2 Defects in Lamin B1 Expression or Processing Affect Interphase Chromosome 
Position, Gene Expression, and Other Nuclear Functions: 
Association of lamin B1 with the nuclear lamina is dependent on processing of its CAAX 
motif, this reflex the importance of post-translational modifications for stable lamina 
assembly (Maske et al., 2003). The loss of lamin B1 makes an unstable lamina when CAAX 
farnyesylation, endoproteolysis, or carboxymethylation does not occur (Chapter 1).  
 
From previous studies, cells with defects in lamin B1 expression or in the CAAX processing 
machinery exhibit altered gene expression levels, as a result of the absence of processed 
lamin B1 in the lamina (Malhas et al., 2007). Others found that unprocessed lamin B1 in the 
nuclear interior plays an important role in regulating gene expression (Kennedy et al., 2000; 
Hutchison and Worman, 2004). Lamin B1 might associate with the machinery of 
transcription and RNA processing similar to that observed for lamin A within the 
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nucleoplasm. However, a more indirect effect via specific transcription factors is suggested 
by lamin B1 binding to the transcriptional repressor protein, Oct1, (Imai et al., 1997). This 
binding could lead to regulation of gene expression that is lost when processed lamin B1 is 
missing at the nuclear periphery. Malhas et al., in 2007 suggested that the presence of up-
regulated genes at the nuclear periphery might be due to disruption of peripheral lamin 
localisation because of the absence of proteolysed lamin B1. Malhas et al., in 2007, found 
that chromosome 18 is located at the nuclear periphery in three independent wild type (WT) 
mouse embryo fibroblast populations. This peripheral localisation was observed in negative 
isoprenylcysteine carboxyl methyltransferase cells (ICMT
−/−
), but in both deleted LMNB 
(LMNB1
−/−
) and ras converting enzyme 1 (Rce1
−/−
) cells, it became centrally located, like 
chromosome 19. This suggests that farnesylated and proteolysed lamin B1 anchors 
chromosome 18 to the periphery and that carboxymethylation of lamin B1 is not important 
for chromosome positioning. The authors also showed that this positioning played an 
important role in the expression of genes on this chromosome. Chromosome 19, on the other 
hand, showed a central location in the WT cells and in all the knockouts and none of its genes 
were up-regulated in both LMNB1
−/−
 and Rce1
−/−
 cells. Therefore, the genes that are 
disregulated in the absence of processed lamin B1 are specific to defects on the enzymes that 
are involved in farnesylation and are not due to abnormality in the nuclear lamina. 
Furthermore, the change in chromosome position as a result of the absence of lamin B1 or its 
processing is specific to lamin B1 (Malhas et al., 2007).  
 
From literature, it can be seen that there is clear difference in the roles played by A- and B-
type lamins with both lamin protein contributing to the structure of lamin protein network. 
Lamin B1 is essential to maintain correct levels of gene expression, chromosome position, 
and other nuclear functions.  
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4.1.3 The Nucleolus and Other Bodies: 
4.1.3.1 The Nucleolus: 
The nucleolus is a non-membranous structure within the nucleus and is composed of proteins 
and nucleic acids. It is considered to be 25% of the total volume of the nucleus. It is involved 
in the biogenesis and transcription of ribosomal RNA (rRNA). There are three main 
components of the nucleolar structure: the fibrillar centres (FC), the dense fibrillar 
component (DFC), and the granular component (GC). Nucleoli are formed around specific 
genetic loci called Nucleoli Organising Regions (NORs) (Maggi and Weber, 2005; Martin et 
al., 2009). The NORs are composed of tandem repeats of rRNA genes. The human genome 
contains more than 200 copies of rRNA genes on five different chromosomes (13, 14, 15, 21, 
and 22) (Arsuaga et al., 2004). The rRNA gene consists of a promoter and coding sequences 
(18S, 5.8S, and 28S). The nucleolus is involved in making rRNA, genome organisation and 
chromosome positioning (Martin et al., 2009). Recent studies demonstrated that lamin B 
expression is required to maintain the architecture and functional plasticity of nucleoli (Raz et 
al., 2006; Chi et al., 2009).  
 
4.1.3.2 Promyeolocytic Leukaemia (PML): 
Promyeolocytic leukaemia (PML) bodies also known as ND10 domains (Bridger et al., 
1998a) and Kremer bodies contain the PML protein which is encoded by pml gene (Stuurman 
et al., 1992; Bernardi and Pandolfi, 2007). PML bodies position non-randomly in the nucleus 
with respect to chromatin and other sub-nuclear structures. Over-expression of small 
ubiquitin-like modifier (SUMO-1) prevents stress that induces the disassembly of PML 
bodies, implicating SUMO-1 as an important factor to regulate PML body integrity, 
organisation and function. Down regulation of SUMO-1 may be the mechanism to change 
PML body association with local chromatin domains. PML bodies may provide useful 
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information for the dynamics and integrity of other important molecular proteins involved in 
nuclear processes such as transcription, RNA processing, DNA repair and replication ((Dundr 
and Misteli, 2001; Eskiw et al., 2003; Bernardi and Pandolfi, 2007). They are heterogeneous 
and dynamic structures implicated in tumour suppression in leukemia and cancer 
pathogenesis as well as implicated in induction of apoptosis and cellular senescence, 
inhibition of proliferation, maintenance of genomic stability, DNA repair and antiviral 
responses (Bernardi and Pandolfi, 2003; Dellaire et al., 2006). They are found near other 
nuclear bodies such as Cajal bodies, splicing speckles and nucleoli (Bernardi and Pandolfi, 
2007). Therefore, PML bodies play a pivotal role in nuclear functions, organisation, and gene 
expression. 
 
4.1.3.3 The Ki-67 Protein (Proliferation Marker): 
The Ki-67 antigen was identified by Gerdes et al in 1983 as a nuclear non-histone protein and 
highly susceptible to protease treatment, in the city of Kiel, Germany (hence “Ki”) after 
immunisation of mice with the Hodgkin’s lymphoma cell line L428 (67 refers to the clone 
number on the 96-well plate in which it was found) (Gerdes et al., 1983). It belongs to a class 
of antigens associated with the structural organisation of metaphase and anaphase 
chromosomes, and proteins located near the regions of prenucleolar bodies and nucleoli (van 
Dierendonck et al., 1989). Furthermore, Ki-67 antigen associates with a fibrillarin-deficient 
region of the dense fibrillar component of the nucleolus. Integrity of this region is lost 
following either nucleolar dispersal or nucleolar segregation (Kill, 1996). The Ki-67 gene is 
on the long arm of human chromosome 10q25 (Fonatsch et al., 1991). During G1, Ki67 
expression is in low levels and this is increased during S-phase and G2 to reach maximum 
expression during mitosis of cell cycle. Ki67 is associated with the nucleolar region in larger 
foci as well as with some heterochromatin regions (Gerdes et al., 1984; van Dierendonck et 
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al., 1989; Bridger et al., 1998b; Scholzen and Gerdes, 2000; Urruticoechea et al., 2005). Ki67 
is absent in quiescent cells (Gerdes et al., 1984; Gerdes, 1990; Gerdes et al., 1991).  
 
4.1.4 B-type Lamins and Lamin B Receptor are Affected in Human Breast Cancer 
Cells: 
 Due to the alterations in gene and chromosome position, as well as gene expression revealed 
in the breast cancer cell lines it became pertinent to assess the structural integrity of the nuclei 
in these cells. Thus, the presence and distribution of a range of nuclear envelope proteins was 
assessed in all the cancer cell lines under study. It was found that nuclear structure was 
hugely affected in these cells with some cells lacking B-type lamins and their receptor LBR. 
Cells displayed large aggregates of lamin B inside the nucleoplasm and it was found that 
these aggregates colocalised, at some level, with PML bodies and nucleoli. With these data 
collaborators at the London Breast Clinic screened 183 breast samples and found that 
severity, prognosis were correlated with a decrease in lamin B and LBR. Further survival of 
women with breast cancer was positively correlated with the extent of lamin B expression 
(Wazir, Hassan Ahmed; Harvey; Bridger; Sharma and Mokbel (2013), The 
Clinicopathological Significance of Lamin A, Lamin B and Lamin B receptor mRNA 
Expression in Human Breast Cancer in preparation).   
 
The goal of this chapter was to understand the presence and distribution of nuclear envelope 
proteins in breast cancer cell lines. To help this understanding, experiments have assessed 
and analysed distribution and expression of nuclear envelope proteins including nuclear 
lamins (lamins A, C, A/C, B1, and B2), lamin B receptor (LBR), lamin binding proteins, 
PML, Ki67, and nucleolin in breast cancer (T-47D, BT-474, Sk-Br-3, and GI-101) and 
compared their localisation to normal breast cell line (MCF-10A) using 
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indirectimmunofluorescence (IIF). This investigation followed by gene expression 
assessment to LMNB1, LMNB2, and LBR using qRT-PCR. These data reveal aberrant and 
unequal distribution of these proteins between different cell lines.  
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4.2 Material and Methods: 
4.2.1 Cell Culture:  
As per chapter 2, Section 2.2.1. 
 
4.2.2 Indirect Immunofluoresence:  
4.2.2.1 Cell preparation: 
The human breast cancer (Sk-Br-3, GI-101, T-47D and BT-474) and normal breast (MCF-
10A) cell lines were prepared for indirect immunofluorescence. The cells were grown and 
seeded onto sterile 13 mm glass coverslips in plastic petri dishes. They were grown and 
cultured under the standard conditions in appropriate medium and supplemented with 10% 
fetal calf or bovine serum (FC/BS) with/without additives according to the cell lines needs 
and maintained in a humidified environment at 37ºC with 5% CO2. The cells were allowed to 
proliferate for 3 days prior to fixation. 
 
4.2.2.2 Cell Fixation: 
Cells on coverslips were prepared for fixation and staining techniques using different fixation 
procedures. Firstly, the medium was removed and then the cells were washed 3 times with 
1X phosphate buffer saline (PBS) to be ready for fixation. There were two different fixation 
procedures used; (1) cells were fixed with fresh cold methanol: acetone (1:1, v/v) for 10 
minutes on ice to precipitate the proteins and permeablise the cells followed by 3 washes in 
1X PBS; and the other method (2) cells were fixed with  paraformaldehyde 4% (w/v) for 4 
minutes at room temperature (RT) followed by 3 washes in 1X PBS and then detergent was 
added to the dish 1% Triton-X100 in 1X PBS (Sigma-Aldrich) for 10 minutes at RT and then 
washed again 3 washes with 1X PBS.  
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4.2.2.3 Primary and Secondary Antibodies Immuno-reactivity: 
After fixation, cells were prepared for indirect immunofluorescence. The primary monoclonal 
(mAbs) and polyclonal antibodies were raised in goats, mice and rabbits. They were diluted 
in 1% newborn calf serum (NCS, v/v) in 1X PBS according to the manufacturer’s 
instructions. The cells on coverslips were covered with 20 µl of the diluted primary antibody 
and then incubated at 4ºC overnight, 37ºC for 30 minutes or RT for 1 hour. The primary 
antibodies that were used at final concentration were; goat anti-Lamin A antibody (diluted 
1:100, Santa Cruz Biotechnology), mouse anti-Lamin B1 antibody (diluted 1:50, Abcam), 
mouse anti- Lamin B2 antibody (diluted 1:500, Abcam), rabbit anti-LAP2α antibody (diluted 
1:250, Abcam), goat anti-MAN1 antibody (diluted 1:100, Santa Cruz Biotechnology), mouse 
anti-Lamin A/C antibody (diluted 1:100, Santa Cruz Biotechnology), rabbit anti-Lamin C 
antibody (diluted 1:50, Novocastra), goat anti-Emerin antibody (diluted 1:100, Santa Cruz 
Biotechnology), mouse anti-nucleolin antibody (diluted 1:200, Abcam), rabbit anti-PML 
antibody (diluted 1:100, Chemicon), rabbit anti-Lamin B receptor antibody (diluted 1:500, 
Abcam), rabbit anti-Ki67 antibody (diluted 1:1500, Novocastra), mouse anti-LAP2 antibody 
(diluted 1: 100, Abcam), and mouse anti-Lamin B2 antibody (diluted 1:100, Novocastra). 
After incubation for 1 hour at RT, the cells on glass coverslips were washed 3 times in 1X 
PBS and then covered with 20 µl of the diluted appropriate secondary antibody at final 
concentration using donkey anti-goat (FITC) antibody (diluted 1:50, Jackson), donkey anti-
mouse (FITC) antibody (diluted 1:70, Jackson), Cy3 conjugated donkey anti-mouse antibody 
(diluted 1:100, Jackson), Cy5 conjugated donkey anti-goat antibody (diluted 1:100, Jackson) 
and swine anti-rabbit (TRITC) antibody (diluted 1:30, DAKO). The cells were incubated for 
1 hour at room temperature (RT) in the dark. The cells on coverslips were washed again in 
triplicate in 1X PBS followed by rinsing in double distilled water (ddH2O). Single, Dual and 
Triple colour experiments were performed to observe co-localisations. 
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4.2.2.4 Mounting Cells: 
Cells were mounted onto glass microscope slides using Vectashield (Vecta Labs) mounting 
medium containing 4`, 6-diamidino-2-phenylindole (DAPI, 1.5 µg/ml). Mounted slides were 
viewed and images captured by Fluorescence Microscopy. These slides were stored at 4ºC 
and protected from light in a black box. 
 
4.2.2.5 Evaluation and Detection using Microscopy and Images Analysis: 
Fluorescence microscopy was performed with a microscope (Olympus BX41 with 
Smartcapture 3 Software) with a CCD digital scientific camera. All slides were examined 
under 100X Olympus UPLAN FLN lens immersion oil (Immersol)™ and images captured 
with the camera and previewed on Macintosh Apple Computer (MAC) operated by 
SmartCapture3 programme. Cells were screened to analyse the presence and distribution of 
LAP2α, MAN1, lamin A/C, lamin C, emerin, lamin A, lamin B1, lamin B2, lamin B receptor, 
PML, nucleolin, LAP2, and Ki67 proteins.  
 
4.2.3 qRT-PCR: 
As per chapter 3, section 3.2.1 
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4.2.3.1 Gene Description: 
4.2.3.1.1 LMNB1 and LMNB2 (Lamins B1 and B2, Respectively): 
Lamins are reviewed in more details in Chapter 1. 
 
4.2.3.1.2 LBR (Lamin B Receptor): 
Gene Symbol Gene Location Gene Description 
LBR gene located on 
1q42.12 
(OMIM) 
It encodes the lamin B receptor, an inner nuclear 
membrane protein that binds lamin B and has been 
characterised in avian cells (Worman et al., 1990). 
The nuclear envelope is composed of the nuclear 
lamina, the nuclear pore complexes, and the nuclear 
membranes. The nuclear lamina, a meshwork of 
intermediate filament proteins termed lamins, may 
interact directly with the chromatin. Several integral 
proteins, including lamin B receptor (LBR), of the 
nuclear inner membrane that may be associated with 
the lamina and the chromatin have been identified (Ye 
and Worman, 1994 and Chapter 1). 
 
4.2.3.1.3 β-Actin (ACTB): 
β-Actin was reviewed in details in chapter 3. 
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Table 4.1: The List of Primers LMNB1, LMNB2, LBR, and β-Actin Genes for qRT-PCR: 
Forward and reverse primers as well as melting temperature used for each set of primer are 
displayed in the table below: 
 
Primer Name Primer Sequence (5` → 3`) Product 
Length 
(bp) 
%GC Tm (°C) 
LMNB1 (F) AGGATCAGATTGCCCAGTTG 125 50.00 60.07 
LMNB1 (R) GCGAAACTCCAAGTCCTCAG  55.00 59.99 
LMNB2 (F) AAGGACCTGGAGTCCCTGTT 153 55.00 59.97 
LMNB2 (R) CTTCTCCAGCTGCTTTTTGG  50.00 60.13 
LBR (F) CCGTGAATTAAACCCTCGAA 128 45.00 59.93 
LBR (R) CGCGGTCCTGTATTTTCATT  45.00 59.96 
β-Actin (F) AAGAGAGGCATCCTCACCCT 216   
β-Actin (R) TACATGGCTGGGGTGTTGAA    
 
 
4.2.3.2 Primers Dilution: 
As per chapter 3, section 3.2.2 – 3.2.3 
 
4.2.3.3 RNA Extraction: 
As per chapter 3, section 3.2.4 - 3.2.6 
 
4.2.3.4 Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR): 
As per chapter 3, section 3.2.7 - 3.2.8 
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4.2.4 Western Blot:  
This is an important method that was used to assess the expression and detection of different 
proteins (lamin B1, lamin B2, LBR, LAP2 isoforms, and MAN1). In this study, it is 
necessary to mention that the experiment was performed by starting with lysates preparation, 
loading 5X10
5
 cells per well, bands separated, proteins transferred on nitrocellulose 
membrane, blocking of the blots, detection of these proteins using commercial primary and 
secondary antibodies, and then processed with substrate and enhancer to develop colour and 
visualise the bands using BIO-RAD gel document system supported by IPLAB software. 
 
This experiment was repeated more than 11-12 times by changing the protocol (changes to 
antibody concentration, marker, blocking solution, timing, detection method, method of 
lysates preparation, and concentration of loading samples) but it did not work properly (Data 
not shown). 
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4.3 Results:  
The genetic basis of cancer has been investigated at the structural and genomic levels, and 
many fundamental questions have begun to be addressed. The molecular basis for the link 
between nuclear deformation and malignancy has not been determined (Capo-chichi et al., 
2011). Nuclear lamins and lamin binding proteins are essential components of nuclear 
architecture and genome organisation and they are essential for correct gene expression and 
normal functions of cells and the loss of this organisation or aberrant distribution in lamins, 
lamin binding proteins, other important nuclear compartments, and genome are associated 
with cancer.  
 
4.3.1 Distribution of Lamins and Lamin Binding Proteins by Indirect 
Immunofluorescence (IIF): 
The study in this chapter aims to assess and analyse the presence and distribution of lamins 
and lamin binding proteins in human normal breast MCF-10A and breast cancer cell lines T-
47D, GI-101, BT-474, and Sk-Br-3. This was determined by indirect immunofluorescence 
using a range of antibodies (see material and methods). The cell lines were fixed with 
methanol: acetone (1:1) and paraformaldehyde 4% (Figures 4.1 and 4.2, respectively) and the 
results showed how the cell nuclei influenced by the type fixation. Metanol: acetone: it is 
organic fixative and perfect fixation that can immoblise the proteins. This type of fixation can 
remove lipids and dehydrate the cells as well as precipitating proteins on the cellular 
architecture. Paraformaldehyde 4%: it is cross-linking reagent and form intermolecular 
bridges, thus creating a network of linked antigens which is better than organic solvents (keep 
or preserve the cell structure). However, this type of fixation may reduce the antigenicity of 
some cell components and require the addition of Triton-X100 to increase the permeability of 
cells and allow access of antibodies to inside the cells. Both methods may denature proteins 
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and this is the reason why I used antibodies against these proteins which is more useful for 
cell staining.  
 
(1) Cell Fixation with Paraformaldehyde 4%: 
Panel (I):
MCF-10A
T-47D
GI-101
BT-474
Sk-Br-3
A B C D E
F G H I J
K L M N O
P Q R S T
U V W X Y
Lamin A               Lamin B1            Lamin B2          Lamin A/C           Lamin C
 
155 
 
Panel  (II): 
LAP2α               MAN1           Emerin
MCF-10A
T-47D
GI-101
BT-474
Sk-Br-3
A B C D
D E F
G IH
J K L
M N O
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Figure 4.1: Different Distributions of Nuclear Lamins and Lamin Binding Proteins: 
Cells were fixed with 4% paraformaldehyde and lamin and lamin binding protein 
distributions were processed and determined by indirect immunofluorescence method. The 
DNA was stained with DAPI (Blue). Panel (I): demonstrates the images of MCF-10A cells 
when immunostained with anti-lamin A, anti-lamin B1, anti-lamin B2, anti-lamin A/C, and 
lamin C antibodies (A-E), T-47D cells (F-J), GI-101 cells (K-O), BT-474 cells (P-T), and Sk-
Br-3 cells (U-Y) with same antibodies. Panel (II): displays representative images of MCF-
10A when immunostained with anti-LAP2α, anti-MAN1, and anti-emerin antibodies (A-C), 
T-47D cells (D-F), GI-101 cells (G-I), BT-474 cells (J-L), and Sk-Br-3 cells (M-O) with 
same antibodies. The secondary antibodies at final concentration were donkey anti-goat 
(FITC) antibody, donkey anti-mouse (FITC) antibody, and swine anti-rabbit (TRITC) 
antibody. Cells were mounted using Vectashield mounting medium containing DAPI to 
facilitate its visualisation and detection, Magnification = X100 and Scale Bar = 10µM.  
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(2) Cell Fixation with Methanol: Acetone, 1:1 
Panel (I):
Lamin A Lamin B1 Lamin B2 Lamin A/C Lamin C
MCF-10A
T-47D
GI-101
BT-474
Sk-Br-3
A B C D E
F G H I J
K L M N O
P Q R S
U
T
WV YX
 
158 
 
Panel  (II): 
LAP2α               MAN1           Emerin
NA
MCF-10A
T-47D
GI-101
BT-474
Sk-Br-3
A B C
ED
HG I
LKJ
ONM
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Figure 4.2: Different Distributions of Nuclear Lamins and Lamin Binding Proteins: 
Cells were fixed with methanol: acetone (1:1) and lamin and lamin binding protein lamins 
distributions were processed and determined by indirect immunofluorescence method. The 
DNA stained with DAPI (Blue). Panel (I): demonstrates the images of MCF-10A cells when 
immunostained with anti-lamin A, anti-lamin B1, anti-lamin B2, anti-lamin A/C, and lamin C 
antibodies (A-E) as well as T-47D cells (F-J), GI-101 cells (K-O), BT-474 cells (P-T), and 
Sk-Br-3 cells (U-Y) with same antibodies. Panel (II): displays representative images of 
MCF-10A when immunostained with anti-LAP2α, anti-MAN1, and anti-emerin antibodies 
(A-C), T-47D cells (D and E), GI-101 cells (G-I), BT-474 cells (J-L), and Sk-Br-3 cells (M-
O) with same antibodies. The secondary antibodies at final concentration were donkey anti-
goat (FITC) antibody, donkey anti-mouse (FITC) antibody, and swine anti-rabbit (TRITC) 
antibody. Cells were mounted using Vectashield mounting medium containing DAPI to 
facilitate its visualisation and detection, Magnification = X100 and Scale Bar = 10µM. 
 
 
 
4.3.2 Distribution Analyses of Lamins and Lamin Binding Proteins by Indirect 
Immunofluorescence: 
In order to analyse the results from these experiments, 200 nuclei were scored for each 
antibody, in each cell line. The experiment was performed in triplicate for each sample. The 
analysis was performed and nuclei scored for different categories rim only, rim and spot, 
homogenous, spots only - either a few large or many small spots and negative. These proteins 
should all be found at the nuclear rim except for LAP2α which is found as throughout the 
nucleoplasm. The results from this study showed that the nuclear architecture of breast cancer 
cell nuclei is often altered and this could be important for diagnosis and prognosis, as well as 
correct genome organisation and control of gene expression. Tables 4.4 - 4.11 display the 
percentages of these characteristics in each of the cell lines.  
 
There are clear differences in nuclear lamins presence and distribution between these cell 
lines and we noticed that the most severely affected cells were T-47D and BT-474 when 
stained with lamin B1 and lamin B2 and fixed with methanol: acetone (1:1). It is found that 
lamin B1 and B2 proteins were found in large foci inside the nucleoplasm (Figure 4.2, Panel 
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I: G, H and Q, R). The pattern of anti-lamins and lamin binding proteins were different 
between cell lines. They had strong rim staining in some cells which was absent in others. 
Some cells showed positive staining throughout the nucleoplasm (homogenous) and some 
cells were negative.  
 
Lamin B1 Distribution: 
The distribution of lamin B1 in normal cells in interphase nuclei is localised at the nuclear 
periphery as a rim structure with a few small foci in some cells. These cancer cells showed 
different distributions of this protein. It is found that 87% of MCF-10A cells displayed rim of 
lamin B1 distribution and 13% of cells had a homogeneous stain within their nuclei after cells 
fixation with methanol: acetone and 83% of cells had rim and spots after fixation with 
paraformaldehyde 4% whereas 17% of these cells had many spots. T-47D cells showed lamin 
B1 distribution as many spots in 100% when fixed with paraformaldehyde and 10% of cells 
after fixation with methanol: acetone, 1:1. It was found that there were large foci in these 
cells (25%) when fixed with methanol: acetone as well as rim and spots (65%).   GI-101 cells 
had nuclei with many spots when fixed with paraformadehyde (90%) as well as cells with 
large foci when fixed with methanol: acetone (55% of cells displayed large spots) as well as 
many spots (15%). BT-474 cells had lamin B1 in rim and spots within the nucleoplasm with a 
high percentage 72% when fixed with methanol: acetone and 33% when fixed with 
paraformadehyde whereas the same cells have displayed the protein around the nuclear 
membrane (28%) and within the nucleoplasm as many spots (67%) when fixed with 
methanol: acetone and paraformaldehyde, respectively. Moreover, Sk-Br-3 cells showed an 
abnormal distribution of the protein with 70% of the cells having many spots when fixed with 
methanol: acetone and paraformaldehyde although some of nuclei showed abnormal 
homogeneous in both fixations. 20% of these nuclei were negative after fixation with 
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methanol: acetone. The large aggregates of lamin B1 observed were widely distributed 
throughout the nucleoplasm. This is indeed an aberrant distribution of lamin B1 and may well 
lead to affected genome organisation and gene expression as seen in Chapters 2 and 3. Due to 
their unusual shape lamin B1 may have been associated with other nuclear structures such as 
PML bodies or nucleoli.  
 
Table 4.2: The Percentages of Lamin B1 Distribution: 
 MCF-10A  T-47D  GI-101  BT-474  Sk-Br-3 
Type of Fixation MA P MA P MA P MA P MA P 
Rim Only 87 0 0 0 30 0 0 0 0 0 
Rim & Spots 0 83 65 0 0 0 72 33 0 0 
Large Spots 0 0 25 0 55 10 0 0 0 0 
Homogeneous 13 0 0 0 0 0 0 0 10 30 
Many Spots 0 17 10 100 15 90 28 67 70 70 
Negative 0 0 0 0 0 0 0 0 20 0 
MA=Methanol: Acetone, 1:1                          P=Paraformaldehyde 4% 
 
Lamin B2 Distribution: 
All cells were immunostained with anti-lamin B2 antibodies. The distribution of lamin B2 in 
normal cells during interphase nuclei is localised at the nuclear periphery as a rim structure 
with a few small foci in some cells. The breast cancer cells displayed different patterns of this 
protein. The experiment showed that when fixed with methanol: acetone MCF-10A cells had 
47% of nuclei had a rim and spots, many spots of lamin B2 distribution (20%) ,17% of cells 
had large spots and 16% were homogeneous.When these cells were fixed with 
paraformaldehyde 80% of cells had both rim and spots whereas 20% of cells had the protein 
as rim only when fixed with (. T-47D cells showed lamin B2 distribution as rim and spots in 
a high percentage of cells (85%) and 15% of cells had many spots only when fixed with 
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methanol: acetone. Whereas all cell nuclei showed abnormal homogeneous staining (100%) 
when fixed with paraformaldehyde. It is also observed that GI-101 cells had rim and spots in 
80-85% when fixed with both fixations whereas 15-20% had the protein normally at rim only 
when fixed with both fixations. In addition, BT-474 cells showed nuclei with rim and spots in 
80% when fixed with both fixations and 20% of cells had the protein as normally at  rim only 
when fixed with paraformaldehyde and the same percentage (20%) of cells displayed the 
protein as many spots when fixed with methanol: acetone. BT-474 cells showed the 
distribution of the protein as many spots within the nucleoplasm in 20% of cells when fixed 
with methanol: acetone and 80% of cells showed at rim and spots when fixed with 
paraformadehyde whereas the same cells had the protein around the nuclear membrane and 
within the nucleoplasm as rim and spots (80%) when fixed with methanol: acetone. 
Moreover, Sk-Br-3 cells showed an abnormal distribution of the protein in 76% of cells 
showing many spots and 24% as rim and spots when fixed with paraformadehyde whereas 
80% of cells showed rim and spots and 20% of cells had the protein normally as rim only 
when fixed with methanol: acetone.  
 
Table 4.3: The Percentage of Lamin B2 Distribution: 
 MCF-10A  T-47D  GI-101  BT-474  Sk-Br-3 
Type of Fixation MA P MA P MA P MA P MA P 
Rim Only 0 20 0 0 15 20 0 20 20 0 
Rim & Spots 47 80 85 0 85 80 80 80 80 24 
Large Spots 17 0 0 0 0 0 0 0 0 0 
Homogeneous 16 0 0 100 0 0 0 0 0 0 
Many Spots 20 0 15 0 0 0 20 0 0 76 
Negative 0 0 0 0  0 0 0 0 0 0 
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Lamin A Distribution: 
The cells were immunostained with anti-lamin A antibodies and fixed with both type of 
fixations. The normal distribution of lamin A is localised at the nuclear periphery with some 
small foci inside (Bridger et al., 1993).  The control cells MCF-10A cells displayed a more or 
less normal distribution of lamin A with all cells having a rim stain with internal spots.  
However, the distribution of lamin A in T-47D cells showed abnormal large spots (75%) and 
many spots (25%) when fixed with methanol: acetone with an abnormal homogeneous 
distribution in 24% of cells and many spots in 76% of cells when fixed with 
paraformaldehyde. The same percentage was scored in GI-101 with the protein as many spots 
(75%) and rim only in 25% of cells when fixed with methanol: acetone whereas the same 
cells had the protein in 26% of cells as many spots and 74% had it as a rim and spots when 
fixed with paraformaldehyde. BT-474 cells displayed the protein in 75% as many spots and 
25% of cells as homogeneous when fixed with methanol: acetone whereas the cells had it in 
63% as a rim and spots, 22% as many spots, and 5% of cells as homogenous when fixed with 
paraformadehyde. 10% of BT-474 cells had the protein distribution as a rim only when fixed 
with paraformadehyde. The same experiment assessed the protein in Sk-Br-3 cells, and found 
that half of cells displayed it as abnormal homogeneous and many spots when fixed with 
methanol: acetone whereas 63% displayed it as abnormal many spots, 7% were 
homogeneous, and 29% expressed it as rim and spots when fixed with paraformadehyde. 
Thus lamin A has an aberrant distribution in the breast cancer cells which fits with the data 
for lamin A expression in Wazir et al., in prep).  
 
 
 
 
164 
 
Table 4.4: The Percentage of Lamin A Distribution: 
 MCF-10A  T-47D  GI-101  BT-474  Sk-Br-3 
Type of Fixation MA P MA P MA P MA P MA P 
Rim Only 0 0 0 0 25 0 0 10 0 0 
Rim & Spots 100 100 0 0 0 74 0 63 0 29 
Large Spots 0 0 75 0 0 0 0 0 0 0 
Homogeneous 0 0 0 24 0 0 25 5 50 7 
Many Spots 0 0 25 76 75 26 75 22 50 63 
Negative 0 0 0 0 0 0 0 0 0 0 
 
 
Lamin C and A/C Distribution: 
The distribution of lamins A and C are as for lamin A with a rim staining around the nucleus 
and some internal foci. The normal distribution of lamin A/C in cells and interphase nuclei is 
localised at the nuclear periphery as a rim structure as a main component of the nuclear 
lamina in differentiated cells. None of the cells in this study (from three separate 
experiments) showed any normal rim or rim and spots staining. Since the lamin A antibody 
did reveal normal staining in MCF-10A cells it may be that this antibody is not working 
optimally. This might also be true for the lamin C antibody which was made for the 
laboratory and uncharacterised.  
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Table 4.5: The Percentage of Lamin A/C Distribution: 
 MCF-10A  T-47D  GI-101  BT-474  Sk-Br-3 
Type of Fixation MA P MA P MA P MA P MA P 
Rim Only 0 0 0 0 0 0 0 0 0 0 
Rim & Spots 0 0 0 0 0 0 0 0 0 0 
Large Spots 0 20 0 0 0 0 4 0 0 35 
Homogeneous 60 0 65 30 0 25 10 75 40 65 
Many Spots 40 80 0 70 100 75 86 25 60 0 
Negative 0 0 35 0 0 0 0 0 0 0 
 
 
 
 
Table 4.6: The Percentage of Lamin C Distribution: 
 MCF-10A  T-47D  GI-101  BT-474  Sk-Br-3 
Type of Fixation MA P MA P MA P MA P MA P 
Rim Only 0 0 0 0 0 0 0 0 0 0 
Rim & Spots 0 0 0 0 0 0 0 0 0 0 
Large Spots 40 25 0 0 10 27 15 10 0 6 
Homogeneous 40 75 20 72 15 68 50 80 40 30 
Many Spots 20 0 70 28 75 5 35 10 60 64 
Negative 0 0 10 0 0 0 0 0 0 0 
 
LAP2α Distribution: 
The distribution of LAP2α in the nuclei of normal cells is homogeneously distributed. This 
distribution was seen for both fixations in the MCF-10A control cells. However, the cancer 
cell lines showed aberrant LAP2α distribution with LAP2α being found at the rim in T-47D 
(40%), BT-474 (22%) and a few Sk-Br-3 cells (5%). Other patterns seen in the cancer cell 
lines and not in the control were large spots/aggregates and many small spots. This may be 
indicative of the chromatin being affected in these cells since LAP2α is a chromatin binding 
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protein. The rim staining is unusual and could be because there are proteins missing at the 
nuclear envelope especially in T-47D and BT-474.  
 
Table 4.7: The Percentage of LAP2α Distribution: 
 MCF-10A  T-47D  GI-101  BT-474  Sk-Br-3 
Type of Fixation M P M P M P M P M P 
Rim Only 0 0 30 0 0 0 0   0  0   0 
Rim & Spots   0 0 10 0 0 0 0 22 0 5 
Big Spots 0 0 0 10 40 30 20 10 0 10 
Homogeneous 100 100 60 0 38  60 39 58 20 42 
Many Spots 0 0 0 90 22 10 36 10 80 43 
Negative 0 0 0 0 0 0 5 0 0 0 
 
 
 Emerin Distribution: 
Emerin is normally distributed at the nuclear rim in cells and can be seen in internal foci as 
well. MCF-10A cells which had a homogenous in 75% of cells and 25% of cells were 
negative when fixed with methanol: acetone whereas all cells distributed it as rim and spots 
in 100% of cells when fixed with paraformaldehyde. The distribution of the protein in T-47D 
cells showed 50% of cells had rim and spots, large spots in 30% of cells, and 20% as a 
homogeneous when fixed with paraformaldehyde. GI-101, BT-474 and SkBr3 cells all have 
quite a number of negative cells which will have an impact on the cells, especially with 
control of gene expression.  
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Table 4.8: The Percentage of Emerin Distribution: 
 MCF-10A  T-47D  GI-101  BT-474  Sk-Br-3 
Type of Fixation M P M P M P M P M P 
Rim Only 0 0 ND 0 0 0 15 0 30 5 
Rim & Spots 0 100 ND 50 73 30 50 100 55 65 
Large Spots 0 0 ND 30 0 20 5 0 0 5 
Homogeneous 75 0 ND 20 0 0 0 0 0 0 
Many Spots 0 0 ND 0 0 0 0 0 0 0 
Negative 25 0 ND 0 27 50 30 0 15 25 
*ND=No Data 
 
 
MAN1 Distribution: 
MAN1 should be distributed at the rim in normal cells However, none of the cancer cells 
with either fixation show MAN1 at the nuclear rim. There is a high proportion of nuclei 
displaying the many spots pattern for both fixations even in the control cells. Thus, in these 
cells which are epithelial may be MAN1 distribution is different. Some of the cells especially 
T-47D are displaying large spots of MAN1 which is not a normal distribution. There are also 
negative cells in the Sk-Br-3.  
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Table 4.9: The Percentage of MAN1 Distribution: 
 MCF-10A  T-47D  GI-101  BT-474  Sk-Br-3 
Type of Fixation MA P MA P MA P MA P MA P 
Rim Only 0 0 0 0 0 0 0 0 0 0 
Rim & Spots 0  0 0 0 0 0 0 0 0 0 
Large Spots 0 0 50 10 10 0 0 3 0 0 
Homogeneous 60 0 0 22 20 30 30 0 0 8 
Many Spots 40 100 50 63 70 70 60 97 100 72 
Negative 0 0 0 5 0 0 10 0 0 20 
 
 
 
4.3.3 Distribution of Other Nuclear Structural Proteins by Indirect 
Immunofluorescence (Methanol: Acetone, 1:1):  
Due to the distributions of some of the nuclear envelope antigens, especially the B-type 
lamins, in the nuclear interior as large foci it was pertinent to determine if these structures 
were colocalised or complexed with structures normally found as foci in the nuclear interior. 
This is why the cell lines BT474 and T47D were chosen to be further assessed since they had 
the most aberrant B-type lamin staining. Thus indirect immunofluorescence with rabbit anti-
PML antibody, mouse anti-nucleolin antibody, and rabbit anti-Ki67 antibody was performed 
on cell lines MCF-10A, T47-D, and BT-474 (Figure 4.3 Panel A (A-E) and Figure 4.4 Panel 
A (A-D)). Furthermore, due to proteins being not located at the nuclear periphery in these 
cells we decided to see if antibodies bind to other nuclear envelope proteins i.e. mouse anti-
LAP2β and rabbit anti-lamin B receptor were also in the nuclear interior and colocalised with 
the B-type lamins. The presence of these proteins was also very interesting. Nucleolin and 
LAPβ were present and correctly localised in almost all cells for nucleolin and in all cells for 
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LAP2β. Interestingly, BT-474 had a large number of cells where there were no PML bodies 
present and LBR was very much affected by lacking in BT-474 and T47D cells.  
 
From at least 200 nuclei, the presence of PML, nucleolin, LBR, LAP2β, and Ki67 proteins in 
BT-474, T-47D, and MCF-10A cell lines was scored. These cells were fixed with methanol: 
acetone, 1:1 and these proteins showed clear differences in their nuclear distribution (Table 
4.12). It is found that PML proteins, protein of stress, were distributed 100% in T-47D cells, 
69.5% in BT-474 cells, and 100% in MCF-10A. Moreover, nucleolin, nucleolus protein, was 
found approximately equal in these three cell lines and between 93-98% of cells showed 
positive staining. Ki67 proteins, found in the nucleolus of proliferated cells as proliferation 
marker in breast cancer, were found in high percentages in T-47D cancerous cells (92%) and 
MCF-10A (75%) normal cells whereas it was 44% in BT-474 cancerous cells. Furthermore, 
LAP2β proteins were present in a high percentage and equally in these three cell lines 
(100%). Lamin B receptor (LBR) was present in MCF-10A cells (95%), but reduced in T-
47D cells (64%), and low in BT-474 cells (29%). Interestingly, the percentage of LBR 
positive cells in T-47D and BT-474 was similar to the data from Fischer et al., in 1998, where 
they found the lack of LBR at the NM in papillary thyroid carcinoma might be linked to LBR 
gene mutation or alterations in the expression of LBR (Fischer et al., 1998) (Figure 4.3 Panel 
A (A-E); Figure 4.4 Panel A (A-D); Table 4.12).  
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I. Distribution of Other Nuclear Structure Proteins (Methanol: Acetone, 1:1):
Panel (A):
PML Nucleolin LBR LAP2 Ki67
BT-474
T-47D
MCF-10A
A CB D E
E
DCBA
A
B DC
E
Figure 4.3: Different Localisations of PML, Nucleolin, LBR, LAP2 and KI67
Proteins: These images demonstrate antibody distributions within the nucleoplasm
determined by indirect immunofluorescence (IIF) and fixed with methanol: acetone, 1:1.
The images demonstrate the localisation of these proteins in BT474, T-47D, and MCF-10A
cell lines (A-E) when immunostained with anti-PML (A), anti-nucleolin (B), anti-LBR
(C), anti-LAP2 (D), and anti-Ki67 (E) antibodies. The DNA stained with DAPI (Blue).
Scale Bar = 10µM.
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Table 4.10: The table shows the specific percentages of nuclear proteins which are within 
these cell lines as shown below. From at least 200 positive nuclei, this table compares the 
presence and distribution of nuclear proteins in T-47D, BT-474, and MCF-10A cell lines 
when fixed with methanol: acetone, 1:1. These proteins showed clear differences in their 
nuclear distribution.  
 
 PML Nucleolin Ki67 LAP2 LBR 
T-47D Cell Lines 100 % 98.5 % 92 % 100 %    64 % 
BT-474 Cell Lines 69.5 % 93 % 44 % 100 % 29 % 
MCF-10A Cell Lines 100 % 97.5 % 75 % 100 % 95 % 
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II. Co-Localisation of Lamins B with Ki67 and Lamin B Receptor with Nucleolin and LAP2
Proteins (Methanol: Acetone, 1:1):
Panel (B):
BT-474
B1+Ki67 B2+Ki67   Nucleolin+LBR LAP2+LBR
T-47D
MCF-10A
A CB E
A B C D
E
CB D
A DB C
A
Figure 4.4: Different Co-Localisations of Lamin B with Ki67 and Co-
Localisation of LBR with Nucleolin and LAP2: These images
demonstrate antibody distributions within the nucleoplasm determined
by indirect immunofluorescence (IIF) and fixed with methanol: acetone,
1:1. The images demonstrate the co-localisation of these proteins in
BT474, T-47D, and MCF-10A cell lines (A-D) when immunostained
with anti-lamins B, anti-nucleolin , anti-LBR, anti-LAP2, and anti-Ki67
antibodies. Ki67 protein was associated or co-localised with lamin B in
large spots within the nucleoplasm as well as LBR co-localised with
nucleolin and LAP2 in cancer cells. These spots were very interesting
within the nucleoplasm. Therefore, dual colour experiments were
performed to see these co-localisatioins. The DNA stained with DAPI
(Blue). Scale Bar = 10µM.
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Since there was very interesting spots from lamin B1, lamin B2, it was important to see if 
there are co-localisations with these proteins. Therefore, dual colour experiment was 
performed. The co-localisation assessed lamin B1 with Ki67 antibodies, lamin B2 with Ki67 
antibodies, nucleolin with LBR antibodies, and LAP2β with LBR antibodies (Figure 4.4 
Panel B (A-D)) as well as lamin B with LBR and lamin B with PML bodies (Figure 4.8, 
Panel A (I-IV)). In this experiment, it was found that Ki67 protein associated with lamin B in 
larger foci. LBR colocalised with LAP2β at the nuclear periphery but was also found to 
colocalise with nucleolin in the interior of the nucleus. In addition to this, large foci were 
observed for the B-type lamins and LBR which is an important finding because lamin B and 
LBR has never been seen like this in normal cells and should be at the periphery like a rim in 
normal situation. These data revealed foci of lamin B with LBR and lamin B with PML 
bodies deep within the nucleoplasm (Figures 4.7 and 4.9). 
 
4.3.4 Distribution of Other Nuclear Structure Proteins (Paraformaldehyde 4%):  
Indirect immunofluorescence staining was performed with rabbit anti-PML antibody,  mouse 
anti-nucleolin antibody, mouse anti-LAP2 antibody, rabbit anti-lamin B receptor antibody, 
and rabbit anti-KI67 antibody on different cell lines (MCF-10A, T47-D, and BT-474) 
paraformaldehyde 4% (Figure 4.5, Panel A (A-E)). This experiment was used to assess their 
localisation and co-localisation of these proteins and their distributions throughout the 
nucleoplasm. Therefore, dual colour experiment was performed in order to see is there is co-
localisation with these proteins. The co-ocalisation assessed between lamin B1 with Ki67 
antibodies, lamin B2 with Ki67 antibodies, nucleolin with LBR antibodies, LAP2 with LBR 
antibodies (Figures 4.6, Panel B (A-D)). In this experiment, it is found that Ki67 protein was 
associated with lamin B in larger foci as well as foci were found in association of LBR with 
nucleolin and LBR with LAP2 antibodies. In addition to this, the data revealed very 
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interesting spots of lamin B with LBR and lamins B with PML bodies within the nucleoplasm 
when assessed by dual colour experiments as shown below in Figures 4.7 and 4.9. 
 
From at least 200 nuclei, the percentage were counted from different nuclear structures to 
assess and compare presence and distributions of PML, nucleolin, LBR, LAP2, and Ki67 
proteins in BT-474, T-47D, and MCF-10A cell lines. These cells were fixed with 
paraformaldehyde 4% and these proteins showed clear differences in their nuclear 
distribution (Table 4.13). It is found that PML proteins were distributed approximately 100% 
in MCF-10A and T-47D cells, 61% in BT-474 cells, similarly to methanol: acetone fixed 
cells. Moreover, nucleolin was found in both cancerous cell lines (both T-47D and BT-474) 
and 50% in normal cells (MCF-10A). This is not a normal situation since nucleolin is always 
found at nucleoli in normal cells. Ki67 proteins were found in high percentages in T-47D 
cancerous cells (95.5%) and approximately half of MCF-10A normal cells were expressed it 
(55%) whereas Ki67 was low in BT-474 cancerous cells (33%). Furthermore, LAP2β 
proteins were distributed in high percentage in T-47D cells (100%) and MCF-10A normal 
cells (90%) whereas the same protein was present in very low numbers in BT-474 cells using 
this fixation as compared to methanol: acetone fixation. LBR was seen in half of MCF-10A 
cells (52.5%) but in very low numbers in T-47D and BT-474 cells (1%).  
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I. Distribution of Other Nuclear Structure Proteins(Paraformaldehyde 4%):
Panel (A):
PML Nucleolin LBR LAP2 KI67
A B
A
C D E
EA B C D
A B C D E
BT-474
T-47D
MCF-10A
Figure 4.5: Different Localisations of LBR, Nucleolin, PML, LAP2 and KI67
Proteins: These images demonstrate antibody distributions within the nucleoplasm
determined by indirect immunofluorescence (IIF) and fixed with paraformaldehyde 4%.
The images demonstrate the localisation of these proteins in BT474, T-47D, and MCF-10A
cell lines (A-E) when immunostained with anti-PML (A), anti-nucleolin (B), anti-LBR
(C), anti-LAP2 (D), and anti-Ki67 (E) antibodies. The DNA stained with DAPI (Blue).
Scale Bar = 10µM.
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Table 4.11: The table shows the specific percentages of nuclear proteins which are within 
these cell lines as shown below. From at least 200 positive nuclei, this table compares the 
presence and distribution of expressed nuclear proteins when fixed with paraformaldehyde 
4%. These proteins showed clear differences in their nuclear distribution.  
 
 PML Nucleolin Ki67 LAP2 LBR 
T-47D Cell Line 98.5 %  100 % 95.5 % 100 % 1 % 
BT-474 Cell Line 61 % 97 % 33 % 18.5 % 26.6 % 
MCF-10A Cell Line 100 % 50 % 55 % 90 % 52.5 % 
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II. Co-Localisation of Lamins B with Ki67 and Lamin B Receptor with Nucleolin and LAP2 
Proteins (Paraformaldehyde 4%):
Panel (B):
B1+Ki67 B2+Ki67   Nucleolin+LBR LAP2+LBRA
A DCB
A B C D
A
B C D
Figure 4.6: Different Co-Localisations of Lamin B with Ki67 and Co-
Localisation of LBR with Nucleolin and LAP2: These images
demonstrate antibody distributions within the nucleoplasm determined
by indirect immunofluorescence (IIF) and fixed with paraformaldehyde
4%. The images demonstrate the co-localisation of these proteins in
BT474, T-47D, and MCF-10A cell lines (A-D) when immunostained
with anti-lamins B, anti-nucleolin , anti-LBR, anti-LAP2, and anti-Ki67
antibodies. Ki67 protein was associated or co-localised with lamin B in
large spots within the nucleoplasm as well as LBR co-localised with
nucleolin and LAP2 in cancer cells. These spots were very interesting
within the nucleoplasm. Therefore, dual colour experiments were
performed to see these co-localisatioins. The DNA stained with DAPI
(Blue). Scale Bar = 10µM.
BT-474
T-47D
MCF-10A
 
 
 
178 
 
4.3.5 Distribution of Lamin B with PML and LBR Proteins Co-localisation by Indirect 
Immunofluorescence:  
Since B-type lamins were found localised inside the nucleoplasm as large foci it was 
pertinent to see if they were colocalised with other internal structures such as PML bodies. 
Further since LBR was also seen to be in internal foci with lamin B being its binding protein 
– the colocalisation of these proteins needed to be investigated (Figures 4.7 and 4.9).  
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4.3.5.1 Cells Fixed with Methanol: Acetone, 1:1:
Panel (A):
B1+PML B2+PML B1+LBR B2+LBR
BT-474
T-47D
MCF-10A
I
I
IVIIIII
IVIIIII
I IVIIIII
Figure 4.7: Panel (A): Co-staining of Lamin B1 and Lamin B2 with PML
Bodies and LBR: These images demonstrate co-staining of proteins distributions
within the nucleoplasm and they were processed and determined by indirect
immunofluorescence (IIF) method after fixed with methanol: acetone (1:1). Lamins
B was found as internal foci within the nucleoplasm. Therefore, dual colour
experiments were performed. The images demonstrate the co-localisation of these
proteins in BT474, T-47D, and MCF-10A cell lines. Panel A (I-IV): demonstrates
the images of BT-474 cells when immunostained with both anti-lamins B with anti-
PML and lamins B with anti-LBR antibodies (I-IV). Assessment of co-localisation
between these proteins was also performed in T-47D and MCF-10A cells (I-IV).
The DNA was stained with DAPI (Blue). Scale Bar = 10µM.
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4.3.5.2 Co-Localisation of Lamins B, LBR, and PML (Methanol: Acetone, 1:1): 
Figure 4.8 (Panel B) displays the percentages of PML structures that were localised with 
lamins B1 and B2 as well as the LBR with lamins B1 and B2. These percentages were 
calculated from different number of cell nuclei ranging from 200-700 nuclei. The indirect 
immunofluorescence was performed and the cells fixed with methanol: acetone, 1:1. 
 
Panel (B): 
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Figure 4.8: Panel (B) Co-Localisation of Lamin B, LBR, and PML: This figure compares 
the presence and distribution of these nuclear proteins when fixed with methanol: acetone, 
1:1. These proteins showed clear differences in their nuclear distribution and localisation as 
well as co-localisation between lamin B, LBR, and PML. The co-localisation of lamin B with 
PML in cancer cells is more than the normal cells. 
4.3.5.3 Cells Fixed with Paraformaldehyde 4%: 
Panel (A):
B1+PML B2+PML B1+LBR B2+LBR
BT-474
I
II
II
I
I III
IVIII
IV
II III IV
T-47D
MCF-10A
Figure 4.9: Panel (A): Co-staining of Lamins B with LBR and PML: These
images demonstrate distributions of antibodies within the nucleoplasm and
they were processed and determined by indirect immunofluorescence (IIF)
method after fixation with paraformaldehyde (4%). The aim of this experiment
is to test the co-localisation of lamins B and PML as well as lamins B and
LBR. Lamins B was found as internal foci within the nucleoplasm. The images
demonstrate the co-localisation of these proteins in BT474, T-47D, and MCF-
10A cell lines. Panel (A): demonstrates the images of BT-474 cells when
immunostained with both anti-lamins B with anti-PML and lamins B with anti-
LBR antibodies (I-IV). The same assessment of co-localisation between these
proteins was performed in T-47D and MCF-10A cells (I-IV). The DNA stained
with DAPI (Blue). Scale Bar = 10µM.
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4.3.5.4 Co-Localisation of Lamin B, LBR, and PML (Paraformaldehyde 4%): 
Figure 4.10 (Panel B) displays the percentages of PML structures that were localised with 
lamins B1 and B2 as well as the LBR with lamins B1 and B2. These percentages were 
calculated from different number of cell nuclei ranging from 200-700 nuclei. The indirect 
immunofluorescence was performed and the cells fixed with paraformaldehyde 4%. 
 
Panel (B): 
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Figure 4.10: Panel (B) Co-Localisation of Lamin B, LBR, and PML: The figure compares 
the presence and distribution of these nuclear proteins after fixation with paraformaldehyde, 
4%. These proteins showed clear differences in their nuclear distribution and localisation as 
well as co-localisation of lamin B, LBR, and PML. The co-localisation of lamin B with PML 
in cancer cells is more than the normal cells. 
 
 
 
 
These data show that internal lamin foci of both B-type lamins are indeed colocalised with 
PML bodies in the cancer cell lines which is very unusual and has not been reported before. 
The colocalisation fraction is very much less for the control cells. There are also issues with 
B-type lamins and their colocalisation with LBR which should be 100%.  
 
 
4.3.6 Four Colour Images by Indirect Immunofluorescence in BT-474 and T-474 Cell 
Lines: Panels (I and II) Demonstrate Cells after Fixation with Methanol: Acetone (1:1) 
and Paraformadehyde 4%, Respectively:       
In order to assess the colocalisation of a number of antigens in the same nuclei, four colour 
indirect immunofluorescent experiments were designed. The aim of this experiment was used 
to confirm our results as compared to the previous experiment results and since these cells 
have big foci within the nucleoplasm, it is interesting to assess the co-localisation of lamin 
B1, lamin B2, MAN1, and LAP2α. The images, demonstrate lamins and lamin binding 
proteins distributions, were processed and determined by indirect immunofluorescence 
method when fixed with methanol: acetone, 1:1 and paraformaldehyde 4% (Figure 4.11 
Panels I and II (A and B)) using anti-lamin B (Conjugated Cy3, Red, A and B), anti-MAN1 
(Conjugated Cy5, Pink, A and B), and anti-LAP2α (FITC, Green, A and B) antibodies in both 
BT-474 and T-47D cells.  
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Four Colour Images by Indirect Immunofluorescence in BT-474 and T-474 Cell Lines:
Panel (I): Methanol: Acetone, (1:1):
Panel (II): Paraformadehyde 4%:
BT-474
T-47D
A B
A B
BT-474
T-47D
A B
A B
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Figure 4.11: Panels (I) and (II): Different Distribution of Nuclear Lamins and Lamin 
Binding Proteins. Panel (I): These images, demonstrate lamin B1, lamin B2, MAN1, and 
LAP2α proteins distributions, were processed and determined by indirect 
immunofluorescence method when fixed with methanol: acetone, 1:1 using anti-lamin B 
(Red), anti-MAN1 (Pink), and anti-LAP2α (Green) antibodies in both BT-474 and T-47D 
cells. This figure showed merged colours of anti-lamin B (Red), anti-MAN1 (Pink), and anti-
LAP2α (Green) in T-47D and BT-474 cell lines. In both cells we found lamin B as a rim and 
large foci (A and B) whereas MAN1 is missed or very faint in BT-474 cells and found as foci 
in T-47D cells. LAP2α was homogeneous and as foci in both cell lines. The four colours 
were secondary antibodies; anti-lamin B1 (A) and anti-lamin B2 (B) conjugated with Cy3 
(red), anti-MAN1 conjugated with Cy5 (pink), anti- LAP2α conjugated with FITC (green), 
and DAPI (blue) for DNA staining. Panel (II): It is similar to panel (I) description and the 
difference is that the cells were fixed with paraformaldehyde 4%. In BT-474 cells, lamin B1 
and MAN1 found as a faint rim and spots (A) whereas lamin B2 was well expressed (B) and 
LAP2α was homogeneous. In T-47D cells, lamin B and MAN1 were missed (A and B) 
whereas LAP2α was found as a homogenous and foci (A). Scale Bar = 10µM.  
   
 
These images indicate that there is a significant difference in the presence, distribution and 
organisation of nuclear lamins and lamin binding proteins as well as to some important 
nuclear proteins such as PML, nucleolin, LAP2, and LBR in these cell lines (T-47D and BT-
474).  
 
4.3.7 qRT-PCR for Lamin B and Lamin B Receptor Gene Expression: 
4.3.7.1 qRT-PCR Analysis for Lamin B and Lamin B Receptor Genes from Different 
Cells: 
The data in this chapter showed that there were problems in the cancer cell lines with lamin B 
and LBR presence. It was important to determine if these two genes were being expressed in 
the cell lines. This was assessed by q-RT-PCR. The graphs in Figure 4.12 show the 
percentage of relative quantification of gene expression by fold changes in expression for 
each gene using qRT-PCR. The levels of expression of all genes studied here are calculated 
from 2
-ΔΔC
t or relative quantification (RQ) using RQ Manager and Microsoft Excel software.  
The equations are:  
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ΔCt = Ct (target) – Ct (housekeeping gene) 
ΔΔCt = ΔCt (sample) – ΔCt (normal or calibrator) 
RQ = 2
-ΔΔC
t 
 
  
 
 
Figure 4.12: Expression Levels of LMNB1, LMNB2, LBR, and β-Actin Genes mRNA of 
Breast Cell Lines using qRT-PCR: These histograms show the percentage of relative 
quantification (RQ %) of different genes in present of β-actin as a housekeeping gene with no 
supplement set as 1 (100%) (A-C). The fold changes in different gene expression were 
assessed between cell lines (MCF-10A, T-47D, BT-474, GI-101, and Sk-Br-3) using RQ 
Manager and Microsoft Excel Software. Different mRNA levels showed a two-fold increase 
or decrease change in the gene expression. The expression over 100% is up-regulated and 
below this percentage is down-regulated. Error bars represent the Standard Error of the Mean 
(SEM) of three replicates. 
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The expression data from the qPCR shows that the B-type lamins are expressed well in T-
47D and BT-474, maybe even over-expressed as compared to MCF-10A. What is noticeable 
is that LBR is much less than the other cells. This could cause an issue with the B-type 
lamins being correctly localised in the cell nuclei.  
 
4.3.7.2 Agarose Gels from qPCR Products: 
The figures below show the detection of specific gene qPCR products and their molecular 
sizes (Figure 4.13 and Appendices) by agarose gel electrophoresis. These products are shown 
after 40 cycles of amplification to evaluate the quality and integrity of these primers. 
 
(1) LMNB1 (125 bp):       (2) LMNB2 (153 bp): 
   
 
 
 
 
 
 
300 
200 
100 bp 
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(3) LBR (128 bp):     (4) β-Actin (216 bp): 
   
Figure 4.13: Representative Images of Gels Showing the Identification and Specificity of 
3 Selected Genes of Interest in Breast Normal and Cancerous Cell Lines, Either Treated 
or Untreated Cells: cDNA was synthesised from RNA samples obtained from different cell 
lines. qRT-PCR experiments were performed using specific primers for each of the 3 target 
genes as well as to the β-actin as a reference gene. For amplification of each gene, qPCR was 
also performed in triplicate for positive and negative control at the same time on 96-well 
plate. To confirm and ensure this amplification has worked properly, the amplicons from 
each experiment were run on 2% agarose gel. The table above showed the size of the band for 
each product. Moreover, the dissociation curve can also confirm this accuracy, efficiency, 
specificity, and validity of the cDNA (Data not shown). *The Key: M= Marker (100 bp 
Ladder, BioLabs), 1=T-47D, 2=BT-474, 3=GI-101, 4=Sk-Br-3, 5=MCF-10A, 6=T-47D 
(12uM/48hours), 7=MCF-10A (12uM/48hours, lovastatin), 8=MCF-10A (24uM/48hours, 
lovastatin), 9=BT-474 (12uM/48hours, lovastatin), and 10=-ve Control (H2O). Note: Lanes 6-
9 include cells treated and untreated with lovastatin. 
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4.4 Discussion: 
The architecture of cell nuclei is often altered in cancerous cells. The types of cancers are 
associated with characteristic changes and these may provide important diagnostic features. 
The normal breast (MCF-10A) and cancer cell lines (T47-D, GI-101, Sk-Br-3, and BT-474) 
display different distribution of lamins, lamin binding proteins, integral nuclear membrane 
proteins, and other nuclear proteins such as PML, nucleolin and Ki67 (Figures 4.1 - 4.3, 
Figure 4.5, and Tables 4.4 - 4.13). The study in this chapter was to assess the distribution and 
presence of nuclear proteins that if aberrant could lead to the mis-position or disorganisation 
of the genome. We have found that a number of nuclear envelope proteins and chromatin 
binding proteins are altered in our cancer cells and even in the MCF-10A control cell line.   
 
For over 140 years, different studies showed that much debate about changes in the cell 
nucleus structure in cancer diagnosis. One of these changes was observed in 1860 in patient 
with cancer of the pharynx and observed that there was a clear change in nuclear size and 
shape variation (Zink et al., 2004). This was followed by changes in cytoplasmic and nuclear 
structure features of the cells as well as these include changes in nucleolar size and shape, 
and numbers of nucleoli. These alterations also can be characteristic of cancer type and stage 
which is a very useful for cancer diagnosis and might also be related to the altered functions 
of cancer cells (Zink et al., 2004). In this study, T-47D, GI-101, BT-474, and Sk-Br-3 breast 
cancer cell lines were showed changes and alterations in nuclear proteins distribution when 
compared with the MCF-10A normal but immortalised cell line.   
  
The structural components of the nucleus are strongly linked to the genome. The correlation 
between the genome and nuclear structure is that the nuclear envelope proteins have 
chromatin binding sites and therefore are involved in anchoring interphase chromosomes to 
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the nuclear periphery. These include lamins, LBR, LAPs 1 and 2, emerin, MAN1, and BAF 
(Zuleger et al., 2011).  In humans the acrocentric chromosomes are embedded in nucleoli and 
other chromosomes that do not contain rRNA or tRNA are also associated with nucleoli 
(Bridger et al., 1998b) for example chromosome 17 (van Konigsbruggen et al., 2010) and 
chromosome 19 (Nemeth et al., 2010). The loss of this organisation or aberrant distribution in 
nuclear structure will lead to dis-organisation of the genome and the loss of both nuclear 
structure and genome organisation that are associated with cancer and laminopathies (Young 
et al., 2012). However, there seem to be no issues with nucleoli in these cancer cells as 
shown by Ki67 and nucleolin staining. The main issues are with nuclear envelope proteins 
such as lamin A, emerin and B-type lamins between these five breast cell lines. From the 
literature, mutation in LMNA gene showed a loss of chromatin integrity which is associated 
with deformation of the nuclear envelope and lamina (Sullivan et al., 1999). Gene expression 
and chromosome positioning are abnormal in lamin B1 silenced cells (Malhas et al., 2007), 
while disruption of B-type lamins inhibits DNA replication and RNA pol II transcription 
(Dechat et al., 2008). Interestingly, lamin B is considered as a binding site for the human 
genome since lamins have 1,300 lamin associated domains (LADs) which were found to be 
in gene poor regions at the nuclear periphery of the genome (Guelen et al., 2008). Therefore, 
these changes in nuclear lamins, integral membrane proteins, and other nuclear structure 
proteins will affect chromatin organisation and gene expression. Thus, it is important to 
understand this organisation, regulation and distribution are required and linked to nuclear 
lamins for efficient normal nuclear functions.   
 
 
The lamina is thought to be a principal determinant of the nuclear shape (Goldman et al., 
2002). The nuclei of most normal cells have a regular shape but an irregular nuclear shape is 
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observed in cancerous cells. These changes are characteristics of different cancer types. For 
examples, small-cells lung carcinoma lack the proteins of lamin A whereas lamin B 
expression varied between normal and cancer cells and therefore this may contribute to the 
structural changes observed in the lamina (Broers et al., 1993) (Chapter 1, Table 1.1). 
 
These results show that the nuclear lamins and their binding proteins change during breast 
cancer. Moreover, these changes in distribution might be of the loss of LMNA gene that is 
associated with deformation of the nuclear envelope and lamina. This can lead to changes in 
nuclear morphology such as herniations and blebs structures. These morphological changes 
could lead to lack of nuclear pore complexes that prohibit local export of mRNA, thereby 
inhibiting splicing and transcription. Thus, this will lead to the loss of peripheral 
heterochromatin and mis-localisation of chromosomes as well as to the loss of lamins A/C 
expression (Agrelo et al., 2005; Shimi et al., 2008). Therefore, lamins A is important to 
maintain the stability and regulate transcription. Furthermore, the expression of LMNA gene 
is reduced or absent in cells that are highly proliferating cells (Barboro et al., 2003) but not in 
other cells. This will support the idea that the genome organisation is tissue specific (Chapter 
1, Table 1.1). Moreover, the deregulation of the distribution of these lamins might be due to 
changes in nuclear matrix proteins that anchor the genome, telomeres, nuclear bodies, matrix 
attachment regions and transcriptional machinery. This will cause the morphological 
modifications during the process of carcinogenesis due to disruption in this binding. The 
depolymerisation of one element in the nucleoskeleton structure could collapse the others 
(Hozák et al., 1995). This is the reason why lamins influence the position of the 
chromosomes in the interphase nucleus. Thus, this may affect the epigenetic regulation of 
chromatin. The arrangements in the nucleus are maintained by attachments to nuclear matrix 
proteins (NMPs) (Fey et al., 1986). Lamins attachments will support their assembly into 
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functional macromolecules involved in nuclear processes (Nickerson, 2001). The nucleoli 
and nuclear bodies (PML) also participate in these changes in lamins distribution and 
expression during breast cancer. These changes include changes in their location, structure, 
and function.  
 
Previous studies showed that the inactivation of lamin B1 or truncated lamin A inhibit DNA 
replication and RNA polymerase II transcription, respectively. The effects of lamins on 
chromatin structure, function, and organisation is through the direct interaction of lamins to 
histones or lamins binding proteins (Dechat et al., 2008; Shimi et al., 2008). A lack of lamin 
staining was found to occur in the nuclear periphery in our cells. This could be due to: 
mutation or loss in LMN genes, decreased lamins synthesis, alteration of lamins structure 
after post-translation modifications, degradation of lamins during apoptosis as a first target by 
caspases, deficient in lamins processing pathways or defects in enzymes that are involved in 
prenylation, microtubules disassembly during cell division, and/or epitope masking that binds 
to specific antibodies at the nuclear periphery. However, lamins staining was observed in the 
nucleoplasm of cancer cells as foci. Their presence within the nucleus could be due to 
problems with farnesylation so that they cannot get to the nuclear membrane or that is not 
enough LBR to enable the lamin B to anchor to the nuclear membrane. It was found that 
lamin B was associated with PML bodies in this work. The consequence of this to a cancer 
cell is not easy to ascertain but it could very definitely affect the functionality of PML bodies. 
Lamin B being in the wrong place could also affect DNA replication, transcription sites or 
splicing.  
 
Since PML bodies are transcriptional regulators, they are involved in major nuclear functions. 
In mice, these nuclear bodies are lost and their proteins are dispersed throughout the 
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nucleaoplasm. These proteins display effects on cell growth, tumourgenesis, and the 
development of blood cells. Regarding the diffusion of PML bodies and their colocalisation 
throughout the nucleoplasm, chromatin dynamics have considered in understanding nuclear 
functions (Chubb and Bickmore, 2003) and PML bodies may also be required for nuclear 
functions. These nuclear bodies are capable of assembly and disassembly in response to 
physiological stimuli and have mobility properties in the nucleoplasm. Moreover, their 
presence surrounding chromatin, either the assembly or disassembly, may be influenced by 
the local chromatin organisation (Boisvert et al., 2000).  
 
Nuclear structure and genome organisation are essential and important for correct gene 
expression and normal function of cells (Malhas et al., 2007). Understanding the nuclear 
behaviour of breast cancer cells will aid in the goal to eliminate cancer as a major health 
problem. Lamins can be used to distinguish normal tissue from tumour cells. In 2011, 
Coffinier et al. demonstrated that lamin B1 deficiency is sufficient to cause severe 
neurodevelopmental and nuclear shape abnormalities. In contrast, Yang et al., in 2011, 
generated mice lacking both lamin B1 and lamin B2 in skin keratinocytes and found that skin 
histology and keratinocyte proliferation was entirely normal. Thus, losing the expression of 
the B-type lamins are significantly different in the brain and skin. In this study, nuclear lamin 
B, which is involved in chromosome positioning within cells, is aberrant in T-47D, GI-101, 
and BT-474  cell lines displaying large foci within the nucleoplasm. However, the functional 
assessment of lamin B would be difficult and the reason that the function of lamin B2 is not 
precisely defined particularly when compared with lamin B1. The range of potential roles of 
lamin B2 includes supporting the inner side of the nuclear envelope, stabilising the nucleus 
and chromatin, and regulating gene expression.  
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Chromatin and DNA binding sites are found in LBR (Worman et al., 1990). Since lamins B 
bind to chromatin, therefore, there is preferential binding between lamins B, chromatin, and 
LBR within the nucleoplasmic domain. Since lamin B attachment site to LBR, may also 
function in the attachment of DNA to the inner nuclear membrane. It is also possible that the 
DNA binding activity of LBR is responsible for targeting mitotic membrane vesicles to 
decondensing chromosomes at the end of mitosis. These vesicles are targeted to chromatin 
before nuclear lamins or nuclear pore complex proteins and may initiate nuclear envelope 
reassembly in vivo (Foisner and Gerace, 1993). Thus issues with B-type lamins and LBR 
could affect chromatin and chromosome binding at the nuclear envelope leading to genome 
misorganisation and gene repositioning.  
 
Lamin B1 silenced or missed showed clear change of both lamin A/C and lamin B2 structure 
suggesting that lamin B1 is a critical and provides scaffold required for the proper structural 
integrity and organising of the nuclear lamins, lamin A/C and B2 (Shimi et al., 2008). 
Interestingly, the gene poor chromosomal regions are associated with lamin B1 in the lamina 
at the periphery whereas lamins A are preferentially associated with gene rich regions in the 
nuclear interior (Goldman et al., 2002; Dechat et al., 2010). Clearly, there is a relationship 
between lamins, lamin associated proteins, histone and RNA Pol II transcription and their 
roles in chromatin organisation and gene regulation.  
 
 
Lamins interact and connect to chromatin through other proteins (lamin binding proteins). 
This interaction could participate in heterochromatin formation at the nuclear periphery. 
However, in cancer cells, nuclei can become irregular and nucleoli can be enlarged (Zink et 
al., 2004). Clearly, any alteration of nuclear shape is associated with alteration in 
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heterochromatin organisation. This alteration will affect chromatin organisation and gene 
expression. The variable regulation of gene expression may be due to differences in specific 
gene regulation at the nuclear periphery of lamina (Shimi et al., 2008).  
 
In order to explain the distribution of nuclear lamina in all these breast cancer cell lines. The 
possible explanation for the absent of nuclear lamins due to decreased, altered or degradation 
of nuclear lamin protein synthesis. The steps of processing and modifications are important 
and critical for lamins localisation into the lamina that means blocking the farnesylation, will 
inhibit lamins post-translation processing. Although lamin C does not undergo any post-
translational modifications and have no CAAX box motif at the C-terminal, it is incorporated 
to the nuclear periphery in normal cells (Vergnes et al., 2004; Malhas et al., 2007). 
Therefore, the mechanism of lamins C to be mature and incorporated to the nuclear periphery 
is unclear. Interestingly, inhibition of lamins farnesylation does not inhibit their incorporation 
to the lamina. For example, lamins C that lack 98 amino acids in their C-terminal and only 
have 6 amino acids lacking a CAAX box become incorporated into the nuclear lamina 
(Dechat et al., 2008). That means CAAX only is not enough for incorporation to the nuclear 
periphery and other parts are also necessary for full incorporation. Mutations in LMNA gene 
will affect its charge and this will lead to instability of interaction between the α-helix at the 
rod domain preventing lamins dimerisation thus, inhibit the lamin binding proteins. 
Moreover, deficient in lamin B1 or the processing pathway could be of the Ras converting 
enzyme 1 endoprotease deficient or loss of ICMT in the carboxmethyl transferease which is 
important for the final carboxymethylation step and for Ras functions. This will lead to 
defective in CAAX processing to be mature and active (Malhas et al., 2007). However, 
changes in lamina proteins or other nuclear proteins, involved in the process of cancer 
transformation, remain unclear.  
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From the data in this chapter, most of the nuclear functions involve not only the nuclear 
lamina, but also other components of the nuclear structure. This will increase our knowledge 
to understand the abnormal lamina affects other nuclear structures and functions. To assess 
the differences in the expression and distribution of other nuclear proteins such as PML, 
nucleolin, and Ki67 which are included in this chapter between two different cancerous (T-
47D and BT-474) cell lines and one normal (MCF-10A) cell line are linked their expression 
to cancer pathology. The various percentages of nucleolin distribution between normal (50%) 
and cancer (more than 93%) cells may affect translation and post-translation of proteins and 
this may lead to nuclear abnormalities and cell cycle deregulation. Moreover, these proteins 
may affect other proteins that are attached to the nuclear matrix and then perturbed leading to 
low amount of proteins involved in nuclear processes and functions.  
 
The nuclei that showed negative expression of nucleolin may have dysfunctional nucleoli due 
to defects in ribosome biogenesis. These defects alter transcription, translation, post-
translation modification, apoptosis, and oncogenic pathways. This protein is involved in 
maintenance of normal nuclear function and structure by maintaining the nucleoplasmic 
proteins such as nuclear motors and this suggest its interaction with chromosomes therefore, 
nucleolin can participate in chromosomal organisation and reorganisation (nucleolar 
organising regions, NORs) (Gautier et al., 1992; Cong et al., 2012).  
 
The various percentages of Ki67 protein distribution between normal and cancer cells depend 
on the cell cycle phase and cell type. It is seen in early G1 phase when the nuclear 
compartments broken down during mitosis that includes nuclear envelope and nucleolus 
reassemble. In addition, Ki67, has been implicated in the regulation of cell cycle, cell 
proliferation, rRNA synthesis and protection of chromosomes during mitosis, maintenance of 
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nucleolar structure (Kill, 1996), and can interact with heterochromatin that suppress the 
transcription and distribution of this protein (Goldman et al., 2004). Furthermore, to these 
proteins is PML bodies that contain many proteins and have been implicated in multiple 
regulatory pathways, from the control of cell proliferation to DNA repair or apoptosis and 
can colocalise with the p53 locus to facilitate cell cycle regulation.  
 
Therefore, the proper distribution of all these proteins within nuclei and nucleolei may result 
in proper cell functions. Therefore, the presence and distribution of lamins and these proteins 
may be disturbed resulting in cancer with abnormal nuclear shape, cell cycle up-regulation, 
and hyperproliferation (Zimber et al., 2004). 
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4.5 Conclusion:  
There is a fundamental correlation between the nuclear structure and genome which is the 
nuclear structure participates in genome organisation. This organisation and the strong 
relationship can be influenced by chromatin localisation for correct nuclear functions. 
 
The findings in this chapter have been corroborated in a study by our collaborators, which 
was suggested by these data in this chapter whereby they show lamin A, B-type lamins and 
LBR lacking to various extents in actual breast cancers by q-RT-PCR. The expression of all 
these proteins is negatively correlated with prognosis and positively with survival (Wazir et 
al., man in prep).  
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Chapter 5: Investigating the Role of the 
Drug Lovastatin on Restoration of Nuclear 
Structure and Genome Organisation in 
Breast Cancer Cell Lines 
 
 
 
 
 
 
Manuscript in Preparation: M. Hassan Ahmed; Harvey A: Bridger JM.  
 
5.1 Introduction: 
The regulation, activation, and intracellular targeting of biological molecules are often 
mediated through the attachment of specific chemical groups. The post-translational 
modification of specific proteins by phosphorylation, acetylation, fatty acylation, and 
methylation has been studied extensively, and a variety of biological functions have been 
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studied are linked to these processes (Karve and Cheema, 2011). Protein prenylation is a 
process which, until recently, was poorly understood. Prenylation is a post-translation 
modification of proteins. Some prenylated proteins that have been identified are p21
ras
, Ras 
related GTP binding protein, lamin B and prelamin A. This post-translational modification 
plays a critical role in the association of p21
ras
 and lamins to the cell membrane and nuclear 
envelope, respectively in normal situations (Maltese, 1990). The mevalonate pathway that 
leads to the production of farnesyl can be targeted through different drugs such as 
farnesyltransferase inhibitors, statins and bisphosphonates. Lovastatin is a statin that impacts 
on this pathway. 
 
5.1.1 The Effects of Lovastatin in Cancer: 
Statins are used to decrease or reduce the cholesterol levels in the serum as well as inhibition 
of mevalonate biosynthesis pathways by inhibiting the enzyme 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase. Mevalonate is a precursor of dolichol (regulates the cell 
cycle and DNA synthesis), geranyl-pyrophosphate (GPP) and farnesyl-pyrophosphate (FPP) 
(cause isoprenylation of the intra-cellular G-proteins Ras and Rho, that regulate the signal 
transduction of the transcription of genes involved in cell proliferation, differentiation, and 
apoptosis). The natural inhibitor to HMG-CoA reductase is statin (Hindler et al., 2006; 
Viccica et al., 2007). Statins have the ability to block the synthesis of mevalonate and 
isoprenoids and block tumour cell growth for example, lovastatin has been shown to stabilise 
the cell cycle kinase inhibitors p21 and p27 and to arrest breast cancer cell lines in G1 phase 
(Rao et al., 1998). Inhibition of GTP binding proteins Ras, is dependent on proper 
isoprenylation for localisation and function, plays an important role in mediating the 
biological effects of statins (Liao, 2002) (Chapter 1). 
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The HMG-CoA reductase inhibitors, or statins, are used to decrease the incidence and risk of 
cardiovascular diseases, including death, myocardial infarction, stroke, artrial fibrillation, and 
renal dysfunction, due to their effects on serum cholesterol levels. Statin may also play a 
potential role in the prevention and treatment of cancer as well as several anti-neoplastic 
properties, including decreased tumour growth (Hindler et al., 2006), inhibition of 
angiogenesis (Frick et al., 2003), induction of apoptosis by up-regulating Bax and Bim and 
down regulating Bcl-2 as well as the activation of caspase proteases involved in programmed 
cell death and repression of metastasis because of its efficacy in the prevention and treatment 
of cancer (Hindler et al., 2006).  
 
5.1.2 Mutation Can Affect Lamins Assembly to the Nuclear Lamina: 
Prelamin A, lamin A and B precursors, is the substrate of ZMPSTE24 in mammals. This 
enzyme is involved in post-translational proteolytic cleavage of carboxy terminal residues of 
farnesylated prelamin A to form mature lamin A (Leung et al., 2001; Young et al., 2005). 
Chapter 1 reviewed in detail lamin biosynthesis, their assembly to the nuclear lamina, and 
their role in diseases. The role of ZMPSTE24 gene mutations in human disease has been also 
revealed. The lack of ZMPSTE24 protein or its activity in cell lines that derived from 
ZMPSTE24 mutated patients resulted in misshapen nuclei containing abnormal distribution to 
lamin A/C associated with accumulation of unprocessed prelamin A (Navarro et al., 2004; 
Navarro et al., 2005) whereas, the ZMPSTE24 mutations found in B type mandibuloacral 
dysplasia (MADB) encoded a protein with considerable reduced residual activity, the 
mutations found in Restrictive Dermopathy (RD) led to null ZMPSTE24 activity suggesting 
that a positive correlation between enzyme activity, accumulated prelamin A levels and the 
severity of the phenotype (Smigiel et al., 2010). In ZMPSTE24 knockout mice, severe growth 
and skeletal abnormalities were reported as well as premature death, these characteristics 
were due to total loss of mature lamin A and an accumulation of prelamin A (Pendás et al., 
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2002 and Smigiel et al., 2010). Most interestingly, several studies have demonstrated that 
blocking prelamin A farnesylation using farnesyltransferase inhibitors (FTI) could lead to 
prelamin A accumulation and prevent lamin A and lamin B maturation. Homozygous 
ZMPSTE24 mutation will lead to loss of enzymatic activity, then progeroid and muscle 
diseases. Therefore, the cleavage cannot occur and the protein remains farnesylated and 
carboxymethylated and the process is not completed. That means lamins are still on the 
nuclear envelope and nucleoplasm and not incorporated to the nuclear lamina.  
 
In Progeria where lamin A remains farnesylated there is evidence that statins i.e. Pravastatin 
can be used to prevent the farnesylation  
(http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/06/WC
500094023.pdf. 
 
The data in this chapters shows that there is a problem with B-type lamins associating with 
the nuclear envelope and possibly a lack of A-type and B-type lamins in cells. A paper by 
Swamy et al., 2002 has shown that lamin B expression can be increased by treatment with a 
statin called Lovastatin. The hypothesis for this chapter is that gene expression is affected in 
these cells because the genome is mislocalised and this in turn is due to lamin B not being 
localised properly to the nuclear envelope because it is missing or mislocalised (perhaps by 
the reduction of LBR) in specific cancer cells. Thus, it was decided to treat T-47D and BT-
474 and the control cell line MCF-10A with Lovastatin to determine if nuclear structure and 
genome organisation could be improved leading to gene expression changes. 
 
This chapter displays the expression of EGFR, PTEN, CCND1, AKT1, HSP90AA1, HER2, 
LMNB1, LMNB2, and LBR genes in breast cancer cells using qRT-PCR. It also demonstrates 
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the biological role of statin in the function of specific lamin proteins (lamin A, lamin B1, and 
lamin B2) and their presence and expression as shown by indirect immunofluorescence (IIF) 
and the positioning of AKT1, HSP90AA1, and ERBB2/HER2 genes using 2D-FISH after 
treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 Material and Methods: 
5.2.1 Cell Culture:  
As per chapter 2, section 2.2.1 
The human breast cancer (T-47D and BT-474) and normal (MCF-10A) cell lines were 
prepared for indirect immunofluorescence  
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5.2.1.1 Treatment with Lovastatin: 
The cells were treated with lovastatin (Sigma-Aldrich) which was dissolved in absolute 
ethanol at final concentrations of 0 μM and 12 μM, 24 μM, and 29 μM (lovastatin ) for 24 
and 48 hours, (Appendices). 
 
5.2.2 Indirect Immunofluoresence:  
5.2.2.1 Cell preparation: 
As per chapter 4, section 4.2.2.1.  
 
5.2.2.2 Cell Fixation: 
As per chapter 4, section 4.2.2.2 
 
5.2.2.3 Primary and Secondary Antibodies Immuno-reactivity: 
As per chapter 4, section 4.2.2.3 
 
The primary antibodies used were; goat anti-lamin A (diluted 1:100, Santa Cruz 
Biotechnology), mouse anti-lamin B1 (diluted 1:50, Abcam), and mouse anti-lamin B2 
antibody (diluted 1:500, Abcam). The diluted secondary antibodies were donkey anti-mouse  
 
conjugated to cyanine (Cy3) (diluted 1:100, Jackson Laboratories) and Cy5 conjugated 
donkey anti-goat (diluted 1:100, Jackson Laboratories). 
 
5.2.2.4 Mounting on Slides: 
As per chapter 4, section 4.2.2.4 
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5.2.2.5 Evaluation and Detection using Fluorescence Microscopy: 
As per chapter 4, section 4.2.2.5 
 
5.2.3 2-Dimensional Fluorescence In Situ Hybridization (2D-FISH):   
As per chapter 2, section 2.2.2 to 2.2.3.10 
 
5.2.4 qRT-PCR 
5.2.4.1 RNA Extraction: 
As per chapter 3, section 3.2.4 and 3.2.5 
 
5.2.5 cDNA Synthesis: 
As per chapter 3, section 3.2.6 
 
 
 
 
 
 
 
Table 5.1: RNA Standardisation Calculation: 
The RNA concentrations from each sample were used as shown in table 5.1. Large samples 
can use up to 500 ng RNA for cDNA synthesis; smaller concentrations can use 100 ng for 
cDNA synthesis: 
 
Cell Lines With and Conc. of Standard RNA Needed H2O 
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Without Lovastatin 
Treatment 
RNA (ng/ 
µl) 
Amount 
(ng) 
(µl) Needed (µl) 
 X Y Y / X 10 – (Y / X) 
(6) T-47D (12µM/48 
Hours) 
423.9 500 1.17 8.83 
(7) BT-474 (12µM/48 
Hours) 
362.7 500 1.37 8.63 
(8) MCF-10 A 
(12µM/48 Hours) 
84.1 500 5.94 4.06 
(9) MCF-10A 
(24µM/48 Hours) 
72.0 500 6.94 3.06 
 
 
 
5.2.6 Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR): 
As per chapter 3, section 3.2.8 
 
5.2.7 Western Blots: 
As per chapter 4, section 4.2.7 
 
 
 
 
5.3 Results: 
5.3.1 Restoration of Lamins A and B with Lovastatin in MCF-10A, T-47D, and BT-474 
Cells:  
The cells were treated with different lovastatin concentrations (0 µM, 12 µM, 24 µM, and 29 
µM) for 24 and 48 hours. Some cells were killed but a large number of cells survived. Then, 
the cells were harvested and fixed with methanol: acetone (1:1) for indirect 
immunofluorescence. The immunoreactivity of lamins A, B1, and B2 within MCF-10A, T-
207 
 
47D, and BT-474 cells was assessed. MCF-10A cells showed clear change in shape from its 
normal shape as shown in chapter 4 (Results Section) to cells with a more rounded shape 
(Table 5.2). T-47D cells were less influenced by the drug than BT-474 cells. T47D is the cell 
line that is used in drug resistance (http://icbp.lbl.gov/breastcancer/list_data.php?id=1, July 
2009 and Chapter 1). The drug concentration was shown to be harmful to both T-47D and 
BT-474 cells at 24 µM and 29 µM concentrations as well as in MCF-10A cells at 29 µM 
concentration, since these cells showed apoptotic features. The morphological features of 
apoptosis were observed in these cells were chromatin condensation, cell shrinkage, DNA 
fragmentation, and membrane blebbing. Thus 12 µM concentration in cells was the best 
concentration of the drug to use. This concentration has also been used by Corcos and Le 
Jossic-Corcos in 2013. The presence and distribution of lamins A, B1, and B2 within MCF-
10A, T-47D, and BT-474 cells was assessed (Figure 5.1). 
 
I. Panel (i): T-47D Cells Treated with Lovastatin/24hrs:
0 µM                12 µM               24 µM              29 µM 
Lamin A 
Lamin B1 
Lamin B2 
A
GFE
DCB
H
KJI L
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Panel (ii): T-47D Cells Treated with Lovastatin/48hrs:   
0 µM   12 µM     24 µM  29 µM 
Lamin A 
Lamin B1 
Lamin B2 
CA B D
HGFE
I J K L
II. Panel (i): BT-474 Cells Treated with Lovastatin/24hrs:
0 µM                        12 µM                         24 µM                          29 µM 
Lamin A 
Lamin B1 
Lamin B2 
A
E
I J K L
DB C
HGF
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Panel (ii): BT-474 Cells Treated with Lovastatin/48hrs:
0 µM  12 µM         24 µM           29 µM 
Lamin A 
Lamin B1 
Lamin B2 
A
J K L
E F
I
G H
B C D
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III Panel (i): MCF-10A Cells Treated with Lovastatin/24hrs:
Lamin A 
Lamin B1 
Lamin B2 
0 µM                       12 µM                      24 µM                       29 µM 
A
K
F G H
L
E
A
CB
I J
D
 
Panel (ii): MCF-10A Cells Treated with Lovastatin/48hrs:
Lamin A 
Lamin B1 
Lamin B2 
0 µM                        12 µM                            24 µM                     29 µM 
A
GFE
I J K L
H
DB C
 
 
 
 
 
 
 
Figure 5.1: The Proteins Presence and Expression of Lamin Proteins by Indirect 
Immunofluorescence in T-47D, BT-474, and MCF-10A Cell Lines before and after 
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Treatment with Lovastatin for 24 and 48 Hours at Different Concentrations: These 
images demonstrate the effects of lovastatin treatment on different cell lines that affect lamins 
distributions. Cells were processed and determined by indirect immunofluorescence method 
when fixed with methanol: acetone (1:1) using anti-lamins and anti-lamin binding proteins 
and the DNA stained with DAPI (Blue). I. Panels (i and ii): T-47D cells treated with 
Lovastatin/24 and 48hrs (0 µM, 12 µM, 24 µM, and 29 µM): demonstrates the images of T-
47D cells when immunostained with goat anti-lamin A, mouse anti-lamin B1, and mouse 
anti-lamin B2 antibodies (A-L). The secondary antibodies at final concentration using Cy5 
conjugated donkey anti-goat (pink) and Cy3 conjugated donkey anti-mouse (red) antibodies 
were employed at final concentration as shown in Chapter 4, Methods Section and 
Appendices. The same experiment was applied to II. Panels (i and ii): BT-474 cells treated 
with Lovastatin/24 and 48hrs (A-L). III. Panels (i and ii): MCF-10A cells treated with 
Lovastatin/24 and 48hrs (A-L),. Cells were mounted using Vectashield mounting medium 
containing DAPI to facilitate its visualisation and detection. The DNA stained with DAPI 
(Blue), Scale Bar = 10µM.  
 
 
 
5.3.2 Cellular Morphology: 
The cells were treated with lovastatin showed changes in nuclear structure when fixed with 
methanol: acetone (1: 1) and immunostained with lamin A, lamin B1, and lamin B2 
antibodies. The cells were treated with lovastatin at different concentrations 0 µM and 12 µM 
(MCF-10A, T-47D and BT-474 cells) for 48 hours. The most affected cells by the drug were 
MCF-10A which showed abnormal morphology in around 80% of cells followed by BT-474 
(57%) and then T-47D (29%) cells. 
 
Table 5.2: Cell Morphology after Lovastatin Treatment at 12 µM Concentration for 48 
Hours: The table displays the percentages of cellular morphology influenced by lovastatin at 
concentration 12 µM for 48 hours. The cells were harvested and counted by haemocytometer. 
The data showed that the more severely affected cells were MCF-10A as showed high 
number of abnormal nuclei (80%) followed by BT-474 (57%) and T-47D (28%) which is less 
affected and more resistant to the drug. MCF-10A cells changed their normal shape to 
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rounded float shape. This was evaluated by light microscope that used to determine the 
number and shape of these cells. 
 
 Cells with Normal 
Morphology 
Cells with Abnormal 
Morphology 
(1) T47-D 71.6% 28.4% 
(2) BT-474 43.3% 56.7% 
(3) MCF-10A 20.2% 79.8% 
 
 
 
5.3.3 Gene Loci position after Treatment with Lovastatin: 
Fluorescence in situ hybridisation (FISH) was performed to assess the position of human 
genes AKT1, HSP90AA1, and ERBB2/HER2 that are located on human chromosomes 14 and 
17 territories. Cells were treated with:  0 µM and 12 µM lovastatin for 48 hours. In treated 
T47-D and BT-474 cell lines, the genes occupy altered localisations in interphase nuclei 
when compared to MCF-10A treated cells (Figure 5.1I, II, and III Panels i and ii). The 
position of the genes in treated cells was located at the periphery in MCF-10A and T-47D and 
in the interior in BT-474. The effect of this drug on the nuclear localisation of these genes in 
T47-D, BT-474, and MCF-10A cell lines was determined. Treatment with lovastatin relocates 
the positions of the genes AKT1, HSP90AA1, ERBB2/HER2 (Table 5.3). To determine the 
movements and localisations of AKT1, HSP90AA1, and ERBB2/HER2 genes in T47-D, BT-
474, and MCF-10A cell lines, 2D-FISH was performed to determine the gene positions. It 
was found that AKT1 was changed its location in MCF-10A from interior to periphery and in 
BT-474 cells from periphery to interior but there was no change in position in T-47D cells. 
Moreover, HSP90AA1 did not change its location in any of the cells after treatment whereas, 
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ERBB2/HER2 was changed after treatment in MCF-10A cells from interior to periphery and 
in BT-474 cells from periphery to interior but no change was found in T-47D cells. These 
data suggest that lovastatin treatment allows cells to reposition genes in response to the drug 
(Figures 5.2 and 5.3). 
6.3.4 2D-FISH for Gene Loci after Treatment with Lovastatin
AKT1
HSP90AA1
ERRBB2/HER2
MCF-10A (12 µM/48hrs) T-47D (12 µM/48hrs BT-474 (12µM/48hrs)
A CB
E FD
G IH
 
Figure 5.2: 2D-FISH for Gene Loci After Treatment with Lovastatin: Using 2D-FISH to 
analyse the positioning of specific genes AKT1, HSP90AA1, and ERBB2/HER2 in normal 
breast MCF-10A and cancer T-47D and BT-474 treated cell lines. DNA has been 
counterstained using DAPI (Blue) whereas; gene signals can be seen in Red (labled Cy3-
streptavidin) and then pseudocoloured green to facilitate their positioning analysis. 
Magnification = X100; Scale Bar = 10µM. 
 
 
 
 
 
 
5.3.4 Analyses of Gene Loci after Treatment with Lovastatin: 
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Figure 5.3: Image Analyses of Gene Positioning Before and After Treatment with 
Lovastatin using 2D-FISH and Erosion Analysis: The histograms display positions of 
human genes AKT1 (A, D, and G), HSP90AA1 (B, E, and H), and ERBB2/HER2 (C, F, and I) 
that are located and resided on human chromosomes 14 and 17 territories in T47-D and BT-
474 breast cancer and MCF-10A normal breast cell lines that occupy altered localisations 
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during interphase nuclei after treatment with lovastatin. These genes have not changed their 
position in T-47D cells as well as HSP90AA1 in BT-474 cells. AKT1 and ERBB2/HER2 
genes moved from the nuclear periphery to the nuclear interior in BT-474 cells whereas the 
same genes moved from the nuclear interior to the nuclear periphery in MCF-10A cells. No 
change was observed in HSP90AA1 gene in MCF-10A. Their positions were assessed by 2D-
FISH and analysed by erosion analysis. Error bars indicate standard error of the mean (SEM). 
Y Axis = % of Chromosome and Gene Signal / % of DAPI Signal whereas X Axis = the 
position from periphery to interior (1 to 5).  
  
 
 
5.3.5 Statistical Analysis After Treatment with Lovastatin using Student’s t-test: 
The Student’s t-test with Excel Software Programme was used to compare statistically the 
positions of genes (AKT1, HSP90AA1, and ERBB2/HER2) in the treated cell lines as 
compared to no treatment. The probability-value (p-value) in the test was known; p<0.5 
(Green) was considered significant and any less than 0.05 (Red) that means there is a 
significant difference in position and indicated with star and more than 0.5 (Black) that 
means no significant difference in position. 
 
5.3.5.1 Statistical Analyses for Gene Position: 
(1) AKT1: 
 MCF-10A T-47D BT-474 
Area 1    
Area 2    
Area 3    
Area 4    
Area 5    
 
 
(2) HSP90AA1: 
 MCF-10A T-47D BT-474 
Area 1    
Area 2    
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Area 3    
Area 4    
Area 5    
 
 
(3) ERBB2/HER2: 
 MCF-10A T-47D BT-474 
Area 1    
Area 2    
Area 3    
Area 4    
Area 5    
 
The Key: 
Black = Indicates no significant difference between the positions with the p-value >0.5 
Green = Indicates significant difference between the positions with the p-value <0.5 
Red = Indicates significant difference between the positions with the p-value <0.05 
 
 
5.3.6 Gene Expression by qRT-PCR Analysis: 
The graphs below show the percentages of relative quantification (RQ) of gene expression by 
fold changes in expression for each gene in treated cell lines using qRT-PCR. The levels of 
expression of all genes studied here are calculated from 2
-ΔΔC
t or relative quantification using 
RQ Manager and Microsoft Excel softwares (Figure 5.4). From the literature, the relocation 
of chromosomes and genes to different sites within the nucleus can affect the gene expression 
and this is more noticeably in MCF-10A and BT-474 cell lines.  
 
 
It is observed that an increase in the expression of LBR gene in treated BT-474 and T-47D 
cells whereas it down regulated in MCF-10A treated cells. LMNB1 and LMNB2 genes were 
up-regulated in treated MCF-10A (12 µM/48hrs) and HSP90AA1 gene was down regulated in 
T-47D cells and slightly up-regulated in BT-474 and MCF-10A cells. In addition, HER2 gene 
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was up-regulated in treated BT-474 cells and CCND1 gene expression was also up-regulated 
in treated MCF-10A and T-47D cells. Moreover, EGFR gene was up-regulated in treated 
MCF-10A cells and BT-474 whereas, PTEN was up-regulated in all treated cells. AKT1 was 
up-regulated in BT474 after treatment and slightly in MCF-10A with no change in T-47D. 
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Figure 5.4: Expression Level of EGFR, PTEN, CCND1, AKT1, HSP90AA1, HER2, 
LMNB1, LMNB2, LBR, and β-Actin Genes mRNA After Treatment with Lovastatin in 
Breast Cell Lines using Quantitative Real Time-PCR (qRT-PCR): These histograms 
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show the percentage of relative quantification (RQ %) of expression of different genes in 
present of β-actin as a housekeeping, an endogenous gene with no supplement set as 1. The 
fold changes in these different gene expressions were assessed in treated T-47D, BT-474, and 
MCF-10A cell lines using RQ Manager and Microsoft Excel software. Error bars indicate 
standard error of the mean (SEM) of three replicates. 
 
 
Changes in gene position were correlated with any changes in gene expression in Table 5.3. 
For the T-47D cells notably, there were no major alterations in gene positions with the three 
genes that were positioned.  AKT1 and ERBB2/HER2 genes changed their positions in treated 
BT-474 cells from the nuclear periphery to the nuclear interior with 12 µM/48hrs and the 
expression was up-regulated in all the cell lines tested; fitting the hypothesis that gene 
movement to the interior is correlated with gene up-regulation. HSP90AA1 gene position was 
shifted more to the periphery in MCF-10A cells and T-47D cells with an up-regulation and a 
down-regulation in gene expression, respectively. In BT-474 cells this gene moved slightly 
towards the interior and became slightly up-regulated. After treatment, AKT1, HSP90AA1, 
and ERBB2/HER2 genes did not change their positions in treated T-47D cells from the 
periphery and AKT1 and ERBB2/HER2 genes expression did not change in the same cells. 
HSP90AA1 gene expression was down-regulated in T-47D cells after treatment. AKT1 and 
ERBB2/HER2 genes in treated MCF-10A cells also changed their position from interior to 
periphery and AKT1 was up-regulated whereas ERBB2/HER2 gene had no change in 
expression in the same cell line. HSP90AA1 gene in MCF-10A cells did not change its 
position from periphery but down regulated in expression.  
 
 
Table 5.3: Image Analyses for Gene Positioning and Expression After Treatment with 
Lovastatin: The table displays positions of human genes AKT1, HSP90AA1, and 
ERBB2/HER2 that are located on human chromosomes 14 and 17 territories in T-47D, BT-
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474, and MCF-10A cells occupy altered localisations in interphase nuclei after treatment with 
lovastatin at 12 µM concentrations when incubated for 48 hours.  
 
               
Gene 
MCF-10A 
(12µM/48hrs) 
T-47D 
(12µM/48hrs) 
BT-474 
(12µM/48hrs) 
 
 
AKT1 
Gene 
Position 
Interior → 
Periphery  
Periphery  Periphery → 
Interior  
Gene 
Expression 
Up-regulated No Change  Up-regulated  
 
 
HSP90AA1 
Gene 
Position 
More 
Peripheral 
More 
Peripheral  
Slightly More 
Interior  
Gene 
Expression 
Up-regulated  Down-
regulated 
Up-regulated 
Slightly 
 
 
ERBB2/HER2 
Gene 
Position 
Interior → 
Periphery  
More 
Peripheral 
Periphery → 
Interior  
Gene 
Expression 
No Change No Change Up-regulated  
 
 
After treatment and some changes to gene position and expression it was important to 
determine what had happened to the B-type lamins and LBR. Table 5.4 displays quantitative 
changes seen with respect to alterations in the fraction of cells displaying more normal 
distributions of these proteins. Notably, there was improvement and an increase in the 
presence of lamin B protein within treated MCF-10A cells (12µM/48hrs) and LBR within 
treated BT-474 and T-47D cells (12µM/48hrs). LMNB gene expression was up-regulated in 
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treated MCF-10A cells whereas treated BT-474 and T-47D cells showed up-regulation in 
LBR gene expression levels. The table below displays these findings before and after 
treatment with lovastatin. 
 
Table 5.4: Proteins Presence Before and After Treatment and Genes Expression After 
Treatment with Lovastatin: The table displays the presence of lamin B1, lamin B2, and 
lamin B receptor (LBR) proteins when fixed with methanol: acetone (1:1) and the expression 
of their genes (LMNB1, LMNB2, and LBR) in T47-D, BT-474, and MCF-10A cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MCF-10A T-47D BT-474 
  Before Faint Rim (in Rim + Large Rim + Large 
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Lamin B1 
Protein 
Presence 
Treatment 87% of cells) Brighter Spots  
(in 65% of 
cells) 
Spots (in 72% 
of cells) 
After 
Treatment 
Rim only (in 
97% of cells) 
Rim + 
Brighter Spots 
(in 93% of 
cells) 
Rim + 
Brighter Spots 
(in 70% of 
cells 
Gene 
Expression 
 Up-regulated  No change No change 
 
 
 
 
 
Lamin B2 
 
Protein 
Presence 
Before 
Treatment 
Faint Rim and 
Spots (in 47% 
of cells) 
Rim + Large 
Brighter Spots 
(in 85% of 
cells) 
Rim + Large 
Spots (in 80% 
of cells) 
After 
Treatment 
Rim (in 100% 
of cells) 
Rim only (in 
78 % of cells) 
Rim + 
Brighter Spots 
+ (in 74% of 
cells 
Gene 
Expression 
 Up-regulated No change No change 
 
Lamin B 
Receptor 
(LBR) 
 
Protein 
Presence 
Before 
Treatment 
Faint (in 95% 
of cells) 
Faint (in 64% 
of cells) 
Faint (in 29% 
of cells) 
After 
Treatment 
NA NA NA 
Gene 
Expression 
 No Change Up-regulated Up-regulated 
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*NA = Not Available 
5.4 Discussion: 
The question that the spatial organisation of the genome in the nucleus can modulate gene 
expression is still unanswered. In mammals, regions with low gene-density, and that are late-
replicating, locate toward the periphery of the nucleus and inactive genes also locate close to 
the nuclear periphery and their movement away from the periphery correlates with their 
transcriptional activation (Szczerbal et al., 2009). However, the expression of other genes in 
mammalian cells appears to be unaffected by their location to the nuclear periphery (Finlan et 
al., 2008). Therefore, to what degree this level of nuclear organisation directly affects gene 
function and position? 
 
In this study, the position of AKT1, HSP90AA1, and ERBB2/HER2 genes was assessed and it 
was found that these genes changed their positioning within BT-474 and MCF-10A after 
treatment with lovastatin. In BT-474 breast cancer cell lines, the position of AKT1 was 
relocated from the periphery to nuclear interior in with up-regulation of expression. In 
addition to this, the position of AKT1 was changed or altered from interior to periphery in 
normal breast MCF-10A cell line with down-regulation of expression. In T-47D breast cancer 
cell line, the position of AKT1 remains unchanged at the periphery with no change in its 
expression. In BT-474 and T-47D breast cancer cell lines, the position of HSP90AA1 remains 
unchanged at the interior and peripheral sites, respectively, in both concentrations of 0 µM 
and 12 µM with increase in expression in BT-474 cells and decrease in expression in T-47D 
cells. In addition to this, the position of HSP90AA1 remains unchanged at the periphery in 
concentrations of 0 µM and 12 µM, for 48 hours in normal breast MCF-10A cell line with 
increase in its expression within the same cells. In BT-474 breast cancer cell line, the position 
of ERBB2/HER2 was changed from periphery in concentration of 0 µM for 48 hours to 
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interior in concentration of 12 µM for the same time. In addition to this, the position of 
ERBB2/HER2 was altered from interior in concentration of 0 µM for 48 hours to periphery in 
concentration of 12 µM for the same time in normal breast MCF-10A cell line. In T-47D 
breast cell line, the position of ERBB2/HER2 remains unchanged at the peripheral in both 
concentrations of 0 µM and 12 µM for the same time (Figures 5.4 and 5.5, Table 5.3). 
 
In these cell lines it has been shown some correlations with genes being relocated after 
treatment and either down-regulating their expression with a move to the periphery and up-
regulating their expression with a move to the interior. However, the opposite is also true 
with genes that have moved to the nuclear periphery being up-regulated and genes moving to 
the interior being down-regulated. Therefore, these findings regarding gene position and 
expression, it is untrue to consider that the periphery is the site for gene repression in cancer 
cells. What is important to realise from these studies is that changes to gene behaviour have 
been elicited by a drug treatment leading to changes in gene expression. Indeed in T-47D 
there are desirable changes with respect to health and treatment with AKT1 and HSP90AA1 
being down-regulated and PTEN being up-regulated. 
 
The treatment with lovastatin has also increased LBR expression which in cells is correlated 
with a stronger nuclear B-type lamins, suggesting that the lamin B that was mislocalised as 
aggregates has been able to locate to the nuclear envelope. In BT-474 this has changed gene 
positioning back to a more normal situation as in MCF-10A.  
 
The mammalian nuclear lamina protein lamin B1 is post-translationally modified by 
farnesylation, endoproteolysis, and carboxymethylation processes at a carboxyl-terminal 
CAAX motif. In 2003, Maske et al. demonstrated that the CAAX endoprotease Rce1 is 
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required for lamin B1 endoproteolysis, demonstrated that proteolysed but non-methylated 
lamin B1 is required for fully processed lamin B1 during interphase nuclei and showed the 
role of methylation in the organisation and incorporation of lamin B1 into the nuclear lamina. 
Deficiency in the endoproteolysis or methylation of lamin B1 results in loss of integrity and 
deformity of the nuclear lamina. These data showed that the organisation of the nuclear 
envelope and lamina is dependent on a mechanism that involves the methylation of lamin B1.  
Since B-type lamins are expressed but not localised properly investigation into their 
processing in these breast cancer cells would help determine why they are not localised at the 
membrane if it is not due to the LBR. 
 
However, lamin A and lamin B both are involved in cell proliferation, cell cycle regulation, 
genome organisation and other nuclear functions such as replication, repair, transcription, 
expression, and apoptosis. Mutations in LMNA and LMNB genes may cause disrupting of 
these pathways. Alteration in these proteins presence, organisation and their distribution in 
these cell lines after treatment as demonstrated in (Figure 5.2I, II, and III Panels i and ii) 
influence the changes in gene expression. Alteration in gene expression and the need for 
specific genes to be expressed lead to the changes in organisation and gene locations. The 
results demonstrating that the position of AKT1 and ERBB2/HER2 genes remains unaltered in 
T-47D cells as well as HSP90AA1 gene in MCF-10A, T-47D, and BT-474 cells, the reason is 
that could be of genes that are found in sets or clusters or may be on loops away from their 
chromosomes, stage of the cancer, solidity of the tumour, dose of the drug, and time for 
incubation and thus cannot be reorganised (Figure 5.4 and Table 5.3). Moreover, the number 
of cells showed similar morphology to the cells nuclei before treatment (0 µM/48 hours), 
while other nuclei showed morphological features of apoptosis (cell death) in response to the 
drug. The morphological features of apoptosis consist of chromatin condensation, shrinking 
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of nuclear envelope, and membrane blebbing, DNA fragmentation which can be clearly 
observed by fluorescence microscopy (Figure 5.2I, II, and III Panels i (Images H, K) and ii 
(Images G, H)). In addition, there are a number of cells within the treated cultures that are 
behaving normally and without changing that can still respond to the drug (Figure 5.2I, II, 
and III Panels i (Images B, F, and J) and ii (Images B, F, and J)). Furthermore, there is still 
some functioning of lamin A and lamin B within these nuclei. In addition, the repositioning 
or reorganisation of gene loci could be affected by nuclear motor such as actin and myosin 
dependent and that mutation in LMNA gene may result in perturbed interaction of lamin A 
with nuclear motor or SUN proteins and other specific inner nuclear membrane proteins 
(emerin and LAP2α) suggesting that the role of lamin A in chromosomal organisation and 
chromosomal movement. Similar to this, mutation in LMNB gene may result in perturbed 
interaction of lamin B with its specific receptor (LBR), chromatin, LAP2 β, MAN1, BAF, R-
Smad, E2F, and β-catenin proteins and thus, this will lead to changes and alterations in gene 
repositioning, gene expressions, and dysfunctional characters due to changes in structures. 
 
Although the wide use of lovastatin in vivo and in vitro as well as animal model is highly 
successful, limitations of using this treatment should be considered. To our knowledge that 
lovastatin treatment plays a crucial role in post-translational modifications of proteins such as 
lamins and RAS that are required to undergo farnesylation and thus may result in various 
effects. Because lamin A undergoes further proteolytic processing of the CAAX 
modifications (Kilic et al., 1999), stable interactions of carboxymethyl moiety in the nuclear 
envelope are probably limited to B-type lamins. Lovastatin treatment may not be able to 
restore tissues that are already damaged. Similar to this was noticed in MCF-10A cells as it 
was more influenced by the drug than in other cancerous cells (BT-474 then T-47D cells) 
(Table 5.2). The improvement of that seen in cell nuclei after lovastatin treatment requires 
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further study in breast cancer and other cancers. Furthermore, lovastatin could cause changes 
in the expression and distribution of lamin B1 within treated cells. With this in mind further 
studies should still go forward to determine if lovastatin or other similar drugs could 
potentially be used in combination with other treatments to help restore normal nuclear 
structure and genome organisation to cancerous cells.  
 
The cancer chemotherapeutic agent, lovastatin, has antiproliferative effect through the 
inhibition of ICMT (by increasing metabolites that directly inhibits the enzyme) and, thus, 
carboxylmethylation inhibition of prenylated proteins. Because all of the CAAX processing 
enzymes are potential chemotherapeutic targets, an understanding of the effects of inhibition 
on nuclear structure, gene expression, and gene activation or repression are essential in the 
development of therapeutic molecules. Treatment with lovastatin that are used in cancers to 
induce the apoptosis, improve and increase LBR expression and the nuclear lamina 
distribution.  
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5.5 Conclusion: 
The effect of lovastatin, as a modern signal transduction inhibitor, was clearly seen in breast 
cancer cells (T-47D and BT-474) by increasing and up-regulating the expression of LBR 
gene. LMNB1 and LMNB2 genes in MCF-10A cells were also increased and up-regulated. 
This up-regulation allowed these proteins to be more abundant and located in the right place 
at the nuclear periphery. I also showed that AKT1 and HER2 genes changed their position and 
their expression as well as some other genes that are involved in breast cancer progression. 
The drug can restore and correct the aberrant nuclear structure and genome organisation in 
breast cancer cells maybe because lamin B is required for correct gene position and 
expression and also involved in normal nuclear function. Therefore, lovastatin may provide 
greater role in tumour specificity and clinical effectiveness than existing systemic 
chemotherapy and is a promised drug for cancer treatment and for correct gene expression, 
normal nuclear structures and functions. 
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Chapter 6:  General Discussion and Future 
prospective 
 
 
 
 
 
 
 
 
 
 
 
230 
 
6.1 General Discussion and Future Prospective: 
Properly functioning processes, correctly positioned structures, and a well organised genome 
are required in cell nuclei for regulated gene expression and genome stability. The nuclear 
lamina is a fundamental nuclear structure composed of lamins proteins that is important in 
DNA replication, DNA repair and gene positioning at the nuclear envelope. Genes can also 
be in a different nuclear compartment to their chromosomes, as they can be out on loops 
away from the chromosome territories. Changes in nuclear positions could severely affect 
gene expression and the normal function of cells. Here, it is hypothesised that the 
dysregulation of B-type lamins has contributed to tumour development by relocalisation of 
genes involved in breast cancer affecting their regulation and expression. In this study, breast 
cancer cell lines (T-47D and BT-474) were treated with lovastatin which has restored LBR 
expression and the localisation of lamin B, altering gene positioning and changing expression 
of genes involved in breast cancer progression such as AKT1 and HER2. Since the drug 
(lovastatin) affects the prenylation as a post-translation modification process, it is found that 
B-type lamins and its receptor expression and distribution were improved and increased in 
the most affected cells (MCF-10A, T-47D, and BT-474). Further, this drug induced cell death 
in a fraction of cells (Chapter 5).  
 
One of the major roles for lamins is in genome organisation, which can result in correct and 
regulation of genome organisation, expression, and function (Foster and Bridger, 2005). The 
lamina is juxtaposed to the inner nuclear membrane and functions in tethering chromatin to 
the nuclear envelope through both the alpha-helical rod and the carboxyl-terminal end of 
lamins and in maintaining nuclear shape. A and B type lamins, the main components of the 
nuclear lamina proteins, contatin a DNA binding domain and have affinity for 
choromosomes, chromatin and/or DNA (Höger et al., 1991; Glass et al., 1993; Stierlé et al., 
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2003). The interactions of these lamins with chromatin suggest that alterations in 
lamin−DNA interactions may play a role in the pathophysiology of some lamin-linked 
diseases and cancers, as well as in ageing. Studies have assessed chromatin reorganisation as 
a main contributor to cancer, laminopathies, and ageing in humans. Changes in nuclear 
architecture are a hallmark of cancers in human cells, laminopathesis and ageing. These 
changes seem to be driven by DNA damage, gene aberrant expression and localisation which 
results in alterations and/or diseases that affect gene expression, and may cause cancer 
(Oberdoerffer and Sinclair, 2007). Not that many studies have looked at nuclear structure in 
cancer especially breast cancer and as far as we know no studies have correlated gene 
repositioning in cancer with aberrant nuclear architecture. 
 
Generally, chromosome positioning within cell nuclei is non-random and positioned 
according to their gene density and activity. From genome organisation theory, the most gene 
poor chromosomes found at the nuclear periphery and gene rich chromosomes found at the 
nuclei interior. Different studies showed that the non-random positioning of the genome is 
involved in controlling and regulating gene expression, but alterations in the levels of 
transcription and expression have been observed when specific loci change position in nuclei 
(Misteli, 2004). Furthermore, these genes may be found on loops towards the areas of the 
nucleus that more active and specified for transcription (Foster and Bridger, 2005). In this 
study, the experiments have assessed the positioning of specific chromosomes and genes 
within specific breast cell lines (MCF-10A, T-47D, BT-474, Sk-Br-3, and GI-101) and any 
aberrant impact of nuclear structure. This assessment was achieved by analysing the presence 
and distribution of nuclear lamin proteins, genes and chromosome localisation and gene 
expression. It found that the nuclear architecture of breast cancer cells is often altered. The 
most severely affected cells (T-47D and BT-474) which have aberrant distribution of nuclear 
232 
 
lamins B1, lamins B2 and lamin B receptor (LBR). B-type lamins were found as large foci 
within the nucleoplasm and not at the nuclear periphery with little LBR to localise the lamin 
B. The same cell lines showed that the genes were positioned more peripherally in these two 
cancer cell lines than in normal cells (MCF-10A). They were also not in the same nuclear 
compartment as their chromosomes they can be out on loops away from the chromosome. 
From the literature, B-type lamins are involved in chromosome positioning and correct gene 
expression (Malhas et al., 2007). This is the first time that B-type lamins, A-type lamins and 
LBR have been shown to be affected in breast cancer, as well as all the other aberrations in 
NE proteins and chromatin binding proteins in breast cancer cells. These results were 
communicated to Prof Mokbel to screen his large array of breast cancer RNA samples finding 
a correlation with the lack of lamins A, B and LBR (Wazir et al., in prep). 
 
Since lamins and lamin binding proteins disorganisation have the ability of the nuclear 
membrane to anchor chromatin within the interphase, it is important to consider the possible 
implications and dysfunction on the nucleus by failing to anchor matrix attachment regions 
(MARs) and transcription factories correctly. Moreover, the nuclear envelope or nuclear 
membrane provides the basis for normal function of transcription factories (Iborra et al., 
1996). Any incorrect genes positioning, may change the normal local environment and 
therefore, altering the type of transcription factories and transcription status. Thus, gene 
expression could be mis-regulated and could lead to cancer. The mis-regulation of transcribed 
genes and lamin proteins may affect the transcription, translation, and other proper nuclear 
processes and functions. In 2002, Spann and his co-workers reported that lamin A and B 
mutation inhibits the activity of RNA polymerase. Furthermore, deletion in lamin B1 levels 
disrupts RNA polymerase II synthesis and affects interphase chromosome position and gene 
expression (Malhas et al., 2007; Tang et al., 2008). 
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These findings suggest that the nuclear membrane contributes to the dysfunctional of lamins 
and their binding proteins in different ways, by inefficient recruitment of proteins involved in 
gene and chromosome localisations as well as DNA repair, transcription, cell cycle, gene 
expression, and apoptosis. However, a few number of published papers regarding the 
hypothesis that the nuclear lamin subtypes play a role in genome organisation in health and 
disease cells. 
 
Therefore, nuclear structure and genome organisation are essential and important for correct 
gene expression and normal function of cells. Understanding the nuclear structure and 
genome behaviour of breast cancer cells will aid in the goal to eliminate cancer as a major 
health problem. The mechanistic basis by which alterations in nuclear structure and function 
lead to cancer is an exciting new area of study.  
 
6.2 Summary of this Project: 
To summarise this work, Figure 6.1 describes the findings of this study.  
 
 
 
 
Figure 6.1 Summary of This Project: Loss or aberrant lamins expression will lead to 
changes in chromosomes and genes positioning. This alteration may change the gene 
expression and then lead to cancer. 
 
 
 
 
 
The work in this thesis has a number of novel findings by describing the relocation of genes, 
and chromosomes in breast cancer cells correlated with changes in gene expression of these 
genes. The presence and distribution of nuclear lamins and other nuclear structural proteins 
Nuclear 
Lamins 
Chromosomes 
+ Genes 
Repositioning 
Gene 
Expression 
Changes 
Disease (Cancer) 
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are affected in the cell lines. With a drug treatment a number of these aberrations can be 
corrected or changed. Thus, there is potential to restore nuclear architecture to cancer cells 
and re-regulate gene expression. 
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Appendices 
 Indirect Immunofluorescence:  
Methanol : Acetone, 1:1 (v/v): 
25 ml Methanol in 25 ml Acetone 
4% Paraformaldehyde: 
4g paraformaldehyde in 100 ml 1XPBS (heated in 50ºC till to be dissolved) 
10X PBS: 
160g NaCl, 4g KCl, 22.9g Na2HPO4, and 4g KH2PO4 adjust this to 2 litres ddH2O then 
autoclave it. 
1XPBS (v/v): 
100 ml 10XPBS in 900 ml ddH2O 
1% Triton-X100: 
1 ml Triton-X100 in 99 ml 1XPBS 
10% Fetal Calf Serum (FCS): 
10 ml Fetal Calf Serum (FCS) in 90 ml 1XPBS (Phosphate Buffer Saline) 
1% New Born Calf Serum (NCS, v/v): 
1 ml New Calf Serum (NCS) in 99 ml 1XPBS 
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 Summary of Antibodies Used in Indirect Immunofluorescence Method: 
Primary Antibodies (v/v) Secondary Antibodies (v/v) 
Protein Species Dilution (µl) Species Dilution (µl) 
LAP2 α Rabbit 1:250  
 
Swine 
(FITC) 
 
 
1:30 
Lamin Cy Rabbit 1:50 
Lamin Cw Rabbit 1:50 
LBR Rabbit 1:500 
PML Rabbit 1:100 
KI67 Rabbit 1:1500 
Lamin A/C Mouse 1:100  
 
 
(1) Donkey 
(Red) 
(2) Cy3 
Conjugated 
Donkey 
 
 
 
(1) 1:70 
(2) 1:100 
Lamin B1 Mouse 1:50 
Lamin B2 Mouse 1:100 
Pre-lamin A Mouse 1:100 
Cleaved  
Pre-lamin A 
Mouse 1:100 
Nucleolin Mouse 1:200 
LAP2 Mouse 1:100 
MAN1 Goat 1:100  
(1) Donkey 
(FITC) 
(2) Cy5 
Conjugated 
Donkey 
(Pink) 
 
(1) 1:50 
(2) 1:100 
Emerin Goat 1:100 
Lamin A Goat 1:100 
 
290 
 
 Isolation of Genes from Bacterial Artificial Chromosomes 
(BACs):  
Luria-Bertani (LB) Agar Plate: 
1 % NaCl (w/v), 1 % Tryptone (w/v), 0.5 % Yeast Extract (w/v), 1.5 % Agar Technical 
(w/v), and 12.5 % µg/ml Chloramphenicol (w/v). 
LB Broth:  
1 % NaCl (w/v), 1 % Bactotryptone (w/v), 0.5 % Yeast Extract (w/v), and 12.5 % µg/ml 
Chloramphenicol (w/v). 
P1 Solution:  
15 mM Tris (pH 8), 100 µg/ml RNase A, and 10 mM EDTA 
P2 Solution:  
0.2 M NaOH and 1 % SDS 
P3 Solution:  
3 M CH2COOK 
10X TBE:  
108 g Tris, 55 g Boric Acid, and 9.3 g EDTA in 1 Litre ddH2O 
1X TBE:  
100ml 10X TBE in 900ml Sterilised water 
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 Preparation for Running DOP-PCR: 
  Master Mix for Running DOP-PCR (v/v): 
 Without Biotin (µl) With Biotin (µl) 
10x DOP PCR Buffer 10  10  
dACGTP (2µM) 10  10  
dTTP (2µM) 10  4  
DOP-PCR Primer (20 µM) 10  10  
Sterilised Water 57  35  
DNA Template 2  10  
Biotin-16-dUTP - 20  
Taq-KAPA HIFI 1  1  
Total 100  100 
 
 DOP-PCR Programme: 
Phase Step (Cycle) Temperature (ºC) Time (Minutes) 
Initial Denaturation 1  94 3  
Denaturation  
30  
94 1  
Annealing 62 1  
Extension 68 1.5  
Final Extension 1  68 8  
For Collection  4 ∞ 
 
 Preparation DOP-PCR Gel: 
1 % Agarose in 1X TBE and 2 µl Ethidioum Bromide (10 mg/ml) 
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 2 Dimensional- Fluorescence In Situ Hybridisation (2D-
FISH): 
3M Na Acetate pH 5.0: 
0.5g Na Acetate in 2 ml ddH2O 
Adjust pH to 5.0 
Methanonl : Acetic Acid, 3:1 (v/v): 
30 ml Methanol in 10 ml Acetic Acid 
0.075M KCl: 
0.7g KCl in 125 ml ddH2O 
70% Ethanol: 
70 ml Ethanol in 30 ml ddH2O 
90% Ethanol: 
90 ml Ethanol in 10 ml ddH2O 
100% Ethanol: 
100 ml Absolute Ethanol 
70% Formamide with 2X SSC pH 7.0 (v/v): 
70 ml Formamide in 30 ml 2XSSC (10 ml of 2XSSC + 20 ml ddH2O), then adjust pH to 7.0 
Buffer A: 
50% Formamide 2XSSC, pH 7.0: 
150 ml Formamide in 30 ml 20XSSC +120 ml ddH2O, then adjust pH to 7.0 
Buffer B: 
0.1XSSC pH 7.0 (v/v): 
1.5 ml 20XSSC in 298.5 ml ddH2O, then adjust pH to 7.0 
20XSSC (w/v): 
180.3g NaCl and 88.2g Na Citrate in 1 L ddH2O, pH7.0 and autoclave it. 
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4XSSC: 
20 ml 20XSSC in 80 ml ddH2O 
4% Bovine Serum Albumin (BSA): 
4g BSA in 10 ml 4XSSC 
1% BSA: 
0.1g BSA in 10 ml 4XSSC 
FITC-Streptavidin (1:200 dilution, v/v): 
1µl Cy3 in 199µl 1% BSA 
Anti-Dig Antibody (1:100 dilution, v/v): 
1µl Anti-Dig in 99µl 1% BSA 
4XSSC in 0.05% Tween-20 (v/v): 
320 ml ddH2O in 80 ml 20XSSC + 0.2 ml Tween-20 
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 Polymerase Chain Reaction (PCR): 
 RNA Analysis (Nano – drop): 
(1) Untreated Cell Lines: 
 
Cell Lines Sample 
Number 
Concentration 
(ng/µl) 
260/280 260/230 Base Line 
(nm) 
 
 
T-47D  
(1a) 170.7 2.04 1.39 340 
(1b) 197.4 2.05 1.33 340 
(2a) 420.2 2.05 1.80 340 
(2b) 372.5 2.06 1.37 340 
 
 
 
MCF-10A  
(1a) 26.4 2.25 0.72 340 
(1b) 42.0 2.11 1.08 340 
(2a) 50.0 2.09 1.42 340 
(2b) 37.4 2.18 0.37 340 
(3a) 56.3 2.12 0.95 340 
(3b) 59.3 2.12 0.54 340 
 
 
BT-474  
(1a) 234.1 2.05 1.22 340 
(1b) 284.8 2.06 1.52 340 
(2a) 261.5 2.1 1.74 340 
(2b) 226.9 2.11 1.27 340 
 
 
GI-101  
(1a) 380.8 2.07 1.20 340 
(1b) 389.8 2.09 0.77 340 
(2a) 263.3 2.11 1.63 340 
(2b) 252.7 2.06 1.93 340 
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Sk-Br-3  
(1a) 718.1 2.10 1.99 340 
(1b) 647.8 2.06 1.86 340 
(2a) 409.9 2.02 2.36 340 
(2b) 399.7 2.06 1.78 340 
 
 
(2) Cell Lines Treated with Lovastatin: 
Cell Lines Sample 
Number 
Concentration 
(ng/µl) 
260/280 260/230 Base Line 
(nm) 
T-47D 
(12µM/48hours) 
(1a) 384.9 2.11 1.46 340 
(1b) 423.9 2.10 1.57 340 
MCF-10A 
(12µM/48hours) 
(1a) 84.1 2.11 1.46 340 
(1b) 63.0 2.18 0.64 340 
MCF-10A 
(24µM/48hours) 
(1a) 72.0 2.14 1.73 340 
(1b) 69.5 2.10 0.35 340 
BT-474 
(12µM/48hours) 
(1a) 362.7 2.06 2.00 340 
(1b) 320.2 2.08 1.32 340 
 
 Master Mix 1: 
1 µl Random Primers (Oligonucleotide) + 1 µl dNTPs mix (10 mM) + 10 µl RNA + H2O (to 
make up standardised RNA amount in ng) 
 Master Mix 2: 
4 µl First Strand Buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl2) + 1 µl 
Molecular Grade H2O + 2 µl 0.1M DDT (Dithiothreitol), A Reducing Agent to Prevent DNA 
Forming Dimmers in Solution + 1 µl Superscript II Reverse Transcriptase. 
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 RNA Standardisation Calculation (Table Below): 
Large samples can use up to 500 ng RNA for cDNA synthesis; smaller concentrations can 
use 100 ng for cDNA synthesis: 
 
Cell Lines With and 
Without Lovastatin 
Treatment 
Concentration 
of RNA (ng/ µl) 
Standard 
Amount (ng) 
RNA Needed 
(µl) 
H2O Needed 
(µl) 
 
 X Y Y / X 10 – (Y / X) 
(10) T-47D 420.2 500 1.18 8.82 
(11) BT-474 284.8 500 1.75 8.25 
(12) GI-101 389.8 500 1.28 8.72 
(13) Sk-Br-3 718.1 500 0.69 9.31 
(14) MCF-10A 59.3 500 8.43 1.57 
(15) T-47D 
(12µM/48 Hours) 
423.9 500 1.17 8.83 
(16) BT-474 
(12µM/48 Hours) 
362.7 500 1.37 8.63 
(17) MCF-10 A 
(12µM/48 Hours) 
84.1 500 5.94 4.06 
(18) MCF-10A 
(24µM/48 Hours) 
72.0 500 6.94 3.06 
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 PCR Master Mix as Follows:  
Component from KAPA HiFi Total Volume in a 25 μl Reaction 
PCR Grade Water 16.25ul 
5X KAPA HiFi Fidelity Buffer 
(contains 2.0 mM Mg
2+
 at 1X) 
5ul 
dNTP Mix (10 mM each dNTP) 0.75ul 
Forward Primer (100nM) 0.75ul 
Reverse Primer (100nM) 0.75ul 
cDNA Template 1.0ul (end) 
KAPA HiFi DNA Polymerase (1 U/μl) 0.5ul 
 
 
 
 The Programme Parameters for PCR Machine: 
Phase Step (Cycle) Temperature (ºC) Time (Minutes) 
Initial Denaturation  94 3 
Denaturation  
35 
94 1 
Annealing 55 1 
Extension 72 1.5 
Final Extension  72 10 
For Collection  4 ∞ 
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 Primers Description: 
Primer Name Primer Sequence Product 
Length 
%GC Size 
(bases) 
Tm 
(°C) 
EGFR (F) CAGCGCTACCTTGTCATTCA 195 50.00 20 60.01 
EGFR (R) TGCACTCAGAGAGCTCAGGA  55.00 20 60.01 
PTEN (F) CATAACGATGGCTGTGGTTG 106 50.00 20 59.99 
PTEN (R) CCCCCACTTTAGTGCACAG  55.00 20 60.03 
CCND1 (F) GAGGAAGAGGAGGAGGAGGA 237 60.00 20 59.88 
CCND1 (R) GAGATGGAAGGGGGAAAGAG  55.00 20 60.01 
AKT1 (F) AGAAGCAGGAGGAGGAGGAG 139 60.00 20 60.09 
AKT1 (R) CCCAGCAGCTTCAGGTACTC  60.00 20 60.01 
HSP90AA1 (F) AGACCCAGTCTTGTGGATGG 120 55.00 20 59.96 
HSP90AA1 (R) ACTCCCCTTTCCCCCTAAAT  50.00 20 60.01 
HER2 (F) ACAGTGGCATCTGTGAGCTG 148 55.00 20 60.06 
HER2 (R) CCCACGTCCGTAGAAAGGTA  55.00 20 59.99 
LMNB1 (F) AGGATCAGATTGCCCAGTTG 125 50.00 20 60.07 
LMNB1 (R) GCGAAACTCCAAGTCCTCAG  55.00 20 59.99 
LMNB2 (F) AAGGACCTGGAGTCCCTGTT 153 55.00 20 59.97 
LMNB2 (R) CTTCTCCAGCTGCTTTTTGG  50.00 20 60.13 
LBR (F) CCGTGAATTAAACCCTCGAA 128 45.00 20 59.93 
LBR (R) CGCGGTCCTGTATTTTCATT  45.00 20 59.96 
Beta-Actin (F) AAGAGAGGCATCCTCACCCT 216    
Beta-Actin (R) TACATGGCTGGGGTGTTGAA     
* F=Forward, R=Reverse, and Tm=Temperature 
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 Images of 100 bp Ladder Used for PCR Studies: 
 
 
Figure: 100 bp Ladder (Visualized by Ethidium Bromide Staining on a 2% TAE agarose gel). 
 
 
 Drug Treatment: 
Lovastatin Drug (10µg/ml) in Ethanol: 
1M = 404.54g in 1L 
1M = 0.40454g in 1ml 
1M = 1000µM = 404µg in 1ml 
              24µM = 10µg in 1ml 
To make it 1000X Stock 
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